AptarGroup (ATR) 10-K 17 Feb 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Feb. 13, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-11846
Entity Registrant Name	AptarGroup, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-3853103
Entity Address, Address Line One	265 EXCHANGE DRIVE, SUITE 301
Entity Address, City or Town	CRYSTAL LAKE
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60014
City Area Code	815
Local Phone Number	477-0424
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	ATR
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 6,771,678,654
Entity Common Stock, Shares Outstanding		65,400,423
Documents Incorporated by Reference	Portions of the definitive Proxy Statement to be delivered to stockholders in connection with the Annual Meeting of Stockholders to be held May 3, 2023 are incorporated by reference into Part III of this report.
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0000896622
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Auditor Information [Abstract]
Auditor Location	Chicago, Illinois
Auditor Name	PricewaterhouseCoopers LLP
Auditor Firm ID	238

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net Sales	$ 3,322,249	$ 3,227,221	$ 2,929,340
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)	2,158,411	2,070,538	1,842,821
Selling, research & development and administrative	544,262	551,242	500,229
Depreciation and amortization	233,706	234,853	220,300
Restructuring initiatives	6,597	23,240	26,492
Total Operating Expenses	2,942,976	2,879,873	2,589,842
Operating Income	379,273	347,348	339,498
Other (Expense) Income:
Interest expense	(40,827)	(30,284)	(33,244)
Interest income	2,700	3,668	958
Net investment (loss) gain	(2,110)	4,709	3,064
Equity in results of affiliates	467	(692)	(1,443)
Miscellaneous, net	(4,799)	(3,094)	(7,678)
Total Other Expense	(44,569)	(25,693)	(38,343)
Income before Income Taxes	334,704	321,655	301,155
Provision for Income Taxes	95,149	78,017	87,065
Net Income	239,555	243,638	214,090
Net (Income) Loss Attributable to Noncontrolling Interests	(267)	459	(50)
Net Income Attributable to AptarGroup, Inc.	$ 239,288	$ 244,097	$ 214,040
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic (in dollars per share)	$ 3.66	$ 3.72	$ 3.32
Diluted (in dollars per share)	3.59	3.61	3.21
Dividends per Common Share (in dollars per share)	$ 1.52	$ 1.50	$ 1.44

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 239,555	$ 243,638	$ 214,090
Other Comprehensive (Loss) Income:
Foreign currency translation adjustments	(80,431)	(71,742)	79,109
Changes in derivative (losses) gains, net of tax	(6,620)	1,307	315
Defined benefit pension plan, net of tax
Actuarial gain (loss), net of tax	54,149	26,409	(27,268)
Prior service cost, net of tax	0	0	1,879
Amortization of prior service cost included in net income, net of tax	130	127	294
Amortization of net loss included in net income, net of tax	6,256	9,300	5,920
Total defined benefit pension plan, net of tax	60,535	35,836	(19,175)
Total other comprehensive (loss) income	(26,516)	(34,599)	60,249
Comprehensive Income	213,039	209,039	274,339
Comprehensive Loss (Income) Attributable to Noncontrolling Interests	924	726	(60)
Comprehensive Income Attributable to AptarGroup, Inc.	$ 213,963	$ 209,765	$ 274,279

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Cash and equivalents	$ 141,732	$ 122,925
Short-term investments	0	740
Total Cash and equivalents and Short-term investments	141,732	123,665
Accounts and notes receivable, less current expected credit loss ("CECL") of $9,519 in 2022 and $7,374 in 2021	676,987	671,350
Inventories	486,806	441,464
Prepaid and other	124,766	121,729
Total Current Assets	1,430,291	1,358,208
Land	30,197	31,436
Buildings and improvements	693,542	631,897
Machinery and equipment	2,925,517	2,862,142
Property, Plant and Equipment, Gross	3,649,256	3,525,475
Less: Accumulated depreciation	(2,305,592)	(2,249,598)
​Property, Plant and Equipment, Net	1,343,664	1,275,877
Investments in equity securities	52,308	59,485
Goodwill	945,632	974,157
Intangible assets, net	315,744	362,343
Operating lease right-of-use assets	58,675	62,454
Miscellaneous	57,144	48,840
Total Other Assets	1,429,503	1,507,279
Total Assets	4,203,458	4,141,364
Liabilities and Stockholders’ Equity
Revolving credit facility and overdrafts	3,810	147,276
Current maturities of long-term obligations, net of unamortized debt issuance costs	118,981	142,351
Accounts payable, accrued and other liabilities	794,385	692,865
Total Current Liabilities	917,176	982,492
Long-Term Obligations, net of unamortized debt issuance costs	1,052,597	907,024
Deferred income taxes	20,563	27,547
Retirement and deferred compensation plans	48,977	116,809
Operating lease liabilities	42,948	48,010
Deferred and other non-current liabilities	52,993	74,882
Commitments and contingencies	0	0
​Total Deferred Liabilities and Other	165,481	267,248
AptarGroup, Inc. stockholders’ equity
Common stock, $.01 par value, 199 million shares authorized, 70.8 and 70.4 million shares issued as of December 31, 2022 and 2021, respectively	709	704
Capital in excess of par value	968,618	916,534
Retained earnings	1,929,240	1,789,413
Accumulated other comprehensive loss	(341,366)	(316,041)
Less: Treasury stock at cost, 5.6 and 4.9 million shares as of December 31, 2022 and 2021, respectively	(503,266)	(421,203)
Total AptarGroup, Inc. Stockholders’ Equity	2,053,935	1,969,407
Noncontrolling interests in subsidiaries	14,269	15,193
Total Stockholders’ Equity	2,068,204	1,984,600
Total Liabilities and Stockholders’ Equity	$ 4,203,458	$ 4,141,364

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts and notes receivable, less current expected credit loss (in dollars)	$ 9,519	$ 7,374
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	199,000,000	199,000,000
Common stock, shares issued (in shares)	70,800,000	70,400,000
Treasury stock, shares (in shares)	5,600,000	4,900,000

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive (Loss)Income	Common Stock Par Value	Treasury Stock	Capital in Excess of Par Value	Non- Controlling Interest
Balance at beginning of period at Dec. 31, 2019	$ 1,572,252	$ (1,377)	$ 1,523,820	$ (1,377)	$ (341,948)	$ 686	$ (381,238)	$ 770,596	$ 336
Increase (Decrease) in Stockholders' Equity
Net income	214,090		214,040						50
Foreign currency translation adjustments	79,109				79,099				10
Changes in unrecognized pension gains (losses) and related amortization, net of tax	(19,175)				(19,175)
Changes in derivative gains (losses), net of tax	315				315
Stock awards and option exercises	98,229					9	19,655	78,565
Cash dividends declared on common stock	(92,658)		(92,658)
Balance at end of period at Dec. 31, 2020	1,850,785		1,643,825		(281,709)	695	(361,583)	849,161	396
Increase (Decrease) in Stockholders' Equity
Net income	243,638		244,097						(459)
Acquisitions of non-controlling interest	38,543								38,543
Purchases of subsidiary shares from non-controlling interest	(23,020)								(23,020)
Foreign currency translation adjustments	(71,742)				(71,475)				(267)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	35,836				35,836
Changes in derivative gains (losses), net of tax	1,307				1,307
Stock awards and option exercises	85,910					9	18,528	67,373
Cash dividends declared on common stock	(98,509)		(98,509)
Treasury stock purchased	(78,148)						(78,148)
Balance at end of period at Dec. 31, 2021	1,984,600		1,789,413		(316,041)	704	(421,203)	916,534	15,193
Increase (Decrease) in Stockholders' Equity
Net income	239,555		239,288						267
Foreign currency translation adjustments	(80,431)				(79,240)				(1,191)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	60,535				60,535
Changes in derivative gains (losses), net of tax	(6,620)				(6,620)
Stock awards and option exercises	62,152					5	10,063	52,084
Cash dividends declared on common stock	(99,461)		(99,461)
Treasury stock purchased	(92,126)						(92,126)
Balance at end of period at Dec. 31, 2022	$ 2,068,204		$ 1,929,240		$ (341,366)	$ 709	$ (503,266)	$ 968,618	$ 14,269

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net income	$ 239,555	$ 243,638	$ 214,090
Adjustments to reconcile net income to net cash provided by operations:
Depreciation	190,132	193,781	180,513
Amortization	43,574	41,072	39,787
Stock-based compensation	40,937	38,870	34,148
Provision for CECL	3,213	1,601	865
Loss on disposition of fixed assets	397	217	2,627
Net loss (gain) on remeasurement of equity securities	2,110	(4,709)	(64)
Deferred income taxes	(12,106)	(14,356)	(8,198)
Defined benefit plan expense	24,560	29,188	23,372
Equity in results of affiliates	(467)	692	1,443
Impairment loss	307	376	0
Change in fair value of contingent consideration	(8,598)	2,768	5,230
Changes in balance sheet items, excluding effects from foreign currency adjustments and acquisitions:
Accounts and other receivables	(27,937)	(123,251)	13,455
Inventories	(60,354)	(79,961)	13,722
Prepaid and other current assets	(6,787)	(5,538)	(3,078)
Accounts payable, accrued and other liabilities	55,098	52,305	65,592
Income taxes payable	17,081	(4,631)	(6,091)
Retirement and deferred compensation plan liabilities	(13,093)	(8,726)	(7,267)
Other changes, net	(9,005)	107	7
Net Cash Provided by Operations	478,617	363,443	570,153
Cash Flows from Investing Activities:
Capital expenditures	(310,427)	(307,935)	(245,954)
Proceeds from government grants	27,795	2,003	0
Proceeds from sale of property, plant and equipment	93	5,231	5,261
Maturity of short-term investments	740	0	0
Purchase of short-term investments	0	(497)	(243)
Acquisition of business, net of cash acquired	(4,100)	(148,420)	(164,181)
Acquisition of intangible assets	(5,189)	0	(6,092)
Investment in equity securities	0	(6,870)	(39,628)
Proceeds from sale of investment in equity securities	1,599	2,434	0
Notes receivable, net	(6,153)	(3,185)	(1,141)
Net Cash Used by Investing Activities	(295,642)	(457,239)	(451,978)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts	39,944	14,931	22,342
Repayments of notes payable and overdrafts	(38,837)	(13,701)	(36,314)
Proceeds and repayments of short term revolving credit facility, net	(143,055)	92,863	27,000
Proceeds from long-term obligations	412,021	11,703	4,852
Repayments of long-term obligations	(265,085)	(68,845)	(64,735)
Payment of contingent consideration obligation	0	0	(2,765)
Dividends paid	(99,461)	(98,509)	(92,658)
Credit facility costs	(4,009)	(1,718)	0
Proceeds from stock option exercises	28,512	59,906	68,555
Purchase of treasury stock	(92,126)	(78,148)	0
Net Cash Used by Financing Activities	(162,096)	(81,518)	(73,723)
Effect of Exchange Rate Changes on Cash	(1,072)	(6,731)	13,545
Net Increase (Decrease) in Cash and Equivalents and Restricted Cash	19,807	(182,045)	57,997
Cash and Equivalents and Restricted Cash at Beginning of Period	122,925	304,970	246,973
Cash and Equivalents and Restricted Cash at End of Period	142,732	122,925	304,970
Supplemental Cash Flow Disclosure:
Interest paid	35,509	29,070	33,317
Income taxes paid	$ 87,529	$ 94,968	$ 93,575

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restricted cash included in the line item prepaid and other on the Condensed Consolidated Balance Sheets as shown below represents amounts held in escrow.
Cash and equivalents	$ 141,732	$ 122,925	$ 300,137
Restricted cash included in prepaid and other	1,000	0	4,833
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$ 142,732	$ 122,925	$ 304,970	$ 246,973

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION The accompanying consolidated financial statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. AptarGroup’s organizational structure consists of three market-focused business segments which are Pharma, Beauty + Home and Food + Beverage through the year ended December 31, 2022. The COVID-19 pandemic resulted in disruptions to the global economy and supply chains. As the rates of transmission slowed in many regions during 2022, we have seen several of our impacted applications return to more normal (pre-pandemic) volume and growth levels. We have seen improvement in sales of our products to our prescription, beauty, hair care and sun care customers as people return to more active lifestyles. However, we have also experienced volume reductions as applications which benefited from the pandemic, such as our personal cleansing and surface cleaner products, food applications, active material science solutions and injectables components, are now up against challenging comparisons to 2021 volume levels. As of December 31, 2022, the war in Ukraine has not had a significant direct impact on our business, though the near-term visibility for this situation is expected to remain fluid and uncertain for the next several quarters. However, we have experienced some indirect impacts on our business, including higher energy and other input costs as well as certain supply chain disruptions. In late 2017, we began a business transformation plan to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness (see Note 21 – Restructuring Initiatives for further details). The primary focus of the plan was the Beauty + Home segment; however, certain global general and administrative functions have were also addressed. During 2022, 2021 and 2020, we recognized approximately $0.4 million, $23.2 million and $26.5 million, respectively, of restructuring costs related to this plan. As of December 31, 2021, we had completed the vast majority of our planned initiatives related to this plan and do not expect any significant, additional restructuring expenses related to this plan. Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. During the third quarter of 2021, we utilized the Blue Chip Swap and recognized a gain of $1.4 million. Our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues at and for the year ended December 31, 2022. ACCOUNTING ESTIMATES The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). This process requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. CASH AND CASH EQUIVALENTS We consider all investments that are readily convertible to known amounts of cash with an original maturity of three months or less when purchased to be cash equivalents. ACCOUNTS RECEIVABLE AND CURRENT EXPECTED CREDIT LOSSES At December 31, 2022, we reported $677 million of accounts receivable, net of CECL of $9.5 million. The allowance is estimated using reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Changes in CECL were not material for the year ended December 31, 2022. INVENTORIES Inventories are stated at lower of cost or net realizable value. Cost of our inventories is determined by costing methods that approximate a first-in, first-out ("FIFO") basis. Costs included in inventories are raw materials, direct labor and manufacturing overhead. ACQUISITIONS We account for business combinations using the acquisition method, which requires management to estimate the fair value of identifiable assets acquired and liabilities assumed, and to properly allocate purchase price consideration to the individual assets acquired and liabilities assumed. Goodwill is measured as the excess amount of consideration transferred, compared to fair value of the assets acquired and the liabilities assumed. The allocation of the purchase price utilizes significant estimates and assumptions in determining the fair values of identifiable assets acquired and liabilities assumed, especially with respect to intangible assets. These estimates are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset and are reviewed by consulting with outside valuation experts. The purchase price allocation for business acquisitions contains uncertainties because it requires management's judgment. INVESTMENTS IN EQUITY SECURITIES We account for our 20% to 50% owned investments using the equity method. Equity investments that do not result in consolidation and are not accounted for under the equity method are measured at fair value. Any related changes in fair value are recognized in net income unless the investments qualify for a practicality exception. There were no dividends received from affiliated companies in 2022, 2021 and 2020. PROPERTY AND DEPRECIATION Properties are stated at cost. Depreciation is determined on a straight-line basis over the estimated useful lives for financial reporting purposes and accelerated methods for income tax reporting. Generally, the estimated useful lives are 10 to 40 years for buildings and improvements and 3 to 15 years for machinery and equipment. FINITE-LIVED INTANGIBLE ASSETS Finite-lived intangibles, consisting of patents, acquired technology, customer relationships, trademarks and trade names and license agreements acquired in purchase transactions, are capitalized and amortized over their useful lives which range from 1 to 50 years. IMPAIRMENT OF LONG-LIVED ASSETS Long-lived assets, such as property, plant and equipment and finite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset (if any) are less than the carrying value of the asset. GOODWILL The Company has evaluated the excess of purchase price over the fair value of the net assets acquired (“goodwill”) for impairment annually as of October 1 or more frequently if impairment indicators arose in accordance with Accounting Standards Codification (“ASC”) Topic 350, “Intangibles - Goodwill and Other.” We believe that the accounting estimates related to determining the fair value of our reporting units is a critical accounting estimate because: (1) it is highly susceptible to change from period to period because it requires management to make assumptions about the future cash flows for each reporting unit over several years, and (2) the impact that recognizing an impairment would have on the assets reported on our balance sheet as well as our results of operations could be material. Management’s determination of the fair value of our reporting units, based on future cash flows for the reporting units, requires significant judgment and the use of estimates and assumptions related to projected revenue growth rates, the terminal growth factor, as well as the discount rate. Actual cash flows in the future may differ significantly from those forecasted today. The estimates and assumptions for future cash flows and its impact on the impairment testing of goodwill is a critical accounting estimate. Management believes goodwill in purchase transactions has continuing value. Goodwill is not amortized and must be tested annually, or more frequently as circumstances dictate, for impairment. The annual goodwill impairment test may first consider qualitative factors to determine whether it is more likely than not (i.e., greater than 50 percent chance) that the fair value of a reporting unit is less than its book value. This is sometimes referred to as the “step zero” approach and is an optional step in the annual goodwill impairment analysis. Management has performed this qualitative assessment as of October 1, 2022 and October 1, 2021 for each of our reporting units. Based on our review of macroeconomic, industry, and market events and circumstances as well as the overall financial performance of the reporting units, we determined that it was more likely than not that the fair value of these reporting units was greater than their carrying amounts and therefore no impairment of goodwill is required. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Derivative financial instruments are recorded in the Consolidated Balance Sheets at fair value as either assets or liabilities. Changes in the fair value of derivatives are recorded in each period in earnings or other comprehensive income, depending on whether a derivative is designated and effective as part of a hedge transaction. PURCHASE OF TREASURY STOCK During 2022 and 2021, we repurchased 860 thousand and 615 thousand shares, respectively, all of which were returned to treasury stock. In 2020, we did not repurchase any shares of our common stock. If retired, common stock is reduced by the number of shares retired at $0.01 par value per share. We allocate the excess purchase price over par value between additional paid-in capital and retained earnings. RESEARCH & DEVELOPMENT EXPENSES Research and development costs, net of any customer funded research and development or government research and development credits, are expensed as incurred. These costs amounted to $93.5 million, $99.8 million and $92.5 million in 2022, 2021 and 2020, respectively. INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and its reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation on a current or deferred basis. We will provide for the necessary withholding tax, local income taxes, and U.S. federal and state income tax when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. See Note 6 – Income Taxes for more information. We are subject to taxation and file income tax returns in the U.S. federal jurisdiction and many state and foreign jurisdictions. We believe that an adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Consolidated Financial Statements. TRANSLATION OF FOREIGN CURRENCIES The functional currencies of the majority of our foreign operations are their local currencies. Assets and liabilities of our foreign operations are translated into U.S. dollars at the rates of exchange on the balance sheet date. Sales and expenses are translated at the average rates of exchange prevailing during the year. The related translation adjustments are accumulated in a separate section of Stockholders’ Equity. Realized and unrealized foreign currency transaction gains and losses are reflected in income, as a component of miscellaneous income and expense, and represented losses of $7.2 million, $1.4 million and $5.6 million in 2022, 2021 and 2020, respectively. STOCK-BASED COMPENSATION Accounting standards require the application of the non-substantive vesting approach which means that an award is fully vested when the employee’s retention of the award is no longer contingent on providing future service. Under this approach, compensation costs are recognized over the requisite service period of the award instead of ratably over the vesting period stated in the grant. As such, costs are recognized immediately if the employee is retirement eligible on the date of grant or over the period from the date of grant until retirement eligibility if retirement eligibility is reached before the end of the vesting period stated in the grant. Forfeitures are recognized as they occur. See Note 16 – Stock-Based Compensation for more information. REVENUE RECOGNITION At inception of customer contracts, we assess the goods and services promised in order to identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product, tooling and service contract sales; however, we also receive revenues from license, exclusivity and royalty arrangements, which collectively are not material to the results. See specific discussions about methods of accounting for control transfers of product, tooling and service contract sales in Note 2 – Revenue. LEASES We determine if an arrangement is a lease at inception. Operating lease assets are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities are included in Accounts payable accrued and other liabilities in our Consolidated Balance Sheets. Finance leases are included in property, plant and equipment, current maturities of long-term obligations and long-term obligations in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date of the lease in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made as well as initial direct costs incurred and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, we account for the lease and non-lease components as a single lease component. We have elected not to recognize ROU assets and lease liabilities that arise from short-term leases (a lease whose term is 12 months or less and does not include a purchase option that we are reasonably certain to exercise). Certain vehicle lease contracts include guaranteed residual value that is considered in the determination of lease classification. The probability of having to satisfy a residual value guarantee is not considered for the purpose of lease classification, but is considered when measuring a lease liability. GOVERNMENT GRANTS We record non-reimbursable government grants when there is reasonable assurance that we will comply with the relevant conditions of the grant agreement and the grant funds will be received. When a grant is received toward the purchase or construction of an asset, the funds received are recorded as a contra-asset and deducted from the cost of the related asset. Additionally, we record expenses net of reimbursements for government grants from a reimbursement of cost. During 2022, we received a $10.5 million government grant to be used toward the expansion of an existing injectables facility. This award will support the delivery of components for COVID-19 vaccines. The French government will fund approximately $14.0 million for the expansion of the facility, for which there is no clawback option. As of December 31, 2022, we recorded the $10.5 million received as a contra-asset within property, plant and equipment in the Consolidated Balance Sheets and reported in the proceeds from government grants within the investing section of the Consolidated Statements of Cash Flows. During 2022 and 2021, we received $17.3 million and $2.0 million, respectively, in government grants to be used toward the construction of a new facility in Alabama. This award will support expanded domestic production capacity for our active material science solutions proprietary Activ-Film technology, which is used to protect and enhance COVID-19 test kit integrity and accuracy. Under the terms of the grant agreement, the U.S. government will fund approximately $19 million to build an operating facility, for which there is no clawback provision, in exchange for the new facility to be on standby for the government for a period of 16 months after construction. As of December 31, 2022 and 2021, we recorded the $17.3 million and $2.0 million, respectively, received as a contra-asset within property, plant and equipment in the Consolidated Balance Sheets and reported in the proceeds from government grants within the investing section of the Consolidated Statements of Cash Flows. SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program ("SCF") across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. All outstanding amounts related to suppliers participating in the SCF are recorded within Accounts payable, accrued and other liabilities in our Consolidated Balance Sheets, and associated payments are included in operating activities within our Consolidated Statements of Cash Flows. As of December 31, 2022 and 2021, the amounts due to suppliers participating in the SCF and included in Accounts payable, accrued and other liabilities were approximately $30.8 million and $30.1 million, respectively. 2022 2021 SCF obligations outstanding at the beginning of the year $ 30,144 $ 23,000 Additions 133,148 108,439 Settlements (132,459) (101,295) SCF obligations outstanding at the end of the year $ 30,833 $ 30,144 Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain. To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered third party alternatives for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us. ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In September 2022, the FASB issued ASU 2022-04, Liabilities-Supplier Finance Programs (Topic 405), which enhances the transparency of supplier finance programs and requires certain disclosures for a buyer in a supplier finance program. The requirements are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 13, 2023. Early adoption is permitted. We adopted this guidance in the fourth quarter of 2022 and expanded our disclosure to include a roll forward of our supply chain finance program. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy including the nature of the transaction, the financial statement line items affected by the transaction and any significant terms and conditions associated with the transactions. We adopted this guidance in the fourth quarter of 2021 using the prospective approach. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. As of December 31, 2022, we have amended the revolving credit facility to provide mechanics relating to a transition away from LIBOR (in the case of USD) and the designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. We are evaluating any further impact this standard may have on our Consolidated Financial Statements and anticipate no further significant impacts. We plan on adopting this guidance during the second quarter of 2023. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our consolidated financial statements.

REVENUE

REVENUE	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Revenue by segment and geography based on shipped from locations for the years ended December 31, 2022, 2021 and 2020 is as follows: For the Year Ended December 31, 2022 Segment Europe Domestic Latin Asia Total Pharma $ 836,447 $ 426,401 $ 27,075 $ 71,333 $ 1,361,256 Beauty + Home 801,798 373,125 160,827 102,784 1,438,534 Food + Beverage 135,150 300,633 47,561 39,115 522,459 Total $ 1,773,395 $ 1,100,159 $ 235,463 $ 213,232 $ 3,322,249 For the Year Ended December 31, 2021 Segment Europe Domestic Latin Asia Total Pharma $ 830,552 $ 374,063 $ 21,482 $ 58,527 $ 1,284,624 Beauty + Home 765,071 412,761 147,569 108,621 1,434,022 Food + Beverage 129,559 294,999 46,992 37,025 508,575 Total $ 1,725,182 $ 1,081,823 $ 216,043 $ 204,173 $ 3,227,221 For the Year Ended December 31, 2020 Segment Europe Domestic Latin Asia Total Pharma $ 808,834 $ 350,265 $ 23,157 $ 43,523 $ 1,225,779 Beauty + Home 681,936 384,004 141,846 90,365 1,298,151 Food + Beverage 113,286 231,717 29,040 31,367 405,410 Total $ 1,604,056 $ 965,986 $ 194,043 $ 165,255 $ 2,929,340 We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the invoicing for the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance. The opening and closing balances of our contract asset and contract liabilities are as follows: Balance as of December 31, 2021 Balance as of December 31, 2022 Increase/ Contract asset (current) $ 16,878 $ 16,736 $ (142) Contract liability (current) $ 86,340 $ 80,241 $ (6,099) Contract liability (long-term) $ 21,905 $ 25,361 $ 3,456 The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the invoicing. The total amount of revenue recognized during 2022 against contract liabilities is $141.5 million, including $64.2 million relating to contract liabilities at the beginning of the year. Current contract assets and long-term contract assets are included within the Prepaid and Other and Miscellaneous assets, respectively, while current contract liabilities and long-term contract liabilities are included within Accounts Payable, Accrued and Other Liabilities and Deferred and Other Non-current Liabilities, respectively, within our Consolidated Balance Sheets. Determining the Transaction Price In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identifies reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which it will be entitled. Product Sales We primarily manufacture and sell drug delivery, consumer product dispensing and active material science solutions. The amount of consideration is typically fixed for customers. At the time of delivery, the customer is invoiced the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer. To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. For a majority of product sales, control of the goods transfers to the customer at the time of shipment of the goods. Once the goods are shipped, we are precluded from redirecting the shipment to another customer. Therefore, our performance obligation is satisfied at the time of shipment. For sales in which control transfers upon delivery, shipping and/or handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs and revenue is recorded upon final delivery to the customer location. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale. There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress toward completion using the Output Method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks. We believe this measurement provides a faithful depiction of the transfer of goods as the costs incurred reflect the value of the products produced. As a part of its customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties. Tooling Sales We also build or contract for molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress toward completion using the Input Method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any material significant payment terms as payment is typically either received during the mold-build process or shortly after completion. In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of December 31, 2022 or December 31, 2021. Service Sales We also provide services to our pharmaceutical customers. As with product sales, we recognize revenue based on completion of each performance obligation of the service contract. Milestone deliverables and upfront payments are tied to specific performance obligations and recognized upon satisfaction of the individual performance obligation. Contract Costs We do not incur significant costs to obtain or fulfill revenue contracts. Credit Risk We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review. We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables. Current uncertainty in credit and market conditions due to the COVID-19 pandemic, the war in Ukraine, rising interest rates and inflation may slow our collection efforts if customers experience significant difficulty accessing credit and paying their obligations. Retaliatory sanctions imposed by the U.S. and other NATO members in relation to the Russia-Ukraine war could delay payment, which may lead to higher than normal accounts receivable and increased CECL charges. Practical Expedients Significant financing component: We elected not to adjust the promised consideration for the time value of money for contracts where the difference between the time of payment and performance is one year or less. Remaining performance obligations: We elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for our contracts that are one year or less, as the revenue is expected to be recognized within the next year. In addition, we have elected not to disclose the expected consideration related to performance obligations where we recognize revenue in the amount it has a right to invoice (e.g., usage-based pricing terms).

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories, by component net of reserves, consisted of: 2022 2021 Raw materials $ 159,041 $ 140,818 Work in process 153,592 137,654 Finished goods 174,173 162,992 Total $ 486,806 $ 441,464

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amount of goodwill for the year ended December 31, 2022 are as follows by reporting segment: Pharma Beauty + Food + Total Balance as of December 31, 2020 $ 436,731 $ 333,111 $ 128,679 $ 898,521 Acquisition 104,433 — — 104,433 Foreign currency exchange effects (20,967) (7,392) (438) (28,797) Balance as of December 31, 2021 $ 520,197 $ 325,719 $ 128,241 $ 974,157 Acquisitions 3,029 — — 3,029 Foreign currency exchange effects (24,484) (6,708) (362) (31,554) Balance as of December 31, 2022 $ 498,742 $ 319,011 $ 127,879 $ 945,632 We have completed the annual impairment analysis of our reporting units as of October 1, 2022. Based on our review of macroeconomic, industry, and market events and circumstances as well as the overall financial performance of the reporting units, we determined that it was more likely than not that the fair value of these reporting units was greater than their carrying amounts. No impairment was recognized during the years ended December 31, 2022, 2021 or 2020. The table below shows a summary of intangible assets for the years ended December 31, 2022 and 2021. 2022 2021 Weighted Average Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 8.8 $ 8,044 $ (1,968) $ 6,076 $ 2,767 $ (1,528) $ 1,239 Acquired technology 11.5 135,191 (56,628) 78,563 140,936 (45,613) 95,323 Customer relationships 13.4 305,994 (99,130) 206,864 311,964 (77,512) 234,452 Trademarks and trade names 7.2 43,998 (28,190) 15,808 44,893 (22,886) 22,007 License agreements and other 38.6 15,425 (6,992) 8,433 16,179 (6,857) 9,322 Total intangible assets 13.2 $ 508,652 $ (192,908) $ 315,744 $ 516,739 $ (154,396) $ 362,343 Aggregate amortization expense for the intangible assets above for the years ended December 31, 2022, 2021 and 2020 was $43,574, $41,072 and $39,787, respectively. Future estimated amortization expense for the years ending December 31 is as follows: 2023 $ 43,723 2024 40,547 2025 39,061 2026 36,863 2027 29,720 2028 and thereafter 125,830 Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of December 31, 2022.

ACCOUNTS PAYABLE, ACCRUED AND O

ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES	ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES At December 31, 2022 and 2021, Accounts payable, accrued and other liabilities consisted of the following: 2022 2021 Accounts payable, principally trade $ 320,281 $ 285,262 Accrued employee compensation costs 209,566 195,308 Customer deposits and other unearned income 80,113 86,953 Other accrued liabilities 184,425 125,342 Total $ 794,385 $ 692,865

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income before income taxes consists of: Years Ended December 31, 2022 2021 2020 United States $ 65,350 $ 101,353 $ 91,555 International 269,354 220,302 209,600 Total $ 334,704 $ 321,655 $ 301,155 The provision (benefit) for income taxes is composed of: Years Ended December 31, 2022 2021 2020 Current: U.S. Federal $ 12,791 $ 11,932 $ 9,934 State/Local 2,265 4,917 3,094 International 92,199 75,524 82,235 $ 107,255 $ 92,373 $ 95,263 Deferred: U.S. Federal/State $ (882) $ (11,168) $ (2,270) International (11,224) (3,188) (5,928) $ (12,106) $ (14,356) $ (8,198) Total $ 95,149 $ 78,017 $ 87,065 A reconciliation of the provision for income taxes with the amount computed by applying the statutory federal income tax rate of 21% to income before provision for income taxes is as follows: Years Ended December 31, 2022 2021 2020 Income tax at statutory rate $ 70,288 $ 67,547 $ 63,243 State income taxes, net of federal tax effect 1,475 1,616 2,396 Excess tax benefits from share-based compensation (3,306) (16,060) (11,625) Deferred tax (benefits) charges, incl. tax rate changes (2,349) (1,040) 4,110 U.S. Global Intangible Low-Taxed Income ("GILTI") and Base Erosion Anti-Abuse Tax ("BEAT") 3,129 — (3,909) Valuation allowance 1,486 4,485 1,332 Legal entity reorganization 5,850 — — Rate differential on earnings of foreign operations 19,165 20,831 24,901 Other items, net (589) 638 6,617 Actual income tax provision $ 95,149 $ 78,017 $ 87,065 Effective income tax rate 28.4 % 24.3 % 28.9 % The 2022 effective tax rate of 28.4% includes a $5.9 million charge for taxes related to a legal entity reorganization intended to enhance our dividend and cash management capabilities. Excluding this impact, the effective tax rate was 26.7%. The provision for income tax is favorably impacted by excess tax benefits on deductible share-based compensation. The tax provision for 2022 reflects a $3.3 million benefit from this item compared with a $16.1 million and $11.6 million tax benefit for 2021 and 2020, respectively. Valuation allowances against deferred tax assets are comprised of cumulative losses, credits and other timing differences. Our mix of earnings has an unfavorable tax rate impact since a majority of our pretax income is earned in higher tax jurisdictions. Significant deferred tax assets and liabilities as of December 31, 2022 and 2021 are composed of the following temporary differences: 2022 2021 Deferred Tax Assets: Net operating loss carryforwards $ 45,823 $ 47,660 Operating and finance leases 20,974 22,492 Pension liabilities 8,178 29,770 Share-based compensation 9,970 6,764 U.S. federal tax credits — 4,226 U.S. state tax credits 6,777 7,047 Vacation and bonus 14,681 13,450 U.S. capitalized research expenditures 27,840 19,633 Inventory 4,736 6,969 Accrued liabilities and other reserves 10,346 3,109 Other 11,744 16,194 Total gross deferred tax assets $ 161,069 $ 177,314 Less valuation allowance (46,239) (47,149) Net deferred tax assets $ 114,830 $ 130,165 Deferred Tax Liabilities: Acquisition related intangibles $ 59,084 $ 68,174 Depreciation and amortization 29,142 30,997 Operating and finance leases 23,041 24,560 Other 6,563 7,489 Total gross deferred tax liabilities $ 117,830 $ 131,220 Net deferred tax liabilities $ (3,000) $ (1,055) We evaluate the deferred tax assets and record a valuation allowance when it is believed it is more likely than not that the benefit will not be realized. We have established a valuation allowance for $39.2 million of the $45.8 million of tax effected net operating loss carryforwards. These losses are generally in locations that have not produced cumulative three year operating profit. A valuation allowance of $4.0 million has also been established against the $6.8 million of U.S. state tax credit carryforwards. There is no expiration date on $42.5 million of the tax-effected net operating loss carryforwards and $3.3 million (tax effected) will expire in the years 2023 to 2042. The U.S. state tax credit carryforwards of $6.8 million (tax effected) will expire in the years 2023 to 2037. None of the earnings accumulated outside of the U.S. will be subject to U.S. taxation under the current U.S. federal income tax laws. Aside from the earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia, we maintain our assertion that all other cash and distributable reserves at our non-U.S. affiliates will continue to be indefinitely reinvested. We estimate the amount of additional local income tax and withholding tax that would be payable on distributions to be in the range of $15 million to $20 million if earnings accumulated outside the U.S. are repatriated to the U.S. We have not provided for taxes on certain tax-deferred income related to a foreign operation. The income arose predominately from government grants. Taxes of approximately $1.3 million would become payable in the event the terms of the grant are not fulfilled. Income Tax Uncertainties We provide a liability for the amount of tax benefits realized from uncertain tax positions. A reconciliation of the beginning and ending amount of income tax uncertainties is as follows: 2022 2021 2020 Balance at January 1 $ 7,225 $ 4,504 $ 3,647 Increases based on tax positions for the current year 1,433 262 212 Increases based on tax positions of prior years 966 3,348 790 Decreases based on tax positions of prior years (2,582) — — Settlements (80) (567) — Lapse of statute of limitations (43) (322) (145) Balance at December 31 $ 6,919 $ 7,225 $ 4,504 The amount of income tax uncertainties that, if recognized, would impact the effective tax rate is approximately $6.9 million. We estimate that it is reasonably possible that the liability for uncertain tax positions will decrease by approximately $3.4 million in the next twelve months from the resolution of various uncertain positions as a result of the completion of tax audits, litigation and the expiration of the statute of limitations in various jurisdictions. We recognize interest and penalties accrued related to unrecognized tax benefits as a component of income taxes. As of December 31, 2022, 2021 and 2020, we had approximately $4.9 million, $4.6 million and $3.6 million, respectively, accrued for the payment of interest and penalties, of which approximately $0.3 million, $1.1 million and $1.7 million was recognized in income tax expense for the years ended December 31, 2022, 2021 and 2020, respectively. Aptar or its subsidiaries file income tax returns in the U.S. Federal jurisdiction and various state and foreign jurisdictions. The major tax jurisdictions we file in, with the years still subject to income tax examinations, are listed below: Major Tax Tax Years United States — Federal 2019-2022 United States — State 2018-2022 France 2019-2022 Germany 2018-2022 Italy 2016-2022 China 2012-2022

DEBT

DEBT	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
DEBT	DEBT Revolving Credit Facility and Overdrafts At December 31, 2022 and 2021, our revolving credit facility and overdrafts consisted of the following: 2022 2021 Revolving credit facility 1.68% $ — $ 144,383 Overdrafts 15.37% 3,810 2,893 $ 3,810 $ 147,276 On June 30, 2021, we entered into an amended and restated multi-currency revolving credit facility (the "revolving credit facility") with a syndicate of banks to replace the then-existing facility maturing July 2022 (the "prior credit facility") and to amend and restate the unsecured term loan facility extended to our wholly-owned UK subsidiary under the prior credit facility (as amended, the "amended term facility"). The revolving credit facility matures in June 2026, subject to a maximum of two one-year extensions in certain circumstances, and provides for unsecured financing of up to $600 million available in the U.S. and to our wholly-owned UK subsidiary. The amended term facility matured in July 2022 and was repaid in full. The revolving credit facility can be drawn in various currencies including USD, EUR, GBP, and CHF to the equivalent of $600 million, which may be increased by up to $300 million subject to the satisfaction of certain conditions. As of December 31, 2022, there were no borrowings under the revolving credit facility in the U.S. or by our wholly-owned UK subsidiary. As of December 31, 2021, $133 million was utilized under the revolving credit facility in the U.S., €10 million (approximately $11.4 million based on the exchange rates at the end of 2021) was utilized by our wholly-owned UK subsidiary and $56 million remained outstanding under the amended term facility. There are no compensating balance requirements associated with our revolving credit facility. Each borrowing under the revolving credit facility will bear interest at rates based on LIBOR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. The revolving credit facility provides mechanics relating to a transition away from LIBOR (in the case of USD) and the designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. We incurred approximately $1.2 million and $1.1 million in interest and fees related to our credit facility during 2022 and 2021, respectively. Average borrowings under the revolving credit facility and notes payable were $38.5 million and $37.8 million for 2022 and 2021, respectively. The average annual interest rate on the revolving credit facility and notes payable was 1.2% and 1.1% for 2022 and 2021, respectively. In October 2020, we entered into an unsecured money market borrowing arrangement to provide short term financing of up to $30 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of December 31, 2022 or December 31, 2021. Long-Term Obligations On March 7, 2022, we issued $400 million aggregate principal amount of 3.60% Senior Notes due March 2032 in an underwritten public offering. The form and terms of the notes were established pursuant to an Indenture, dated as of March 7, 2022, as amended and supplemented by a First Supplemental Indenture, dated as of March 7, 2022, each between the Company and U.S. Bank Trust Company, National Association, as trustee. Interest is payable semi-annually in arrears. The notes are unsecured obligations and rank equally in right of payment with all of our other existing and future senior, unsecured indebtedness. We redeemed all $75.0 million of our 3.25% senior unsecured notes during the second quarter of 2022 at a price equal to the principal amount plus accrued interest and a $0.4 million make-whole payment. We redeemed all $125.0 million of our 3.49% senior unsecured notes during the third quarter of 2022 at a price equal to the principal amount plus accrued interest. At December 31, 2022 and 2021, our long-term obligations consisted of the following: December 31, 2022 December 31, 2021 Notes payable 0.00% – 16.42%, due in monthly and annual installments through 2030 $ 29,167 $ 22,785 Senior unsecured notes 3.2%, due in 2022 — 75,000 Senior unsecured debts 2.19% USD floating swapped to 1.36% EUR fixed, due in 2022 — 56,000 Senior unsecured notes 3.5%, due in 2023 — 125,000 Senior unsecured notes 1.0%, due in 2023 106,995 113,830 Senior unsecured notes 3.4%, due in 2024 50,000 50,000 Senior unsecured notes 3.5%, due in 2024 100,000 100,000 Senior unsecured notes 1.2%, due in 2024 213,990 227,660 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Senior unsecured notes 3.6%, due in 2032, net of discount of $1.0 million 399,050 — Finance Lease Liabilities 26,934 30,185 Unamortized debt issuance costs (4,558) (1,085) $ 1,171,578 $ 1,049,375 Current maturities of long-term obligations (118,981) (142,351) Total long-term obligations $ 1,052,597 $ 907,024 The aggregate long-term maturities, excluding finance lease liabilities, which are discussed in Note 8, due annually for the next five years and thereafter are: 2023 $ 115,815 2024 369,183 2025 133,313 2026 131,647 2027 73 Thereafter 399,171 Covenants Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at December 31, 2022 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.71 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 15.00 to 1.00 (1) Definitions of ratios are included as part of the revolving credit facility agreement and the private placement agreements.

LEASE COMMITMENTS

LEASE COMMITMENTS	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
LEASE COMMITMENTS	LEASE COMMITMENTS We lease certain warehouse, plant, and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2034. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”). The components of lease expense for the years ended December 31, 2022 and 2021 were as follows: Year Ended December 31, 2022 2021 Operating lease cost $ 21,105 $ 23,040 Finance lease cost: Amortization of right-of-use assets $ 4,249 $ 4,228 Interest on lease liabilities 1,249 1,360 Total finance lease cost $ 5,498 $ 5,588 Short-term lease and variable lease costs $ 15,454 $ 12,259 Supplemental cash flow information related to leases was as follows: Year Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 20,488 $ 22,821 Operating cash flows from finance leases 1,264 1,374 Financing cash flows from finance leases 3,662 4,349 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 16,754 $ 17,785 Finance leases 1,011 5,922 Supplemental balance sheet information related to leases was as follows: December 31, December 31, Operating Leases Operating lease right-of-use assets $ 58,675 $ 62,454 Accounts payable, accrued and other liabilities $ 16,985 $ 15,356 Operating lease liabilities 42,948 48,010 Total operating lease liabilities $ 59,933 $ 63,366 Finance Leases Property, plant and equipment, gross $ 50,173 $ 51,821 Accumulated depreciation (12,781) (9,864) Property, plant and equipment, net $ 37,392 $ 41,957 Current maturities of long-term obligations, net of unamortized debt issuance cost $ 3,234 $ 3,744 Long-term obligations, net of unamortized debt issuance cost 23,700 26,441 Total finance lease liabilities $ 26,934 $ 30,185 Weighted Average Remaining Lease Term (in years) Operating leases 4.6 5.2 Finance leases 6.6 7.4 Weighted Average Discount Rate Operating leases 4.01 % 3.80 % Finance leases 4.76 % 4.62 % Maturities of lease liabilities as of December 31, 2022, were as follows: Operating Finance Year 1 $ 19,193 $ 4,454 Year 2 14,414 3,691 Year 3 10,011 3,572 Year 4 8,479 2,807 Year 5 6,908 6,003 Thereafter 6,860 11,832 Total lease payments 65,865 32,359 Less imputed interest (5,932) (5,425) Total $ 59,933 $ 26,934 As of December 31, 2022, we have additional operating leases that have not yet commenced of $0.4 million and no finance leases that have not yet commenced. These operating leases will commence in 2023 with lease terms of 3 to 5 years.
LEASE COMMITMENTS	LEASE COMMITMENTS We lease certain warehouse, plant, and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2034. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”). The components of lease expense for the years ended December 31, 2022 and 2021 were as follows: Year Ended December 31, 2022 2021 Operating lease cost $ 21,105 $ 23,040 Finance lease cost: Amortization of right-of-use assets $ 4,249 $ 4,228 Interest on lease liabilities 1,249 1,360 Total finance lease cost $ 5,498 $ 5,588 Short-term lease and variable lease costs $ 15,454 $ 12,259 Supplemental cash flow information related to leases was as follows: Year Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 20,488 $ 22,821 Operating cash flows from finance leases 1,264 1,374 Financing cash flows from finance leases 3,662 4,349 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 16,754 $ 17,785 Finance leases 1,011 5,922 Supplemental balance sheet information related to leases was as follows: December 31, December 31, Operating Leases Operating lease right-of-use assets $ 58,675 $ 62,454 Accounts payable, accrued and other liabilities $ 16,985 $ 15,356 Operating lease liabilities 42,948 48,010 Total operating lease liabilities $ 59,933 $ 63,366 Finance Leases Property, plant and equipment, gross $ 50,173 $ 51,821 Accumulated depreciation (12,781) (9,864) Property, plant and equipment, net $ 37,392 $ 41,957 Current maturities of long-term obligations, net of unamortized debt issuance cost $ 3,234 $ 3,744 Long-term obligations, net of unamortized debt issuance cost 23,700 26,441 Total finance lease liabilities $ 26,934 $ 30,185 Weighted Average Remaining Lease Term (in years) Operating leases 4.6 5.2 Finance leases 6.6 7.4 Weighted Average Discount Rate Operating leases 4.01 % 3.80 % Finance leases 4.76 % 4.62 % Maturities of lease liabilities as of December 31, 2022, were as follows: Operating Finance Year 1 $ 19,193 $ 4,454 Year 2 14,414 3,691 Year 3 10,011 3,572 Year 4 8,479 2,807 Year 5 6,908 6,003 Thereafter 6,860 11,832 Total lease payments 65,865 32,359 Less imputed interest (5,932) (5,425) Total $ 59,933 $ 26,934 As of December 31, 2022, we have additional operating leases that have not yet commenced of $0.4 million and no finance leases that have not yet commenced. These operating leases will commence in 2023 with lease terms of 3 to 5 years.

RETIREMENT AND DEFERRED COMPENS

RETIREMENT AND DEFERRED COMPENSATION PLANS	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
RETIREMENT AND DEFERRED COMPENSATION PLANS	RETIREMENT AND DEFERRED COMPENSATION PLANS We have various noncontributory retirement plans covering certain of our domestic and foreign employees. Benefits under our retirement plans are based on participants’ years of service and annual compensation as defined by each plan. Annual cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Certain pension commitments under our foreign plans are also funded according to local requirements or at our discretion. Effective January 1, 2021, our domestic noncontributory retirement plans were closed to new employees and employees who were rehired after December 31, 2020. These employees are instead eligible for additional contribution to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 are still eligible for the domestic pension plans and continue to accrue plan benefits after this date. The following table presents the changes in the benefit obligations and plan assets for the most recent two years for our domestic and foreign plans. Domestic Plans Foreign Plans 2022 2021 2022 2021 Change in benefit obligation: Benefit obligation at beginning of year $ 255,457 $ 272,471 $ 123,386 $ 134,426 Service cost 15,784 16,356 7,547 8,159 Interest cost 6,970 6,366 1,388 843 Curtailment/Settlement — — 68 5 Prior service cost — — 813 — Actuarial gain (92,724) (18,526) (26,826) (6,489) Benefits paid (21,615) (21,210) (4,615) (4,555) Foreign currency translation adjustment — — (7,762) (9,003) Benefit obligation at end of year $ 163,872 $ 255,457 $ 93,999 $ 123,386 Domestic Plans Foreign Plans 2022 2021 2022 2021 Change in plan assets: Fair value of plan assets at beginning of year $ 193,770 $ 192,034 $ 85,421 $ 85,087 Actual return on plan assets (25,517) 22,480 (4,897) 2,811 Employer contribution 15,513 466 1,871 7,966 Benefits paid (21,615) (21,210) (4,615) (4,555) Transfer — — — 124 Foreign currency translation adjustment — — (5,257) (6,012) Fair value of plan assets at end of year $ 162,151 $ 193,770 $ 72,523 $ 85,421 Funded status at end of year $ (1,721) $ (61,687) $ (21,476) $ (37,965) The following table presents the funded status amounts recognized in our Consolidated Balance Sheets as of December 31, 2022 and 2021. Domestic Plans Foreign Plans 2022 2021 2022 2021 Non-current assets $ 9,304 $ — $ — $ 1,832 Current liabilities (515) (500) (31) (33) Non-current liabilities (10,510) (61,187) (21,445) (39,764) $ (1,721) $ (61,687) $ (21,476) $ (37,965) The following table presents the amounts not recognized as components of periodic benefit cost that are recognized in accumulated other comprehensive (gain) loss as of December 31, 2022 and 2021. Domestic Plans Foreign Plans 2022 2021 2022 2021 Net actuarial (gain) loss $ (3,338) $ 57,627 $ 11,383 $ 32,269 Net prior service cost — — 1,150 509 Tax effects 2,271 (12,873) (5,518) (11,049) $ (1,067) $ 44,754 $ 7,015 $ 21,729 Changes in benefit obligations and plan assets recognized in other comprehensive income in 2022, 2021 and 2020 are as follows: Domestic Plans 2022 2021 2020 Current year actuarial gain (loss) $ 54,295 $ 28,714 $ (33,335) Amortization of net loss 6,670 10,099 5,684 $ 60,965 $ 38,813 $ (27,651) Foreign Plans 2022 2021 2020 Current year actuarial gain (loss) $ 19,181 $ 6,257 $ (2,530) Current year prior service cost (818) — 2,701 Transfer actuarial loss 17 — — Amortization of net loss 1,688 2,325 2,121 Amortization of prior service cost 177 166 398 $ 20,245 $ 8,748 $ 2,690 Components of net periodic benefit cost: Domestic Plans 2022 2021 2020 Service cost $ 15,784 $ 16,356 $ 14,278 Interest cost 6,970 6,366 7,046 Expected return on plan assets (12,912) (12,293) (12,248) Amortization of net loss 6,670 10,099 5,684 Net periodic benefit cost $ 16,512 $ 20,528 $ 14,760 Foreign Plans 2022 2021 2020 Service cost $ 7,547 $ 8,159 $ 7,311 Interest cost 1,388 843 1,410 Expected return on plan assets (2,728) (2,838) (2,620) Amortization of net loss 1,688 2,325 2,121 Amortization of prior service cost 177 166 398 Net periodic benefit cost $ 8,072 $ 8,655 $ 8,620 Curtailment (24) 5 (8) Total Net periodic benefit cost $ 8,048 $ 8,660 $ 8,612 The accumulated benefit obligation (“ABO”) for our domestic defined benefit pension plans was $152.4 million and $236.3 million at 2022 and 2021, respectively. The ABO for our foreign defined benefit pension plans was $73.8 million and $96.0 million at December 31, 2022 and 2021, respectively. The following table provides the projected benefit obligation (“PBO”), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets as of December 31, 2022 and 2021. Domestic Plans Foreign Plans 2022 2021 2022 2021 Projected benefit obligation $ 11,025 $ 255,457 $ 54,455 $ 89,595 Accumulated benefit obligation 10,087 236,295 40,481 63,614 Fair value of plan assets — 193,770 34,446 49,916 The following table provides the PBO, ABO and fair value of plan assets for all pension plans with a PBO in excess of plan assets as of December 31, 2022 and 2021. Domestic Plans Foreign Plans 2022 2021 2022 2021 Projected benefit obligation $ 11,025 $ 255,457 $ 71,730 $ 97,221 Accumulated benefit obligation 10,087 236,295 52,173 69,630 Fair value of plan assets — 193,770 47,236 56,228 Assumptions: Domestic Plans Foreign Plans 2022 2021 2020 2022 2021 2020 Weighted-average assumptions used to determine benefit obligations at December 31: Discount rate 5.15 % 2.75 % 2.40 % 3.69 % 1.09 % 0.54 % Rate of compensation increase 3.20 % 3.17 % 3.19 % 3.21 % 3.05 % 3.05 % Weighted-average assumptions used to determine net periodic benefit cost for years ended December 31: Discount rate 2.75 % 2.40 % 3.20 % 1.20 % 0.66 % 1.12 % Expected long-term return on plan assets 7.00 % 7.00 % 7.00 % 3.53 % 3.56 % 3.59 % Rate of compensation increase 3.20 % 3.17 % 4.00 % 3.20 % 3.05 % 3.05 % We develop the expected long-term rate of return assumptions based on historical experience and by evaluating input from the plans’ asset managers, including the managers’ review of asset class return expectations and benchmarks, economic indicators and long-term inflation assumptions. In order to determine the 2023 net periodic benefit cost, we expect to use the December 31, 2022 discount rates, December 31, 2022 rates of compensation increase assumptions and the same assumed long-term returns on domestic and foreign plan assets used for the 2022 net periodic benefit cost. Our domestic and foreign pension plan weighted-average asset allocations at December 31, 2022 and 2021 by asset category are as follows: Plan Assets: Domestic Plans Assets at December 31, Foreign Plans Assets at December 31, 2022 2021 2022 2021 Equity securities 47 % 48 % 5 % 6 % Fixed income securities 27 % 27 % 1 % 1 % Corporate debt securities — — 1 % 2 % Infrastructure 8 % 8 % — — Hedge funds 10 % 11 % — — Money market 1 % 1 % 1 % 1 % Investment Funds — — 92 % 90 % Real estate 7 % 5 % — — Total 100 % 100 % 100 % 100 % Our investment strategy for our domestic and foreign pension plans is to maximize the long-term rate of return on plan assets within an acceptable level of risk. The investment policy strives to have assets sufficiently diversified so that adverse or unexpected results from one security type will not have an unduly detrimental impact on the entire portfolio and accordingly, establishes a target allocation for each asset category within the portfolio. The domestic plan asset allocation is reviewed on a quarterly basis and the foreign plan asset allocation is reviewed annually. Rebalancing occurs as needed to comply with the investment strategy. The domestic plan target allocation for 2023 is 58% equity securities and 42% fixed income securities and infrastructure. The foreign plan target allocation for 2023 is 100% investment funds. Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows: • Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities. • Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. • Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability. Domestic Fair Value Measurement at December 31, 2022 Foreign Fair Value Measurement at December 31, 2022 (In Thousands $) Total (Level 1) (Level 2) (Level 3) Total (Level 1) (Level 2) (Level 3) Cash and Short-term Securities (a) $ 1,260 $ 1,260 $ — $ — $ 516 $ 516 $ — $ — USD — 1,260 — — — — — — EUR — — — — — 505 — — Others — — — — — 11 — — Equity Securities (a) $ 66,338 $ 66,338 $ — $ — $ 3,769 $ 3,769 $ — $ — U.S. Large Cap Equities — 37,537 — — — — — — U.S. Small Cap Equities — 7,918 — — — — — — International Equities — 20,883 — — — 3,769 — — Fixed Income (a)(b) $ 28,443 $ 28,443 $ — $ — $ 723 $ 723 $ — $ — Corporate debts securities $ — $ — $ — $ — $ 1,135 $ 1,135 $ — $ — Euro Corporate Bonds (a) — — — — — 1,135 — — Investment Funds $ — $ — $ — $ — $ 66,380 $ 21,952 $ 44,428 $ — Mutual Funds in Equities (a) — — — — — 5,221 — — Mutual Funds in Bonds (a) — — — — — 15,901 — — Mutual Funds Diversified (a)(b) — — — — — 830 44,428 — Total Investments in Fair Value Hierarchy $ 96,041 $ 96,041 $ — $ — $ 72,523 $ 28,095 $ 44,428 $ — Investments at Net Asset Value per Share 66,110 — — — — — — — Total Investments $ 162,151 $ 96,041 $ — $ — $ 72,523 $ 28,095 $ 44,428 $ — Domestic Fair Value Measurement at December 31, 2021 Foreign Fair Value Measurement at December 31, 2021 (In Thousands $) Total (Level 1) (Level 2) (Level 3) Total (Level 1) (Level 2) (Level 3) Cash and Short-term Securities (a) $ 1,864 $ 1,864 $ — $ — $ 547 $ 547 $ — $ — USD — 1,864 — — — — — — EUR — — — — — 539 — — Others — — — — — 8 — — Equity Securities (a) $ 82,927 $ 82,927 $ — $ — $ 4,881 $ 4,881 $ — $ — U.S. Large Cap Equities — 49,637 — — — — — — U.S. Small Cap Equities — 9,112 — — — — — — International Equities — 24,178 — — — 4,881 — — Fixed Income (a)(b) $ 34,584 $ 34,584 $ — $ — $ 772 $ 772 $ — $ — Corporate debts securities $ — $ — $ — $ — $ 1,413 $ 1,413 $ — $ — Euro Corporate Bonds (a) — — — — — 1,413 — — Investment Funds $ — $ — $ — $ — $ 77,808 $ 26,381 $ 51,427 $ — Mutual Funds in Equities (a) — — — — — 4,576 — — Mutual Funds in Bonds (a) — — — — — 20,810 — — Mutual Funds Diversified (a)(b) — — — — — 995 51,427 — Total Investments in Fair Value Hierarchy $ 119,375 $ 119,375 $ — $ — $ 85,421 $ 33,994 $ 51,427 $ — Investments at Net Asset Value per Share 74,395 — — — — — — — Total Investments $ 193,770 $ 119,375 $ — $ — $ 85,421 $ 33,994 $ 51,427 $ — (a) Based on third party quotation from financial institution. (b) Based on observable market transactions. Contributions Annual cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by ERISA. We contributed $15.5 million to our domestic defined benefit plans in 2022 and although we have no minimum funding requirement, we plan to contribute approximately $0.5 million to pay our ongoing SERP annuity contracts in 2023. Contributions to fund pension costs accrued under our foreign plans are made in accordance with local laws or at our discretion. We contributed approximately $1.9 million to our foreign defined benefit plan in 2022 and expect to contribute approximately $0.5 million in 2023. Estimated Future Benefit Payments As of December 31, 2022, we expect the plans to make the following estimated benefit payments relating to our defined benefit plans over the next ten years: Domestic Plans Foreign Plans 2023 $ 10,184 $ 2,652 2024 10,948 4,781 2025 11,241 6,658 2026 12,743 5,136 2027 11,828 7,700 2028 - 2032 70,372 38,262 Other Plans We have a non-qualified supplemental pension plan for domestic employees which provides for pension amounts that would have been payable from our principal domestic pension plan if it were not for limitations imposed by income tax regulations. The liability for this plan, which is not funded, was $11.0 million and $14.9 million at December 31, 2022 and 2021, respectively. This amount is included in the liability for domestic plans shown above. We have a defined contribution 401(k) employee savings plan ("401(k) plan") available to substantially all domestic employees. Company matching contributions are made in cash up to a maximum of 3% of the participating employee’s salary subject to income tax regulations. For each of the years ended December 31, 2022, 2021 and 2020, total contributions made to these plans were approximately $5.0 million, $4.5 million and $4.3 million, respectively. As discussed above, domestic employees hired after December 31, 2020 will no longer be eligible for the pension plans and will instead receive an annual Aptar Retirement Savings Account contribution of 5% of their eligible earnings in the 401(k) plan. For the years ended December 31, 2022 and 2021, total contributions for these eligible employees was approximately $2.0 million and $0.7 million, respectively. We have several foreign defined contribution plans, which require us to contribute a percentage of the participating employee’s salary according to local regulations. For each of the years ended December 31, 2022, 2021 and 2020, total contributions made to these plans were approximately $2.9 million, $2.9 million and $2.4 million, respectively. We have no additional postretirement or postemployment benefit plans.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)	12 Months Ended
	Dec. 31, 2022
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)	ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) Changes in Accumulated Other Comprehensive Income/(Loss) by Component: Foreign Defined Benefit Derivatives Total Balance - December 31, 2019 $ (257,124) $ (83,147) $ (1,677) $ (341,948) Other comprehensive (loss) income before reclassifications 79,099 (25,389) (9,172) 44,538 Amounts reclassified from accumulated other comprehensive income — 6,214 9,487 15,701 Net current-period other comprehensive (loss) income 79,099 (19,175) 315 60,239 Balance - December 31, 2020 $ (178,025) $ (102,322) $ (1,362) $ (281,709) Other comprehensive income (loss) before reclassifications (71,475) 26,409 8,584 (36,482) Amounts reclassified from accumulated other comprehensive income (loss) — 9,427 (7,277) 2,150 Net current-period other comprehensive income (loss) (71,475) 35,836 1,307 (34,332) Balance - December 31, 2021 $ (249,500) $ (66,486) $ (55) $ (316,041) Other comprehensive (loss) income before reclassifications (79,240) 54,149 (6,666) (31,757) Amounts reclassified from accumulated other comprehensive income — 6,386 46 6,432 Net current-period other comprehensive (loss) income (79,240) 60,535 (6,620) (25,325) Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366) Reclassifications Out of Accumulated Other Comprehensive Income/(Loss): Details about Accumulated Other Amount Reclassified from Affected Line in the Statement Year Ended December 31, 2022 2021 2020 Defined Benefit Pension Plans Amortization of net loss $ 8,358 $ 12,424 $ 7,805 (1) Amortization of prior service cost 177 166 398 (1) 8,535 12,590 8,203 Total before tax (2,149) (3,163) (1,989) Tax benefit $ 6,386 $ 9,427 $ 6,214 Net of tax Derivatives Changes in cross currency swap: interest component $ (171) $ (13) $ (1,474) Interest Expense Changes in cross currency swap: foreign exchange component 217 (7,264) 10,961 Miscellaneous, net 46 (7,277) 9,487 Total before tax — — — Tax benefit $ 46 $ (7,277) $ 9,487 Net of tax Total reclassifications for the period $ 6,432 $ 2,150 $ 15,701 (1) These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax (see Note 9 - Retirement and Deferred Compensation Plans for additional details).

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks. For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Consolidated Balance Sheets (See Note 12 – Fair Value). Cash Flow Hedge For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Consolidated Statements of Cash Flows. In 2017 our wholly owned UK subsidiary borrowed $280 million in term loan borrowings under our prior credit facility. In order to mitigate the currency risk of U.S. dollar debt on a euro functional currency entity and to mitigate the risk of variability in interest rates, we entered into a EUR/USD floating-to-fixed cross currency swap on July 20, 2017 in the notional amount of $280 million to effectively hedge the foreign exchange and interest rate exposure on the $280 million term loan. This EUR/USD swap agreement fixed our U.S. dollar floating-rate debt to 1.36% euro fixed-rate debt. The swap agreement expired on July 20, 2022. Net Investment Hedge A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign entities. A weakening U.S. dollar relative to foreign currencies has an additive translation effect on our financial condition and results of operations. Conversely, a strengthening U.S. dollar has a dilutive effect. In some cases we maintain debt in these subsidiaries to offset the net asset exposure. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction. On July 6, 2022, we entered into a seven year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203 million of the $400 million 3.60% Senior Notes due March 2032, which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged $203 million of fixed-rate 3.60% USD debt to €200 million of fixed-rate 2.5224% EUR debt. We pay semi-annual fixed rate interest payments on the euro notional amount of €2.5 million and receive semi-annual fixed rate interest payments on the USD notional amount of $3.7 million. This swap has been designated as a net investment hedge to effectively hedge the foreign exchange risk associated with €200 million of our euro denominated net assets. We elected the spot method for recording the net investment hedge. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense in the Consolidated Statements of Income. Gains and losses resulting from the fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. As of December 31, 2022, the fair value of the cross currency swap was a $8.8 million liability. The swap agreement will mature on September 15, 2029. Other As of December 31, 2022, we have recorded the fair value of foreign currency forward exchange contracts of $1.1 million in prepaid and other and $0.3 million in Accounts payable, accrued and other liabilities in the balance sheet. All forward exchange contracts outstanding as of December 31, 2022 had an aggregate notional contract amount of $52.2 million. Fair Value of Derivative Instruments in the Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021 December 31, 2022 December 31, 2021 Balance Sheet Derivatives Derivatives Derivatives Derivatives Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 1,107 $ — $ 331 Cross Currency Swap Contract (1) Prepaid and other — — 511 — $ — $ 1,107 $ 511 $ 331 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 269 $ — $ 221 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 8,840 — — — $ 8,840 $ 269 $ — $ 221 (1) This cross currency swap contract is composed of both an interest component and a foreign exchange component. The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Fiscal Years Ended December 31, 2022 and December 31, 2021 Derivatives in Cash Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount 2022 2021 2022 2021 Cross currency swap contract: Interest component $ 229 $ 1,319 Interest expense $ 171 $ 13 $ (40,827) Foreign exchange component (6,894) 7,265 Miscellaneous, net (217) 7,264 (4,799) $ (6,665) $ 8,584 $ (46) $ 7,277 The Effect of Derivatives Not Designated as Hedging Instruments on the Consolidated Statements of Income for the Fiscal Years Ended December 31, 2022 and December 31, 2021 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2022 2021 Foreign Exchange Contracts Other (Expense) Income: $ 606 $ (87) $ 606 $ (87) Gross Amounts Net Amounts Gross Amounts not Offset Gross Financial Cash Collateral Net Description December 31, 2022 Derivative Assets $ 1,107 $ — $ 1,107 $ — $ — $ 1,107 Total Assets $ 1,107 $ — $ 1,107 $ — $ — $ 1,107 Derivative Liabilities $ 9,109 $ — $ 9,109 $ — $ — $ 9,109 Total Liabilities $ 9,109 $ — $ 9,109 $ — $ — $ 9,109 December 31, 2021 Derivative Assets $ 842 $ — $ 842 $ — $ — $ 842 Total Assets $ 842 $ — $ 842 $ — $ — $ 842 Derivative Liabilities $ 221 $ — $ 221 $ — $ — $ 221 Total Liabilities $ 221 $ — $ 221 $ — $ — $ 221

FAIR VALUE

FAIR VALUE	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows: • Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities. • Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. • Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability. As of December 31, 2022, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 5,297 $ 5,297 $ — $ — Foreign exchange contracts (2) 1,107 — 1,107 — Convertible notes 5,650 — — 5,650 Total assets at fair value $ 12,054 $ 5,297 $ 1,107 $ 5,650 Liabilities Foreign exchange contracts (2) $ 269 $ — $ 269 $ — Cross currency swap contract (2) 8,840 — 8,840 — Contingent consideration obligation 25,310 — — 25,310 Total liabilities at fair value $ 34,419 $ — $ 9,109 $ 25,310 As of December 31, 2021, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 9,006 $ 9,006 $ — $ — Foreign exchange contracts (2) 331 — 331 — Cross currency swap contract (2) 511 — 511 — Total assets at fair value $ 9,848 $ 9,006 $ 842 $ — Liabilities Foreign exchange contracts (2) $ 221 $ — $ 221 $ — Contingent consideration obligation 33,908 — — 33,908 Total liabilities at fair value $ 34,129 $ — $ 221 $ 33,908 (1) Investment in PureCycle Technologies ("PCT" or "PureCycle"). See Note 20 - Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates. The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instrument. We consider our long-term debt obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $0.9 billion as of December 31, 2022 and December 31, 2021. During the first quarter of 2022, we invested $5.0 million in a convertible note in Enable Injections, Inc. This investment is recorded at fair value and is a Level 3 fair value measurement. During the second quarter of 2022, we invested $1.0 million in a convertible note in Siklus Refill Pte. Ltd. ("Siklus"). During the fourth quarter of 2022, Siklus repaid $0.4 million of its convertible note. This investment is recorded at fair value and is a Level 3 fair value measurement. As discussed in Note 19 – Acquisitions, we have a contingent consideration obligation to the selling equity holders of: – Fusion in connection with the Fusion Acquisition (as defined herein) based on 2022 cumulative performance targets, and – Noble in connection with the Noble Acquisition (as defined herein) based on 2024 cumulative performance targets We consider these obligations a Level 3 liability and have estimated the aggregate fair value for these contingent consideration arrangements as follows: December 31, 2022 December 31, 2021 Fusion Acquisition $ 25,310 $ 27,166 Noble Acquisition — 6,742 $ 25,310 $ 33,908 Changes in the fair value of these obligations are recorded within selling, research & development and administrative expenses in our Consolidated Statements of Income. Significant changes to the inputs, as noted above, can result in a significantly higher or lower fair value measurement. The following table provides a summary of changes in our Level 3 fair value measurements: Balance, December 31, 2020 $ 31,140 Increase in fair value recorded in earnings 2,768 Balance, December 31, 2021 $ 33,908 Decrease in fair value recorded in earnings (8,598) Balance, December 31, 2022 $ 25,310

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In the normal course of business, we are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position or results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows. We have various purchase commitments for raw materials, supplies, and property and equipment obtained in the normal course of business. As of December 31, 2022, we have unconditional purchase commitments of approximately $82.6 million over the next five years, for which no liabilities have been recorded. Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of December 31, 2022. A fire caused damage to our facility in Annecy, France in June 2016. We were insured for the damages caused by the fire, including business interruption insurance. During the second quarter of 2022, we filed a lawsuit against the insurance company to recover a part of our claim. No gain contingencies have been recognized as our ability to realize those gains remains uncertain. In March 2017, the Supreme Court of Brazil issued a decision that a certain state value added tax should not be included in the calculation of federal gross receipts taxes. We submitted our claim and on September 30, 2021, we received a formal decision statement from the Federal Regional Court of Brazil that the favorable court decisions are final. In 2021 and 2020, we received favorable court decisions of $7.4 million and $0.7 million, respectively, for the retrospective right to recover part of our claim. These amounts are recorded in cost of sales as a favorable impact of $5.6 million and $0.7 million in 2021 and 2020, respectively, and $1.8 million was recognized as interest income in 2021. We do not expect to receive any further amounts in future periods. We are periodically subject to loss contingencies resulting from custom duties assessments. We accrue for anticipated costs when an assessment has indicated that a loss is probable and can be reasonably estimated. We have received claims worth approximately $13 million in principal and $5 million to $6 million for interest and penalties. We are currently defending our position with respect to these claims in the respected administrative procedures. Due to uncertainty in the amount of the assessment and the timing of our appeal, no liability is recorded as of December 31, 2022. We will continue to evaluate these liabilities periodically based on available information, including the progress of remedial investigations, the status of discussions with regulatory authorities regarding the methods and extent of remediation and the apportionment of costs and penalties among potentially responsible parties.

STOCK REPURCHASE PROGRAM

STOCK REPURCHASE PROGRAM	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
STOCK REPURCHASE PROGRAM	STOCK REPURCHASE PROGRAM On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. In 2022 and 2021, we repurchased approximately 860 thousand and 615 thousand shares, respectively, of our outstanding common stock at a total cost of $92.1 million and $78.1 million, respectively. In 2020, we did not repurchase any shares. As of December 31, 2022, there was $108.3 million of authorized share repurchases available to us.

CAPITAL STOCK

CAPITAL STOCK	12 Months Ended
	Dec. 31, 2022
CAPITAL STOCK
CAPITAL STOCK	CAPITAL STOCK We have 199 million authorized shares of common stock. The number of shares of common stock and treasury stock and the share activity were as follows: Common Shares Treasury Shares 2022 2021 2020 2022 2021 2020 Balance at the beginning of the year 70,370,812 69,516,805 68,608,508 4,852,709 4,528,051 4,836,027 Employee option exercises 301,463 634,572 802,046 (157,682) (290,316) (307,976) Director option exercises — 47,500 26,551 — — — Restricted stock vestings 176,535 171,935 79,700 — — — Common stock repurchases — — — 860,000 614,974 — Balance at the end of the year 70,848,810 70,370,812 69,516,805 5,555,027 4,852,709 4,528,051 The cash dividends paid on the common stock for the years ended December 31, 2022, 2021 and 2020 aggregated $99.5 million, $98.5 million and $92.7 million, respectively.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company's 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. Performance-based RSUs have one of two vesting conditions: (1) based on our internal financial performance metrics or (2) based on our total shareholder return (“TSR”) relative to total shareholder returns of an industrial peer group. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest over one year. The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Year Ended December 31, 2022 2021 2020 Fair value per stock award $ 141.95 $ 171.63 $ 94.98 Grant date stock price $ 114.52 $ 141.59 $ 83.93 Assumptions: Aptar's stock price expected volatility 20.20 % 21.40 % 23.80 % Expected average volatility of peer companies 41.70 % 50.00 % 48.50 % Correlation assumption 41.20 % 58.10 % 63.50 % Risk-free interest rate 2.04 % 0.32 % 0.31 % Dividend yield assumption 1.33 % 1.02 % 1.72 % A summary of RSU activity as of December 31, 2022, and changes during the period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2022 485,479 $ 108.73 650,553 $ 111.04 Granted 205,403 111.50 249,656 123.97 Vested (256,872) 106.07 (43,388) 134.97 Forfeited (7,649) 111.73 (245,950) 100.75 Nonvested at December 31, 2022 426,361 $ 111.60 610,871 $ 118.77 Included in the December 31, 2022 time-based RSUs are 11,797 units granted to non-employee directors and 10,007 units vested related to non-employee directors. Year Ended December 31, 2022 2021 2020 Compensation expense $ 40,937 $ 38,643 $ 32,085 Fair value of units vested 32,013 32,414 12,038 Intrinsic value of units vested 33,024 42,970 14,446 The actual tax benefit realized for the tax deduction from RSUs was approximately $8.0 million for the year ended December 31, 2022. As of December 31, 2022, there was $47.8 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted average period of 1.9 years. Historically we issued stock options to our employees and non-employee directors. We have not issued stock options between 2019 and 2022. Stock options were awarded with the exercise price equal to the market price on the date of grant and generally vest over three years and expire 10 years after grant. For stock option grants, we used historical data to estimate expected life and volatility. A summary of option activity under our stock plans as of December 31, 2022, and changes during the period then ended is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2022 3,072,503 $ 71.99 51,700 $ 63.91 Exercised (447,109) 64.05 — — Forfeited or expired (1,450) 78.30 — — Outstanding at December 31, 2022 2,623,944 $ 73.34 51,700 $ 63.91 Exercisable at December 31, 2022 2,623,944 $ 73.34 51,700 $ 63.91 Weighted-Average Remaining Contractual Term (Years): Outstanding at December 31, 2022 3.3 1.1 Exercisable at December 31, 2022 3.3 1.1 Aggregate Intrinsic Value: Outstanding at December 31, 2022 $ 96,149 $ 2,382 Exercisable at December 31, 2022 $ 96,149 $ 2,382 Intrinsic Value of Options Exercised During the Years Ended: December 31, 2022 $ 20,608 $ — December 31, 2021 $ 69,862 $ 4,248 December 31, 2020 $ 59,179 $ 2,318 Year Ended December 31, 2021 2020 Compensation expense (included in SG&A) $ 185 $ 1,693 Compensation expense (included in Cost of sales) 42 370 Compensation expense, Total $ 227 $ 2,063 Compensation expense, net of tax 174 1,573 Grant date fair value of options vested 2,421 7,601 The reduction in stock option expense is due to our move to RSUs as discussed above. Cash received from option exercises was approximately $28.5 million and the actual tax benefit realized for the tax deduction from option exercises was approximately $4.4 million in the year ended December 31, 2022. As of December 31, 2022, there is no remaining valuation of stock options to be expensed in future periods.

EARNINGS PER SHARE

EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share (“EPS”) for the years ended December 31, 2022, 2021 and 2020 are as follows: Income Shares Per Share For the Year Ended December 31, 2022 Basic EPS Income available to common stockholders $ 239,288 65,402 $ 3.66 Effect of Dilutive Securities Stock options 978 Restricted stock 339 Diluted EPS Income available to common stockholders $ 239,288 66,719 $ 3.59 For the Year Ended December 31, 2021 Basic EPS Income available to common stockholders $ 244,097 65,663 $ 3.72 Effect of Dilutive Securities Stock options 1,600 Restricted stock 419 Diluted EPS Income available to common stockholders $ 244,097 67,682 $ 3.61 For the Year Ended December 31, 2020 Basic EPS Income available to common stockholders $ 214,040 64,418 $ 3.32 Effect of Dilutive Securities Stock options 1,800 Restricted stock 439 Diluted EPS Income available to common stockholders $ 214,040 66,657 $ 3.21

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION During the years ended December 31, 2022, 2021 and 2020, we were organized into three reporting segments. Operations that sell dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets formed the Pharma segment. Operations that sell dispensing systems and sealing solutions primarily to the beauty, personal care and home care markets formed the Beauty + Home segment. Operations that sell dispensing systems, sealing solutions and food service trays to the food and beverage markets formed the Food + Beverage segment. The accounting policies of the segments are the same as those described in Note 1 – Summary of Significant Accounting Policies. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Financial information regarding our reporting segments is shown below: Year Ended December 31, 2022 2021 2020 Total Sales: Pharma $ 1,372,449 $ 1,297,996 $ 1,234,107 Beauty + Home 1,461,894 1,456,208 1,320,988 Food + Beverage 523,643 511,112 407,435 Total Sales $ 3,357,986 $ 3,265,316 $ 2,962,530 Less: Intersegment Sales: Pharma $ 11,193 $ 13,372 $ 8,328 Beauty + Home 23,360 22,186 22,837 Food + Beverage 1,184 2,537 2,025 Total Intersegment Sales $ 35,737 $ 38,095 $ 33,190 Net Sales: Pharma $ 1,361,256 $ 1,284,624 $ 1,225,779 Beauty + Home 1,438,534 1,434,022 1,298,151 Food + Beverage 522,459 508,575 405,410 Net Sales $ 3,322,249 $ 3,227,221 $ 2,929,340 Adjusted EBITDA (1): Pharma $ 441,622 $ 425,714 $ 428,469 Beauty + Home 166,465 154,689 129,299 Food + Beverage 71,531 79,377 71,995 Corporate & Other, unallocated (62,930) (52,314) (43,443) Acquisition-related costs (2) (231) (3,811) (6,087) Restructuring Initiatives (3) (6,597) (23,240) (26,492) Net unrealized investment (loss) gain (4) (3,323) 2,709 — Depreciation and amortization (5) (233,706) (234,853) (220,300) Interest Expense (40,827) (30,284) (33,244) Interest Income 2,700 3,668 958 Income before Income Taxes $ 334,704 $ 321,655 $ 301,155 Depreciation and Amortization: Pharma $ 94,396 $ 90,510 $ 75,874 Beauty + Home 93,027 96,611 95,880 Food + Beverage 40,337 40,323 37,768 Corporate & Other 5,946 7,409 10,778 Depreciation and Amortization $ 233,706 $ 234,853 $ 220,300 Capital Expenditures: Pharma $ 164,396 $ 154,077 $ 117,835 Beauty + Home 86,048 100,531 93,980 Food + Beverage 32,378 34,136 29,956 Corporate & Other 29,491 29,686 15,690 Transfer of Corporate Technology Expenditures (6) (1,886) (10,495) (11,507) Capital Expenditures $ 310,427 $ 307,935 $ 245,954 Total Assets: Pharma $ 1,872,843 $ 1,833,512 $ 1,549,781 Beauty + Home 1,625,596 1,615,917 1,610,058 Food + Beverage 552,871 574,269 549,270 Corporate & Other 152,148 117,666 280,944 Total Assets $ 4,203,458 $ 4,141,364 $ 3,990,053 (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs and purchase accounting adjustments related to acquisitions and investments (see Note 19 – Acquisitions and Note 20 – Investment in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the years ended December 31, 2022, 2021 and 2020 as follows (see Note 21 – Restructuring Initiatives for further details): Year Ended December 31, 2022 2021 2020 Restructuring Initiatives by Segment Pharma $ — $ 76 $ 220 Beauty + Home 6,460 10,447 24,464 Food + Beverage 137 404 1,903 Corporate & Other — 12,313 (95) Total Restructuring Initiatives $ 6,597 $ 23,240 $ 26,492 (4) Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 20 - Investment in Equity Securities for further details). (5) Depreciation and amortization includes amortization related to acquisition purchase accounting adjustments. See the reconciliation of Non-U.S. GAAP measures. (6) The transfer of corporate technology expenditures represents amounts of projects managed by corporate for the benefit of specific entities within each segment. Once the projects are complete, all related costs are allocated from corporate to and paid by the appropriate entity and the associated assets are then depreciated at the entity level. Geographic Information The following are net sales and long-lived asset information by geographic area and product information for the years ended December 31, 2022, 2021 and 2020: 2022 2021 2020 Net Sales to Unaffiliated Customers (1): United States $ 1,100,159 $ 1,081,823 $ 965,986 Europe: France 938,637 906,057 854,639 Germany 512,709 486,928 448,405 Italy 154,823 161,676 148,636 Other Europe 167,226 170,521 152,376 Total Europe 1,773,395 1,725,182 1,604,056 China 156,577 148,671 118,791 Other Foreign Countries 292,118 271,545 240,507 Total $ 3,322,249 $ 3,227,221 $ 2,929,340 Property, Plant and Equipment, Net United States $ 346,382 $ 321,511 $ 298,616 Europe: France 482,091 455,105 426,353 Germany 194,898 197,643 194,553 Italy 42,522 50,828 57,333 Other Europe 53,317 58,121 55,933 Total Europe 772,828 761,697 734,172 China 98,469 74,535 46,005 Other Foreign Countries 125,985 118,134 119,955 Total $ 1,343,664 $ 1,275,877 $ 1,198,748 (1) Sales are attributed to countries based upon where the sales invoice to unaffiliated customers is generated. No single customer or group of affiliated customers represents greater than 5% of our net sales in 2022, 2021 or 2020. Effective January 1, 2023, there was a realignment of two of our segments, allowing us to better serve our customers and positioning us for long-term profitable growth. We will continue to have three reporting segments and they will be called Aptar Pharma, Aptar Beauty and Aptar Closures. We are combining all of our closures operations into a single segment - Aptar Closures. The Aptar Closures business will serve multiple markets, including food, beverage, personal care, home care, beauty and healthcare. Closures that were developed in Beauty + Home and Pharma will move to Aptar Closures together with the operations of legacy Food + Beverage. Aptar's food protection business and our elastomeric flow-control technology business will continue to report through the Aptar Closures segment.

ACQUISITIONS

ACQUISITIONS	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS	ACQUISITIONS Business Combinations On August 31, 2022, we completed the acquisition of all the outstanding capital stock of Metaphase Design Group Inc. ("Metaphase"). Metaphase, located in St. Louis, Missouri, is a leading expert in ergonomic and industrial design of handheld devices including medical devices. The purchase price was approximately $5.1 million (net of $0.1 million cash acquired) and was funded with cash on hand. As of the acquisition date, $1.0 million was held in restricted cash for an indemnity escrow. The results of Metaphase have been included in the consolidated financial statements within our Pharma segment since the date of acquisition. On September 2, 2021, following the signature of a share purchase agreement on July 22, 2021 and the approval of the French Ministry of Economy under the foreign investment clearance regulations, we completed the acquisition of 64.3% of the share capital of Voluntis S.A. ("Voluntis"). Voluntis, based in Paris, France and Boston, MA, is a pioneer in digital therapeutics. We acquired from certain members of the management and certain shareholders the entirety of their shares representing approximately 64.3% of the share capital of Voluntis (on a non-diluted basis) at a price of €8.70 per share for approximately €50.8 million (approximately $60.4 million) funded with available cash on hand. This values the full company equity (on a fully diluted basis) at approximately €79.1 million (approximately $93.9 million). Aptar launched a mandatory cash simplified tender offer to acquire Voluntis's remaining shares for the same price of €8.70 per share (the "tender offer"). During September 2021, Aptar acquired €8.4 million (approximately $9.9 million) of additional shares from the tender offer, bringing the total investment as of September 30, 2021 to approximately €59.2 million (approximately $70.3 million) representing 74.9% of the total share capital, and implies a non-controlling interest valued at €19.9 million (approximately $23.6 million). Following completion of the tender offer, Aptar implemented a mandatory squeeze-out on the remaining outstanding shares of Voluntis on the same financial terms as those of the tender offer. During the fourth quarter of 2021, the tender offer and squeeze-out were completed and funded with available cash on hand and we acquired the remaining 25.1% of the share capital for €19.5 million (approximately $22.6 million), resulting in Aptar owning 100.0% of the share capital of Voluntis. The fair value of the Voluntis assets acquired include an acquired technology intangible asset of $27.9 million and other intangible assets of $8.4 million. The technology intangible asset was valued using the Multi-Period Excess Earnings Method ("MPEEM") valuation approach. Judgment was applied with respect to determining the fair value of the acquired technology, which involved the use of significant estimates and assumptions with respect to the revenue growth rate, technology obsolescence rate and discount rate. On August 17, 2021, we completed the acquisition (the "Hengyu Acquisition") of 80% of the equity interests of Weihai Hengyu Medical Products Co., Ltd. ("Hengyu"). Hengyu, a leading Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery, is based in Weihai, China. Under the terms of the agreement, 90% of the estimated purchase price for 80% ownership, RMB 347.7 million (approximately $53.6 million), was paid to the sellers in August 2021, with available cash on hand. A final purchase price adjustment of RMB 1.5 million (approximately $0.2 million) was recorded to Accounts payable, accrued and other liabilities and was paid in the fourth quarter of 2021. The remaining 10% of the acquisition price for 80% ownership, RMB 38.7 million (approximately $6.0 million), is payable to the sellers eighteen months after closing plus simple interest of 4% and is expected to be funded with available cash on hand. This values the full company equity (on a fully diluted basis) at RMB 484.9 million (approximately $74.8 million) and implies a non-controlling interest valued at RMB 97.0 million (approximately $15.0 million) as of the acquisition date. Pursuant to the agreement, we have the option to acquire the remaining 20% of the equity of Hengyu upon the fifth anniversary of the closing date. The fair value of the Hengyu assets acquired include a customer relationship intangible asset of $24.1 million and other intangible assets of $5.6 million. The customer relationship intangible asset was valued using the MPEEM valuation approach. Judgment was applied with respect to determining the fair value of the customer relationships, which involved the use of significant estimates and assumptions with respect to the revenue growth rates, customer attrition rates, Adjusted EBIT margins and discount rate. For the year ended December 31, 2022, we recognized $0.2 million in transaction costs related to the acquisition of Metaphase. For the year ended December 31, 2021, we recognized $3.8 million in transaction costs related to the acquisitions of Voluntis and Hengyu. These costs are reflected in the selling, research & development and administration section of the Consolidated Statements of Income and within acquisition-related costs as disclosed in Note 18 – Segment Information. Pro forma, 2022, and 2021 reported results of operations for the 2022 and 2021 acquisitions have not been presented as the effects of these business combinations individually and in aggregate were not material to the consolidated results of operations. The following table summarizes the assets acquired and liabilities assumed for the Voluntis and Hengyu acquisitions as of the acquisition date at estimated fair value. 2021 Assets Cash and equivalents $ 3,852 Accounts receivable 5,208 Inventories 606 Other receivable 286 Prepaid and other 1,863 Property, plant and equipment 14,081 Goodwill 104,433 Intangible assets 65,981 Operating lease right-of-use assets 2,309 Other miscellaneous assets 78 Liabilities Current maturities of long-term obligations, net of unamortized debt issuance costs 1,410 Accounts payable, accrued and other liabilities 9,663 Deferred income taxes 16,792 Operating lease liabilities 2,306 Deferred and other non-current liabilities 5,770 Net assets acquired $ 162,756 The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives for the Voluntis and Hengyu acquisitions as of the acquisition date: 2021 Weighted-Average Estimated Acquired technology 10 $ 34,322 Customer relationships 11.6 30,258 License agreements and other 0.25 1,401 Total $ 65,981 Goodwill in the amount of $3.0 million and $104.4 million was recorded related to the 2022 and 2021 acquisitions, respectively, and is included in the Pharma segment. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill acquired in our 2022 acquisition expands our portfolio of services as well as the ability to become a single source provider to our pharmaceutical and biotech customers, while goodwill acquired in our 2021 acquisitions largely consists of expansion into the digital health solutions market, by adding digital therapeutic solutions and broadening our digital health services provided to customers; as well as strengthening our capabilities in high-growth economies by enhancing the ability to respond to changing local market needs in the injectables market. Goodwill will not be amortized, but will be tested for impairment at least annually. For 2022 and 2021 acquisitions, no goodwill will be deductible for tax purposes.

INVESTMENT IN EQUITY SECURITIES

INVESTMENT IN EQUITY SECURITIES	12 Months Ended
	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT IN EQUITY SECURITIES	INVESTMENT IN EQUITY SECURITIES Our investment in equity securities consisted of the following: December 31, 2022 December 31, 2021 Equity Method Investments BTY $ 31,490 $ 33,199 Sonmol 4,997 5,904 Desotec GmbH 863 919 Other Investments PureCycle 5,297 9,006 YAT 5,508 5,978 Loop 2,894 2,894 Others 1,259 1,585 $ 52,308 $ 59,485 Equity Method Investments BTY On January 1, 2020, we acquired 49% of the equity interests in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. Sonmol On April 1, 2020, we invested $5 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”). Sonmol is a leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control. Kali Care During 2017, we invested $5 million to acquire 20% of the equity interests in Kali Care, a technology company that provides digital monitoring systems for medical devices. Since our investment, we have recognized approximately $1.6 million of our cumulative pro-rata share of operating losses. During 2021 and 2020, we recognized an other than temporary impairment of $0.4 million ($0.3 million after-tax) and $3.0 million ($2.3 million after-tax), respectively, on our underlying assets in this investment as a result of a reassessment of the future value of the business and continued reduction in operating cash flows. In addition to our investment, we also hold a note receivable from Kalicare for $1.5 million which is included in accounts and notes receivable in the Consolidated Balance Sheets. In March 2022, we recorded an expected credit loss reserve against the outstanding note receivable from Kali Care for $1.5 million as a result of a proposed sale of the business. During the second quarter, we recovered $0.1 million on this note and expect to receive similar amounts in annual payments over the next three years. Desotec GmbH During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of special assembly machines for bulk processing for the pharmaceutical, beauty and home and food and beverages markets. Other Investments During August 2019, we invested $2.5 million and $1.0 million in the preferred equity of sustainability companies Loop and PureCycle, respectively, that were accounted for at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. During 2020, we invested an additional $0.4 million and $1.0 million in Loop and PureCycle, respectively, and also received $333 thousand of equity in PureCycle in exchange for our resource dedication for technological partnership and support. In November 2020, we increased the value of the PureCycle investment by $3.1 million based on observable price changes and recorded the gain in miscellaneous income in the Consolidated Statements of Income. In March 2021, PureCycle was purchased by a special purpose acquisition company and was subsequently listed on Nasdaq under the ticker PCT. At that time, our investment in PureCycle was converted into shares of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or (loss) in the Consolidated Statements of Income. During 2021, we received $333 thousand of shares of PCT in exchange for our resource dedication for technological partnership and support and exercised an option to purchase $1.0 million of additional shares in connection with an FDA milestone. We have sold the following PCT shares related to the PureCycle investment: Shares Sold Proceeds Realized Gain October 2021 191,349 $ 2,434 $ 2,000 March 2022 107,600 $ 1,088 $ 841 August 2022 50,000 $ 511 $ 372 For the years ended December 31, 2022, 2021 and 2020 we recorded the following net investment gain/(loss) on our investment in PureCycle: 2022 2021 2020 Net investment (loss) gain $ (2,110) $ 4,709 $ 3,064 On July 7, 2021, we investe d approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company. Other than the expected credit loss reserve against the outstanding Kali Care note receivable, there were no indications of impairment noted in the year ended December 31, 2022 related to these investments.

RESTRUCTURING INITIATIVES

RESTRUCTURING INITIATIVES	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
RESTRUCTURING INITIATIVES	RESTRUCTURING INITIATIVES In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan was the Beauty + Home segment; however, certain global general and administrative functions were also addressed. As of the end of 2021, we had completed the vast majority of our planned initiatives related to our transformation plan and do not expect additional restructuring expenses related to this plan going forward. During 2022, 2021 and 2020, we recognized $0.4 million, $23.2 million and $26.5 million of restructuring costs related to this plan, respectively. During 2020, $2.5 million of the $26.5 million recognized was related to asset impairment. The cumulative expense incurred as of December 31, 2022 was $136.6 million. As of December 31, 2022 we have recorded the following activity associated with the transformation plan: Beginning Reserve at 12/31/2021 Net Charges for the Year Ended 12/31/2022 Cash Paid Interest and Ending Reserve at 12/31/2022 Employee severance $ 3,535 $ 303 $ (3,131) $ (153) $ 554 Professional fees and other costs 260 70 (313) (11) 6 Totals $ 3,795 $ 373 $ (3,444) $ (164) $ 560 During the third quarter of 2022, we began an initiative to optimize our operations and SG&A expenses. For the year ended December 31, 2022, we recognized $6.2 million of restructuring costs related to this plan. As of December 31, 2022, we have recorded the following activity associated with our optimization plan: Beginning Reserve at 12/31/2021 Net Charges for the Year Ended 12/31/2022 Cash Paid Interest and Ending Reserve at 12/31/2022 Employee severance $ — $ 5,454 $ (491) $ 30 $ 4,993 Professional fees and other costs — 770 (770) — — Totals $ — $ 6,224 $ (1,261) $ 30 $ 4,993

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	AptarGroup, Inc SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS For the years ended December 31, 2022, 2021 and 2020 Dollars in thousands Balance at Charged to Charged Deductions Balance 2022 CECL $ 7,374 $ 3,213 $ — $ (1,068) $ 9,519 Deferred tax valuation allowance 47,149 3,754 380 (5,044) 46,239 2021 CECL $ 5,918 $ 1,601 $ 391 $ (536) $ 7,374 Deferred tax valuation allowance (b) 23,105 5,355 20,572 (1,883) 47,149 2020 CECL $ 3,626 $ 865 $ 1,647 $ (220) $ 5,918 Deferred tax valuation allowance 23,320 3,085 700 (4,000) 23,105 (a) Write-off accounts considered uncollectible, net of recoveries and foreign currency impact adjustments.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying consolidated financial statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. AptarGroup’s organizational structure consists of three market-focused business segments which are Pharma, Beauty + Home and Food + Beverage through the year ended December 31, 2022. The COVID-19 pandemic resulted in disruptions to the global economy and supply chains. As the rates of transmission slowed in many regions during 2022, we have seen several of our impacted applications return to more normal (pre-pandemic) volume and growth levels. We have seen improvement in sales of our products to our prescription, beauty, hair care and sun care customers as people return to more active lifestyles. However, we have also experienced volume reductions as applications which benefited from the pandemic, such as our personal cleansing and surface cleaner products, food applications, active material science solutions and injectables components, are now up against challenging comparisons to 2021 volume levels. As of December 31, 2022, the war in Ukraine has not had a significant direct impact on our business, though the near-term visibility for this situation is expected to remain fluid and uncertain for the next several quarters. However, we have experienced some indirect impacts on our business, including higher energy and other input costs as well as certain supply chain disruptions. In late 2017, we began a business transformation plan to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness (see Note 21 – Restructuring Initiatives for further details). The primary focus of the plan was the Beauty + Home segment; however, certain global general and administrative functions have were also addressed. During 2022, 2021 and 2020, we recognized approximately $0.4 million, $23.2 million and $26.5 million, respectively, of restructuring costs related to this plan. As of December 31, 2021, we had completed the vast majority of our planned initiatives related to this plan and do not expect any significant, additional restructuring expenses related to this plan. Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. During the third quarter of 2021, we utilized the Blue Chip Swap and recognized a gain of $1.4 million. Our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues at and for the year ended December 31, 2022.
ACCOUNTING ESTIMATES	ACCOUNTING ESTIMATES The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). This process requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
CASH AND CASH EQUIVALENTS	CASH AND CASH EQUIVALENTS We consider all investments that are readily convertible to known amounts of cash with an original maturity of three months or less when purchased to be cash equivalents.
ACCOUNTS RECEIVABLE AND CURRENT EXPECTED CREDIT LOSSES	ACCOUNTS RECEIVABLE AND CURRENT EXPECTED CREDIT LOSSES At December 31, 2022, we reported $677 million of accounts receivable, net of CECL of $9.5 million. The allowance is estimated using reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Changes in CECL were not material for the year ended December 31, 2022.
INVENTORIES	INVENTORIES Inventories are stated at lower of cost or net realizable value. Cost of our inventories is determined by costing methods that approximate a first-in, first-out ("FIFO") basis. Costs included in inventories are raw materials, direct labor and manufacturing overhead.
ACQUISITIONS	ACQUISITIONS We account for business combinations using the acquisition method, which requires management to estimate the fair value of identifiable assets acquired and liabilities assumed, and to properly allocate purchase price consideration to the individual assets acquired and liabilities assumed. Goodwill is measured as the excess amount of consideration transferred, compared to fair value of the assets acquired and the liabilities assumed. The allocation of the purchase price utilizes significant estimates and assumptions in determining the fair values of identifiable assets acquired and liabilities assumed, especially with respect to intangible assets. These estimates are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset and are reviewed by consulting with outside valuation experts. The purchase price allocation for business acquisitions contains uncertainties because it requires management's judgment.
INVESTMENTS IN EQUITY SECURITIES	INVESTMENTS IN EQUITY SECURITIES We account for our 20% to 50% owned investments using the equity method. Equity investments that do not result in consolidation and are not accounted for under the equity method are measured at fair value. Any related changes in fair value are recognized in net income unless the investments qualify for a practicality exception. There were no dividends received from affiliated companies in 2022, 2021 and 2020.
PROPERTY AND DEPRECIATION	PROPERTY AND DEPRECIATION Properties are stated at cost. Depreciation is determined on a straight-line basis over the estimated useful lives for financial reporting purposes and accelerated methods for income tax reporting. Generally, the estimated useful lives are 10 to 40 years for buildings and improvements and 3 to 15 years for machinery and equipment.
FINITE-LIVED INTANGIBLE ASSETS	FINITE-LIVED INTANGIBLE ASSETS Finite-lived intangibles, consisting of patents, acquired technology, customer relationships, trademarks and trade names and license agreements acquired in purchase transactions, are capitalized and amortized over their useful lives which range from 1 to 50 years.
IMPAIRMENT OF LONG-LIVED ASSETS	IMPAIRMENT OF LONG-LIVED ASSETS Long-lived assets, such as property, plant and equipment and finite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset (if any) are less than the carrying value of the asset.
GOODWILL	GOODWILL The Company has evaluated the excess of purchase price over the fair value of the net assets acquired (“goodwill”) for impairment annually as of October 1 or more frequently if impairment indicators arose in accordance with Accounting Standards Codification (“ASC”) Topic 350, “Intangibles - Goodwill and Other.” We believe that the accounting estimates related to determining the fair value of our reporting units is a critical accounting estimate because: (1) it is highly susceptible to change from period to period because it requires management to make assumptions about the future cash flows for each reporting unit over several years, and (2) the impact that recognizing an impairment would have on the assets reported on our balance sheet as well as our results of operations could be material. Management’s determination of the fair value of our reporting units, based on future cash flows for the reporting units, requires significant judgment and the use of estimates and assumptions related to projected revenue growth rates, the terminal growth factor, as well as the discount rate. Actual cash flows in the future may differ significantly from those forecasted today. The estimates and assumptions for future cash flows and its impact on the impairment testing of goodwill is a critical accounting estimate. Management believes goodwill in purchase transactions has continuing value. Goodwill is not amortized and must be tested annually, or more frequently as circumstances dictate, for impairment. The annual goodwill impairment test may first consider qualitative factors to determine whether it is more likely than not (i.e., greater than 50 percent chance) that the fair value of a reporting unit is less than its book value. This is sometimes referred to as the “step zero” approach and is an optional step in the annual goodwill impairment analysis. Management has performed this qualitative assessment as of October 1, 2022 and October 1, 2021 for each of our reporting units. Based on our review of macroeconomic, industry, and market events and circumstances as well as the overall financial performance of the reporting units, we determined that it was more likely than not that the fair value of these reporting units was greater than their carrying amounts and therefore no impairment of goodwill is required.
DERIVATIVES INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Derivative financial instruments are recorded in the Consolidated Balance Sheets at fair value as either assets or liabilities. Changes in the fair value of derivatives are recorded in each period in earnings or other comprehensive income, depending on whether a derivative is designated and effective as part of a hedge transaction.
PURCHASE OF TREASURY STOCK	PURCHASE OF TREASURY STOCK During 2022 and 2021, we repurchased 860 thousand and 615 thousand shares, respectively, all of which were returned to treasury stock. In 2020, we did not repurchase any shares of our common stock. If retired, common stock is reduced by the number of shares retired at $0.01 par value per share. We allocate the excess purchase price over par value between additional paid-in capital and retained earnings.
RESEARCH & DEVELOPMENT EXPENSES	RESEARCH & DEVELOPMENT EXPENSES Research and development costs, net of any customer funded research and development or government research and development credits, are expensed as incurred. These costs amounted to $93.5 million, $99.8 million and $92.5 million in 2022, 2021 and 2020, respectively.
INCOME TAXES	INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and its reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation on a current or deferred basis. We will provide for the necessary withholding tax, local income taxes, and U.S. federal and state income tax when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. See Note 6 – Income Taxes for more information. We are subject to taxation and file income tax returns in the U.S. federal jurisdiction and many state and foreign jurisdictions. We believe that an adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Consolidated Financial Statements.
TRANSLATION OF FOREIGN CURRENCIES	TRANSLATION OF FOREIGN CURRENCIES The functional currencies of the majority of our foreign operations are their local currencies. Assets and liabilities of our foreign operations are translated into U.S. dollars at the rates of exchange on the balance sheet date. Sales and expenses are translated at the average rates of exchange prevailing during the year. The related translation adjustments are accumulated in a separate section of Stockholders’ Equity. Realized and unrealized foreign currency transaction gains and losses are reflected in income, as a component of miscellaneous income and expense, and represented losses of $7.2 million, $1.4 million and $5.6 million in 2022, 2021 and 2020, respectively.
STOCK BASED COMPENSATION	STOCK-BASED COMPENSATION Accounting standards require the application of the non-substantive vesting approach which means that an award is fully vested when the employee’s retention of the award is no longer contingent on providing future service. Under this approach, compensation costs are recognized over the requisite service period of the award instead of ratably over the vesting period stated in the grant. As such, costs are recognized immediately if the employee is retirement eligible on the date of grant or over the period from the date of grant until retirement eligibility if retirement eligibility is reached before the end of the vesting period stated in the grant. Forfeitures are recognized as they occur. See Note 16 – Stock-Based Compensation for more information.
REVENUE RECOGNITION	REVENUE RECOGNITION At inception of customer contracts, we assess the goods and services promised in order to identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product, tooling and service contract sales; however, we also receive revenues from license, exclusivity and royalty arrangements, which collectively are not material to the results. See specific discussions about methods of accounting for control transfers of product, tooling and service contract sales in Note 2 – Revenue.
LEASES	LEASES We determine if an arrangement is a lease at inception. Operating lease assets are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities are included in Accounts payable accrued and other liabilities in our Consolidated Balance Sheets. Finance leases are included in property, plant and equipment, current maturities of long-term obligations and long-term obligations in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date of the lease in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made as well as initial direct costs incurred and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, we account for the lease and non-lease components as a single lease component. We have elected not to recognize ROU assets and lease liabilities that arise from short-term leases (a lease whose term is 12 months or less and does not include a purchase option that we are reasonably certain to exercise). Certain vehicle lease contracts include guaranteed residual value that is considered in the determination of lease classification. The probability of having to satisfy a residual value guarantee is not considered for the purpose of lease classification, but is considered when measuring a lease liability.
GOVERNMENT GRANTS	GOVERNMENT GRANTS We record non-reimbursable government grants when there is reasonable assurance that we will comply with the relevant conditions of the grant agreement and the grant funds will be received. When a grant is received toward the purchase or construction of an asset, the funds received are recorded as a contra-asset and deducted from the cost of the related asset. Additionally, we record expenses net of reimbursements for government grants from a reimbursement of cost. During 2022, we received a $10.5 million government grant to be used toward the expansion of an existing injectables facility. This award will support the delivery of components for COVID-19 vaccines. The French government will fund approximately $14.0 million for the expansion of the facility, for which there is no clawback option. As of December 31, 2022, we recorded the $10.5 million received as a contra-asset within property, plant and equipment in the Consolidated Balance Sheets and reported in the proceeds from government grants within the investing section of the Consolidated Statements of Cash Flows. During 2022 and 2021, we received $17.3 million and $2.0 million, respectively, in government grants to be used toward the construction of a new facility in Alabama. This award will support expanded domestic production capacity for our active material science solutions proprietary Activ-Film technology, which is used to protect and enhance COVID-19 test kit integrity and accuracy. Under the terms of the grant agreement, the U.S. government will fund approximately $19 million to build an operating facility, for which there is no clawback provision, in exchange for the new facility to be on standby for the government for a period of 16 months after construction. As of December 31, 2022 and 2021, we recorded the $17.3 million and $2.0 million, respectively, received as a contra-asset within property, plant and equipment in the Consolidated Balance Sheets and reported in the proceeds from government grants within the investing section of the Consolidated Statements of Cash Flows.
SUPPLY CHAIN FINANCE PROGRAM	SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program ("SCF") across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. All outstanding amounts related to suppliers participating in the SCF are recorded within Accounts payable, accrued and other liabilities in our Consolidated Balance Sheets, and associated payments are included in operating activities within our Consolidated Statements of Cash Flows. As of December 31, 2022 and 2021, the amounts due to suppliers participating in the SCF and included in Accounts payable, accrued and other liabilities were approximately $30.8 million and $30.1 million, respectively. 2022 2021 SCF obligations outstanding at the beginning of the year $ 30,144 $ 23,000 Additions 133,148 108,439 Settlements (132,459) (101,295) SCF obligations outstanding at the end of the year $ 30,833 $ 30,144 Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain.
ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS	ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In September 2022, the FASB issued ASU 2022-04, Liabilities-Supplier Finance Programs (Topic 405), which enhances the transparency of supplier finance programs and requires certain disclosures for a buyer in a supplier finance program. The requirements are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 13, 2023. Early adoption is permitted. We adopted this guidance in the fourth quarter of 2022 and expanded our disclosure to include a roll forward of our supply chain finance program. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy including the nature of the transaction, the financial statement line items affected by the transaction and any significant terms and conditions associated with the transactions. We adopted this guidance in the fourth quarter of 2021 using the prospective approach. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. As of December 31, 2022, we have amended the revolving credit facility to provide mechanics relating to a transition away from LIBOR (in the case of USD) and the designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. We are evaluating any further impact this standard may have on our Consolidated Financial Statements and anticipate no further significant impacts. We plan on adopting this guidance during the second quarter of 2023. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Supply Chain Finance Program	2022 2021 SCF obligations outstanding at the beginning of the year $ 30,144 $ 23,000 Additions 133,148 108,439 Settlements (132,459) (101,295) SCF obligations outstanding at the end of the year $ 30,833 $ 30,144

REVENUE (Tables)

REVENUE (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of revenue by segment by geographic area	Revenue by segment and geography based on shipped from locations for the years ended December 31, 2022, 2021 and 2020 is as follows: For the Year Ended December 31, 2022 Segment Europe Domestic Latin Asia Total Pharma $ 836,447 $ 426,401 $ 27,075 $ 71,333 $ 1,361,256 Beauty + Home 801,798 373,125 160,827 102,784 1,438,534 Food + Beverage 135,150 300,633 47,561 39,115 522,459 Total $ 1,773,395 $ 1,100,159 $ 235,463 $ 213,232 $ 3,322,249 For the Year Ended December 31, 2021 Segment Europe Domestic Latin Asia Total Pharma $ 830,552 $ 374,063 $ 21,482 $ 58,527 $ 1,284,624 Beauty + Home 765,071 412,761 147,569 108,621 1,434,022 Food + Beverage 129,559 294,999 46,992 37,025 508,575 Total $ 1,725,182 $ 1,081,823 $ 216,043 $ 204,173 $ 3,227,221 For the Year Ended December 31, 2020 Segment Europe Domestic Latin Asia Total Pharma $ 808,834 $ 350,265 $ 23,157 $ 43,523 $ 1,225,779 Beauty + Home 681,936 384,004 141,846 90,365 1,298,151 Food + Beverage 113,286 231,717 29,040 31,367 405,410 Total $ 1,604,056 $ 965,986 $ 194,043 $ 165,255 $ 2,929,340
Schedule of opening and closing balances of contract assets and contract liabilities	The opening and closing balances of our contract asset and contract liabilities are as follows: Balance as of December 31, 2021 Balance as of December 31, 2022 Increase/ Contract asset (current) $ 16,878 $ 16,736 $ (142) Contract liability (current) $ 86,340 $ 80,241 $ (6,099) Contract liability (long-term) $ 21,905 $ 25,361 $ 3,456

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of inventories, by component	Inventories, by component net of reserves, consisted of: 2022 2021 Raw materials $ 159,041 $ 140,818 Work in process 153,592 137,654 Finished goods 174,173 162,992 Total $ 486,806 $ 441,464

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying amount of goodwill	The changes in the carrying amount of goodwill for the year ended December 31, 2022 are as follows by reporting segment: Pharma Beauty + Food + Total Balance as of December 31, 2020 $ 436,731 $ 333,111 $ 128,679 $ 898,521 Acquisition 104,433 — — 104,433 Foreign currency exchange effects (20,967) (7,392) (438) (28,797) Balance as of December 31, 2021 $ 520,197 $ 325,719 $ 128,241 $ 974,157 Acquisitions 3,029 — — 3,029 Foreign currency exchange effects (24,484) (6,708) (362) (31,554) Balance as of December 31, 2022 $ 498,742 $ 319,011 $ 127,879 $ 945,632
Summary of amortized intangible assets	The table below shows a summary of intangible assets for the years ended December 31, 2022 and 2021. 2022 2021 Weighted Average Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 8.8 $ 8,044 $ (1,968) $ 6,076 $ 2,767 $ (1,528) $ 1,239 Acquired technology 11.5 135,191 (56,628) 78,563 140,936 (45,613) 95,323 Customer relationships 13.4 305,994 (99,130) 206,864 311,964 (77,512) 234,452 Trademarks and trade names 7.2 43,998 (28,190) 15,808 44,893 (22,886) 22,007 License agreements and other 38.6 15,425 (6,992) 8,433 16,179 (6,857) 9,322 Total intangible assets 13.2 $ 508,652 $ (192,908) $ 315,744 $ 516,739 $ (154,396) $ 362,343
Schedule of future estimated amortization expense	Future estimated amortization expense for the years ending December 31 is as follows: 2023 $ 43,723 2024 40,547 2025 39,061 2026 36,863 2027 29,720 2028 and thereafter 125,830

ACCOUNTS PAYABLE, ACCRUED AND_2

ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Components of accounts payable and accrued liabilities	At December 31, 2022 and 2021, Accounts payable, accrued and other liabilities consisted of the following: 2022 2021 Accounts payable, principally trade $ 320,281 $ 285,262 Accrued employee compensation costs 209,566 195,308 Customer deposits and other unearned income 80,113 86,953 Other accrued liabilities 184,425 125,342 Total $ 794,385 $ 692,865

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of income before income taxes	Income before income taxes consists of: Years Ended December 31, 2022 2021 2020 United States $ 65,350 $ 101,353 $ 91,555 International 269,354 220,302 209,600 Total $ 334,704 $ 321,655 $ 301,155
Components of provision (benefit) for income taxes	The provision (benefit) for income taxes is composed of: Years Ended December 31, 2022 2021 2020 Current: U.S. Federal $ 12,791 $ 11,932 $ 9,934 State/Local 2,265 4,917 3,094 International 92,199 75,524 82,235 $ 107,255 $ 92,373 $ 95,263 Deferred: U.S. Federal/State $ (882) $ (11,168) $ (2,270) International (11,224) (3,188) (5,928) $ (12,106) $ (14,356) $ (8,198) Total $ 95,149 $ 78,017 $ 87,065
Schedule of reconciliation of actual income tax provision and the tax provision computed by applying statutory federal income tax rate	A reconciliation of the provision for income taxes with the amount computed by applying the statutory federal income tax rate of 21% to income before provision for income taxes is as follows: Years Ended December 31, 2022 2021 2020 Income tax at statutory rate $ 70,288 $ 67,547 $ 63,243 State income taxes, net of federal tax effect 1,475 1,616 2,396 Excess tax benefits from share-based compensation (3,306) (16,060) (11,625) Deferred tax (benefits) charges, incl. tax rate changes (2,349) (1,040) 4,110 U.S. Global Intangible Low-Taxed Income ("GILTI") and Base Erosion Anti-Abuse Tax ("BEAT") 3,129 — (3,909) Valuation allowance 1,486 4,485 1,332 Legal entity reorganization 5,850 — — Rate differential on earnings of foreign operations 19,165 20,831 24,901 Other items, net (589) 638 6,617 Actual income tax provision $ 95,149 $ 78,017 $ 87,065 Effective income tax rate 28.4 % 24.3 % 28.9 %
Components of significant deferred tax assets and liabilities	Significant deferred tax assets and liabilities as of December 31, 2022 and 2021 are composed of the following temporary differences: 2022 2021 Deferred Tax Assets: Net operating loss carryforwards $ 45,823 $ 47,660 Operating and finance leases 20,974 22,492 Pension liabilities 8,178 29,770 Share-based compensation 9,970 6,764 U.S. federal tax credits — 4,226 U.S. state tax credits 6,777 7,047 Vacation and bonus 14,681 13,450 U.S. capitalized research expenditures 27,840 19,633 Inventory 4,736 6,969 Accrued liabilities and other reserves 10,346 3,109 Other 11,744 16,194 Total gross deferred tax assets $ 161,069 $ 177,314 Less valuation allowance (46,239) (47,149) Net deferred tax assets $ 114,830 $ 130,165 Deferred Tax Liabilities: Acquisition related intangibles $ 59,084 $ 68,174 Depreciation and amortization 29,142 30,997 Operating and finance leases 23,041 24,560 Other 6,563 7,489 Total gross deferred tax liabilities $ 117,830 $ 131,220 Net deferred tax liabilities $ (3,000) $ (1,055)
Schedule of reconciliation of the beginning and ending amount of income tax uncertainties	A reconciliation of the beginning and ending amount of income tax uncertainties is as follows: 2022 2021 2020 Balance at January 1 $ 7,225 $ 4,504 $ 3,647 Increases based on tax positions for the current year 1,433 262 212 Increases based on tax positions of prior years 966 3,348 790 Decreases based on tax positions of prior years (2,582) — — Settlements (80) (567) — Lapse of statute of limitations (43) (322) (145) Balance at December 31 $ 6,919 $ 7,225 $ 4,504
Summary of major tax jurisdictions the Company files in, with the years still subject to income tax examinations	The major tax jurisdictions we file in, with the years still subject to income tax examinations, are listed below: Major Tax Tax Years United States — Federal 2019-2022 United States — State 2018-2022 France 2019-2022 Germany 2018-2022 Italy 2016-2022 China 2012-2022

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of current debt	At December 31, 2022 and 2021, our revolving credit facility and overdrafts consisted of the following: 2022 2021 Revolving credit facility 1.68% $ — $ 144,383 Overdrafts 15.37% 3,810 2,893 $ 3,810 $ 147,276
Schedule of long-term obligations	At December 31, 2022 and 2021, our long-term obligations consisted of the following: December 31, 2022 December 31, 2021 Notes payable 0.00% – 16.42%, due in monthly and annual installments through 2030 $ 29,167 $ 22,785 Senior unsecured notes 3.2%, due in 2022 — 75,000 Senior unsecured debts 2.19% USD floating swapped to 1.36% EUR fixed, due in 2022 — 56,000 Senior unsecured notes 3.5%, due in 2023 — 125,000 Senior unsecured notes 1.0%, due in 2023 106,995 113,830 Senior unsecured notes 3.4%, due in 2024 50,000 50,000 Senior unsecured notes 3.5%, due in 2024 100,000 100,000 Senior unsecured notes 1.2%, due in 2024 213,990 227,660 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Senior unsecured notes 3.6%, due in 2032, net of discount of $1.0 million 399,050 — Finance Lease Liabilities 26,934 30,185 Unamortized debt issuance costs (4,558) (1,085) $ 1,171,578 $ 1,049,375 Current maturities of long-term obligations (118,981) (142,351) Total long-term obligations $ 1,052,597 $ 907,024
Schedule of maturities of long-term debt	The aggregate long-term maturities, excluding finance lease liabilities, which are discussed in Note 8, due annually for the next five years and thereafter are: 2023 $ 115,815 2024 369,183 2025 133,313 2026 131,647 2027 73 Thereafter 399,171
Schedule of covenants on revolving credit facility and corporate long-term obligations	Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at December 31, 2022 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.71 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 15.00 to 1.00 (1) Definitions of ratios are included as part of the revolving credit facility agreement and the private placement agreements.

LEASE COMMITMENTS (Tables)

LEASE COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Schedule of components of lease expense	The components of lease expense for the years ended December 31, 2022 and 2021 were as follows: Year Ended December 31, 2022 2021 Operating lease cost $ 21,105 $ 23,040 Finance lease cost: Amortization of right-of-use assets $ 4,249 $ 4,228 Interest on lease liabilities 1,249 1,360 Total finance lease cost $ 5,498 $ 5,588 Short-term lease and variable lease costs $ 15,454 $ 12,259
Schedule of supplemental cash flow information related to leases	Supplemental cash flow information related to leases was as follows: Year Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 20,488 $ 22,821 Operating cash flows from finance leases 1,264 1,374 Financing cash flows from finance leases 3,662 4,349 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 16,754 $ 17,785 Finance leases 1,011 5,922
Schedule of supplemental balance sheet information related to leases	Supplemental balance sheet information related to leases was as follows: December 31, December 31, Operating Leases Operating lease right-of-use assets $ 58,675 $ 62,454 Accounts payable, accrued and other liabilities $ 16,985 $ 15,356 Operating lease liabilities 42,948 48,010 Total operating lease liabilities $ 59,933 $ 63,366 Finance Leases Property, plant and equipment, gross $ 50,173 $ 51,821 Accumulated depreciation (12,781) (9,864) Property, plant and equipment, net $ 37,392 $ 41,957 Current maturities of long-term obligations, net of unamortized debt issuance cost $ 3,234 $ 3,744 Long-term obligations, net of unamortized debt issuance cost 23,700 26,441 Total finance lease liabilities $ 26,934 $ 30,185 Weighted Average Remaining Lease Term (in years) Operating leases 4.6 5.2 Finance leases 6.6 7.4 Weighted Average Discount Rate Operating leases 4.01 % 3.80 % Finance leases 4.76 % 4.62 %
Schedule of maturities of lease liabilities	Maturities of lease liabilities as of December 31, 2022, were as follows: Operating Finance Year 1 $ 19,193 $ 4,454 Year 2 14,414 3,691 Year 3 10,011 3,572 Year 4 8,479 2,807 Year 5 6,908 6,003 Thereafter 6,860 11,832 Total lease payments 65,865 32,359 Less imputed interest (5,932) (5,425) Total $ 59,933 $ 26,934

RETIREMENT AND DEFERRED COMPE_2

RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Change in the projected benefit obligation, plan assets at fair value and funded status	The following table presents the changes in the benefit obligations and plan assets for the most recent two years for our domestic and foreign plans. Domestic Plans Foreign Plans 2022 2021 2022 2021 Change in benefit obligation: Benefit obligation at beginning of year $ 255,457 $ 272,471 $ 123,386 $ 134,426 Service cost 15,784 16,356 7,547 8,159 Interest cost 6,970 6,366 1,388 843 Curtailment/Settlement — — 68 5 Prior service cost — — 813 — Actuarial gain (92,724) (18,526) (26,826) (6,489) Benefits paid (21,615) (21,210) (4,615) (4,555) Foreign currency translation adjustment — — (7,762) (9,003) Benefit obligation at end of year $ 163,872 $ 255,457 $ 93,999 $ 123,386 Domestic Plans Foreign Plans 2022 2021 2022 2021 Change in plan assets: Fair value of plan assets at beginning of year $ 193,770 $ 192,034 $ 85,421 $ 85,087 Actual return on plan assets (25,517) 22,480 (4,897) 2,811 Employer contribution 15,513 466 1,871 7,966 Benefits paid (21,615) (21,210) (4,615) (4,555) Transfer — — — 124 Foreign currency translation adjustment — — (5,257) (6,012) Fair value of plan assets at end of year $ 162,151 $ 193,770 $ 72,523 $ 85,421 Funded status at end of year $ (1,721) $ (61,687) $ (21,476) $ (37,965)
Schedule of funded status amounts recognized in the Consolidated Balance Sheet	The following table presents the funded status amounts recognized in our Consolidated Balance Sheets as of December 31, 2022 and 2021. Domestic Plans Foreign Plans 2022 2021 2022 2021 Non-current assets $ 9,304 $ — $ — $ 1,832 Current liabilities (515) (500) (31) (33) Non-current liabilities (10,510) (61,187) (21,445) (39,764) $ (1,721) $ (61,687) $ (21,476) $ (37,965)
Schedule of amounts not recognized as components of periodic benefit cost that are recognized in accumulated other comprehensive loss	The following table presents the amounts not recognized as components of periodic benefit cost that are recognized in accumulated other comprehensive (gain) loss as of December 31, 2022 and 2021. Domestic Plans Foreign Plans 2022 2021 2022 2021 Net actuarial (gain) loss $ (3,338) $ 57,627 $ 11,383 $ 32,269 Net prior service cost — — 1,150 509 Tax effects 2,271 (12,873) (5,518) (11,049) $ (1,067) $ 44,754 $ 7,015 $ 21,729
Schedule of changes in benefit obligations and plan assets recognized in other comprehensive income	Changes in benefit obligations and plan assets recognized in other comprehensive income in 2022, 2021 and 2020 are as follows: Domestic Plans 2022 2021 2020 Current year actuarial gain (loss) $ 54,295 $ 28,714 $ (33,335) Amortization of net loss 6,670 10,099 5,684 $ 60,965 $ 38,813 $ (27,651) Foreign Plans 2022 2021 2020 Current year actuarial gain (loss) $ 19,181 $ 6,257 $ (2,530) Current year prior service cost (818) — 2,701 Transfer actuarial loss 17 — — Amortization of net loss 1,688 2,325 2,121 Amortization of prior service cost 177 166 398 $ 20,245 $ 8,748 $ 2,690
Components of net periodic benefit cost	Components of net periodic benefit cost: Domestic Plans 2022 2021 2020 Service cost $ 15,784 $ 16,356 $ 14,278 Interest cost 6,970 6,366 7,046 Expected return on plan assets (12,912) (12,293) (12,248) Amortization of net loss 6,670 10,099 5,684 Net periodic benefit cost $ 16,512 $ 20,528 $ 14,760 Foreign Plans 2022 2021 2020 Service cost $ 7,547 $ 8,159 $ 7,311 Interest cost 1,388 843 1,410 Expected return on plan assets (2,728) (2,838) (2,620) Amortization of net loss 1,688 2,325 2,121 Amortization of prior service cost 177 166 398 Net periodic benefit cost $ 8,072 $ 8,655 $ 8,620 Curtailment (24) 5 (8) Total Net periodic benefit cost $ 8,048 $ 8,660 $ 8,612
Schedule of projected benefit obligation ("PBO"), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets	The following table provides the projected benefit obligation (“PBO”), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets as of December 31, 2022 and 2021. Domestic Plans Foreign Plans 2022 2021 2022 2021 Projected benefit obligation $ 11,025 $ 255,457 $ 54,455 $ 89,595 Accumulated benefit obligation 10,087 236,295 40,481 63,614 Fair value of plan assets — 193,770 34,446 49,916
Schedule of PBO, ABO, and fair value of plan assets for all pension plans with a PBO in excess of plan assets	The following table provides the PBO, ABO and fair value of plan assets for all pension plans with a PBO in excess of plan assets as of December 31, 2022 and 2021. Domestic Plans Foreign Plans 2022 2021 2022 2021 Projected benefit obligation $ 11,025 $ 255,457 $ 71,730 $ 97,221 Accumulated benefit obligation 10,087 236,295 52,173 69,630 Fair value of plan assets — 193,770 47,236 56,228
Schedule of weighted-average assumptions used to determine benefit obligations and net periodic benefit cost	Assumptions: Domestic Plans Foreign Plans 2022 2021 2020 2022 2021 2020 Weighted-average assumptions used to determine benefit obligations at December 31: Discount rate 5.15 % 2.75 % 2.40 % 3.69 % 1.09 % 0.54 % Rate of compensation increase 3.20 % 3.17 % 3.19 % 3.21 % 3.05 % 3.05 % Weighted-average assumptions used to determine net periodic benefit cost for years ended December 31: Discount rate 2.75 % 2.40 % 3.20 % 1.20 % 0.66 % 1.12 % Expected long-term return on plan assets 7.00 % 7.00 % 7.00 % 3.53 % 3.56 % 3.59 % Rate of compensation increase 3.20 % 3.17 % 4.00 % 3.20 % 3.05 % 3.05 %
Schedule of domestic and foreign pension plan weighted-average asset allocations by asset category	Our domestic and foreign pension plan weighted-average asset allocations at December 31, 2022 and 2021 by asset category are as follows: Plan Assets: Domestic Plans Assets at December 31, Foreign Plans Assets at December 31, 2022 2021 2022 2021 Equity securities 47 % 48 % 5 % 6 % Fixed income securities 27 % 27 % 1 % 1 % Corporate debt securities — — 1 % 2 % Infrastructure 8 % 8 % — — Hedge funds 10 % 11 % — — Money market 1 % 1 % 1 % 1 % Investment Funds — — 92 % 90 % Real estate 7 % 5 % — — Total 100 % 100 % 100 % 100 %
Summary of fair value of pension plan assets	Domestic Fair Value Measurement at December 31, 2022 Foreign Fair Value Measurement at December 31, 2022 (In Thousands $) Total (Level 1) (Level 2) (Level 3) Total (Level 1) (Level 2) (Level 3) Cash and Short-term Securities (a) $ 1,260 $ 1,260 $ — $ — $ 516 $ 516 $ — $ — USD — 1,260 — — — — — — EUR — — — — — 505 — — Others — — — — — 11 — — Equity Securities (a) $ 66,338 $ 66,338 $ — $ — $ 3,769 $ 3,769 $ — $ — U.S. Large Cap Equities — 37,537 — — — — — — U.S. Small Cap Equities — 7,918 — — — — — — International Equities — 20,883 — — — 3,769 — — Fixed Income (a)(b) $ 28,443 $ 28,443 $ — $ — $ 723 $ 723 $ — $ — Corporate debts securities $ — $ — $ — $ — $ 1,135 $ 1,135 $ — $ — Euro Corporate Bonds (a) — — — — — 1,135 — — Investment Funds $ — $ — $ — $ — $ 66,380 $ 21,952 $ 44,428 $ — Mutual Funds in Equities (a) — — — — — 5,221 — — Mutual Funds in Bonds (a) — — — — — 15,901 — — Mutual Funds Diversified (a)(b) — — — — — 830 44,428 — Total Investments in Fair Value Hierarchy $ 96,041 $ 96,041 $ — $ — $ 72,523 $ 28,095 $ 44,428 $ — Investments at Net Asset Value per Share 66,110 — — — — — — — Total Investments $ 162,151 $ 96,041 $ — $ — $ 72,523 $ 28,095 $ 44,428 $ — Domestic Fair Value Measurement at December 31, 2021 Foreign Fair Value Measurement at December 31, 2021 (In Thousands $) Total (Level 1) (Level 2) (Level 3) Total (Level 1) (Level 2) (Level 3) Cash and Short-term Securities (a) $ 1,864 $ 1,864 $ — $ — $ 547 $ 547 $ — $ — USD — 1,864 — — — — — — EUR — — — — — 539 — — Others — — — — — 8 — — Equity Securities (a) $ 82,927 $ 82,927 $ — $ — $ 4,881 $ 4,881 $ — $ — U.S. Large Cap Equities — 49,637 — — — — — — U.S. Small Cap Equities — 9,112 — — — — — — International Equities — 24,178 — — — 4,881 — — Fixed Income (a)(b) $ 34,584 $ 34,584 $ — $ — $ 772 $ 772 $ — $ — Corporate debts securities $ — $ — $ — $ — $ 1,413 $ 1,413 $ — $ — Euro Corporate Bonds (a) — — — — — 1,413 — — Investment Funds $ — $ — $ — $ — $ 77,808 $ 26,381 $ 51,427 $ — Mutual Funds in Equities (a) — — — — — 4,576 — — Mutual Funds in Bonds (a) — — — — — 20,810 — — Mutual Funds Diversified (a)(b) — — — — — 995 51,427 — Total Investments in Fair Value Hierarchy $ 119,375 $ 119,375 $ — $ — $ 85,421 $ 33,994 $ 51,427 $ — Investments at Net Asset Value per Share 74,395 — — — — — — — Total Investments $ 193,770 $ 119,375 $ — $ — $ 85,421 $ 33,994 $ 51,427 $ — (a) Based on third party quotation from financial institution. (b) Based on observable market transactions.
Schedule of estimated benefit payments relating to defined benefit plans over the next ten years	As of December 31, 2022, we expect the plans to make the following estimated benefit payments relating to our defined benefit plans over the next ten years: Domestic Plans Foreign Plans 2023 $ 10,184 $ 2,652 2024 10,948 4,781 2025 11,241 6,658 2026 12,743 5,136 2027 11,828 7,700 2028 - 2032 70,372 38,262

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) (Tables)	12 Months Ended
	Dec. 31, 2022
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Changes in Accumulated Other Comprehensive Income/(Loss) by component	Changes in Accumulated Other Comprehensive Income/(Loss) by Component: Foreign Defined Benefit Derivatives Total Balance - December 31, 2019 $ (257,124) $ (83,147) $ (1,677) $ (341,948) Other comprehensive (loss) income before reclassifications 79,099 (25,389) (9,172) 44,538 Amounts reclassified from accumulated other comprehensive income — 6,214 9,487 15,701 Net current-period other comprehensive (loss) income 79,099 (19,175) 315 60,239 Balance - December 31, 2020 $ (178,025) $ (102,322) $ (1,362) $ (281,709) Other comprehensive income (loss) before reclassifications (71,475) 26,409 8,584 (36,482) Amounts reclassified from accumulated other comprehensive income (loss) — 9,427 (7,277) 2,150 Net current-period other comprehensive income (loss) (71,475) 35,836 1,307 (34,332) Balance - December 31, 2021 $ (249,500) $ (66,486) $ (55) $ (316,041) Other comprehensive (loss) income before reclassifications (79,240) 54,149 (6,666) (31,757) Amounts reclassified from accumulated other comprehensive income — 6,386 46 6,432 Net current-period other comprehensive (loss) income (79,240) 60,535 (6,620) (25,325) Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366)
Reclassifications out of Accumulated Other Comprehensive Income/(Loss)	Reclassifications Out of Accumulated Other Comprehensive Income/(Loss): Details about Accumulated Other Amount Reclassified from Affected Line in the Statement Year Ended December 31, 2022 2021 2020 Defined Benefit Pension Plans Amortization of net loss $ 8,358 $ 12,424 $ 7,805 (1) Amortization of prior service cost 177 166 398 (1) 8,535 12,590 8,203 Total before tax (2,149) (3,163) (1,989) Tax benefit $ 6,386 $ 9,427 $ 6,214 Net of tax Derivatives Changes in cross currency swap: interest component $ (171) $ (13) $ (1,474) Interest Expense Changes in cross currency swap: foreign exchange component 217 (7,264) 10,961 Miscellaneous, net 46 (7,277) 9,487 Total before tax — — — Tax benefit $ 46 $ (7,277) $ 9,487 Net of tax Total reclassifications for the period $ 6,432 $ 2,150 $ 15,701 (1) These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax (see Note 9 - Retirement and Deferred Compensation Plans for additional details).

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair value of derivative instruments in the Consolidated Balance Sheets	Fair Value of Derivative Instruments in the Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021 December 31, 2022 December 31, 2021 Balance Sheet Derivatives Derivatives Derivatives Derivatives Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 1,107 $ — $ 331 Cross Currency Swap Contract (1) Prepaid and other — — 511 — $ — $ 1,107 $ 511 $ 331 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 269 $ — $ 221 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 8,840 — — — $ 8,840 $ 269 $ — $ 221 (1) This cross currency swap contract is composed of both an interest component and a foreign exchange component.
Schedule of effect of derivatives designated as hedging instruments on Accumulated Other Comprehensive Income (Loss)	The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Fiscal Years Ended December 31, 2022 and December 31, 2021 Derivatives in Cash Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount 2022 2021 2022 2021 Cross currency swap contract: Interest component $ 229 $ 1,319 Interest expense $ 171 $ 13 $ (40,827) Foreign exchange component (6,894) 7,265 Miscellaneous, net (217) 7,264 (4,799) $ (6,665) $ 8,584 $ (46) $ 7,277
Schedule of effect of derivatives not designated as hedging instruments on the Consolidated Statements of Income	The Effect of Derivatives Not Designated as Hedging Instruments on the Consolidated Statements of Income for the Fiscal Years Ended December 31, 2022 and December 31, 2021 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2022 2021 Foreign Exchange Contracts Other (Expense) Income: $ 606 $ (87) $ 606 $ (87)
Schedule of offsetting derivative assets and liabilities	Gross Amounts Net Amounts Gross Amounts not Offset Gross Financial Cash Collateral Net Description December 31, 2022 Derivative Assets $ 1,107 $ — $ 1,107 $ — $ — $ 1,107 Total Assets $ 1,107 $ — $ 1,107 $ — $ — $ 1,107 Derivative Liabilities $ 9,109 $ — $ 9,109 $ — $ — $ 9,109 Total Liabilities $ 9,109 $ — $ 9,109 $ — $ — $ 9,109 December 31, 2021 Derivative Assets $ 842 $ — $ 842 $ — $ — $ 842 Total Assets $ 842 $ — $ 842 $ — $ — $ 842 Derivative Liabilities $ 221 $ — $ 221 $ — $ — $ 221 Total Liabilities $ 221 $ — $ 221 $ — $ — $ 221

FAIR VALUE (Tables)

FAIR VALUE (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of fair values of financial assets and liabilities	As of December 31, 2022, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 5,297 $ 5,297 $ — $ — Foreign exchange contracts (2) 1,107 — 1,107 — Convertible notes 5,650 — — 5,650 Total assets at fair value $ 12,054 $ 5,297 $ 1,107 $ 5,650 Liabilities Foreign exchange contracts (2) $ 269 $ — $ 269 $ — Cross currency swap contract (2) 8,840 — 8,840 — Contingent consideration obligation 25,310 — — 25,310 Total liabilities at fair value $ 34,419 $ — $ 9,109 $ 25,310 As of December 31, 2021, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 9,006 $ 9,006 $ — $ — Foreign exchange contracts (2) 331 — 331 — Cross currency swap contract (2) 511 — 511 — Total assets at fair value $ 9,848 $ 9,006 $ 842 $ — Liabilities Foreign exchange contracts (2) $ 221 $ — $ 221 $ — Contingent consideration obligation 33,908 — — 33,908 Total liabilities at fair value $ 34,129 $ — $ 221 $ 33,908 (1) Investment in PureCycle Technologies ("PCT" or "PureCycle"). See Note 20 - Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates.
Schedule of contingent consideration arrangements, fair value	We consider these obligations a Level 3 liability and have estimated the aggregate fair value for these contingent consideration arrangements as follows: December 31, 2022 December 31, 2021 Fusion Acquisition $ 25,310 $ 27,166 Noble Acquisition — 6,742 $ 25,310 $ 33,908
Summary of changes in Level 3 fair value measurements	The following table provides a summary of changes in our Level 3 fair value measurements: Balance, December 31, 2020 $ 31,140 Increase in fair value recorded in earnings 2,768 Balance, December 31, 2021 $ 33,908 Decrease in fair value recorded in earnings (8,598) Balance, December 31, 2022 $ 25,310

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	12 Months Ended
	Dec. 31, 2022
CAPITAL STOCK
Schedule of number of shares of common stock and treasury stock and the share activity	The number of shares of common stock and treasury stock and the share activity were as follows: Common Shares Treasury Shares 2022 2021 2020 2022 2021 2020 Balance at the beginning of the year 70,370,812 69,516,805 68,608,508 4,852,709 4,528,051 4,836,027 Employee option exercises 301,463 634,572 802,046 (157,682) (290,316) (307,976) Director option exercises — 47,500 26,551 — — — Restricted stock vestings 176,535 171,935 79,700 — — — Common stock repurchases — — — 860,000 614,974 — Balance at the end of the year 70,848,810 70,370,812 69,516,805 5,555,027 4,852,709 4,528,051

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Weighted-average assumptions used to estimate fair value of restricted stock units	Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Year Ended December 31, 2022 2021 2020 Fair value per stock award $ 141.95 $ 171.63 $ 94.98 Grant date stock price $ 114.52 $ 141.59 $ 83.93 Assumptions: Aptar's stock price expected volatility 20.20 % 21.40 % 23.80 % Expected average volatility of peer companies 41.70 % 50.00 % 48.50 % Correlation assumption 41.20 % 58.10 % 63.50 % Risk-free interest rate 2.04 % 0.32 % 0.31 % Dividend yield assumption 1.33 % 1.02 % 1.72 %
Summary of restricted stock unit activity	A summary of RSU activity as of December 31, 2022, and changes during the period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2022 485,479 $ 108.73 650,553 $ 111.04 Granted 205,403 111.50 249,656 123.97 Vested (256,872) 106.07 (43,388) 134.97 Forfeited (7,649) 111.73 (245,950) 100.75 Nonvested at December 31, 2022 426,361 $ 111.60 610,871 $ 118.77
Schedule of compensation expense, fair value, and intrinsic value related to RSU's	Year Ended December 31, 2022 2021 2020 Compensation expense $ 40,937 $ 38,643 $ 32,085 Fair value of units vested 32,013 32,414 12,038 Intrinsic value of units vested 33,024 42,970 14,446
Summary of option activity	A summary of option activity under our stock plans as of December 31, 2022, and changes during the period then ended is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2022 3,072,503 $ 71.99 51,700 $ 63.91 Exercised (447,109) 64.05 — — Forfeited or expired (1,450) 78.30 — — Outstanding at December 31, 2022 2,623,944 $ 73.34 51,700 $ 63.91 Exercisable at December 31, 2022 2,623,944 $ 73.34 51,700 $ 63.91 Weighted-Average Remaining Contractual Term (Years): Outstanding at December 31, 2022 3.3 1.1 Exercisable at December 31, 2022 3.3 1.1 Aggregate Intrinsic Value: Outstanding at December 31, 2022 $ 96,149 $ 2,382 Exercisable at December 31, 2022 $ 96,149 $ 2,382 Intrinsic Value of Options Exercised During the Years Ended: December 31, 2022 $ 20,608 $ — December 31, 2021 $ 69,862 $ 4,248 December 31, 2020 $ 59,179 $ 2,318
Schedule of compensation expense, and fair value related to options	Year Ended December 31, 2021 2020 Compensation expense (included in SG&A) $ 185 $ 1,693 Compensation expense (included in Cost of sales) 42 370 Compensation expense, Total $ 227 $ 2,063 Compensation expense, net of tax 174 1,573 Grant date fair value of options vested 2,421 7,601

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Reconciliation of basic and diluted earnings per share	The reconciliation of basic and diluted earnings per share (“EPS”) for the years ended December 31, 2022, 2021 and 2020 are as follows: Income Shares Per Share For the Year Ended December 31, 2022 Basic EPS Income available to common stockholders $ 239,288 65,402 $ 3.66 Effect of Dilutive Securities Stock options 978 Restricted stock 339 Diluted EPS Income available to common stockholders $ 239,288 66,719 $ 3.59 For the Year Ended December 31, 2021 Basic EPS Income available to common stockholders $ 244,097 65,663 $ 3.72 Effect of Dilutive Securities Stock options 1,600 Restricted stock 419 Diluted EPS Income available to common stockholders $ 244,097 67,682 $ 3.61 For the Year Ended December 31, 2020 Basic EPS Income available to common stockholders $ 214,040 64,418 $ 3.32 Effect of Dilutive Securities Stock options 1,800 Restricted stock 439 Diluted EPS Income available to common stockholders $ 214,040 66,657 $ 3.21

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Financial information regarding the company's reportable segments	Financial information regarding our reporting segments is shown below: Year Ended December 31, 2022 2021 2020 Total Sales: Pharma $ 1,372,449 $ 1,297,996 $ 1,234,107 Beauty + Home 1,461,894 1,456,208 1,320,988 Food + Beverage 523,643 511,112 407,435 Total Sales $ 3,357,986 $ 3,265,316 $ 2,962,530 Less: Intersegment Sales: Pharma $ 11,193 $ 13,372 $ 8,328 Beauty + Home 23,360 22,186 22,837 Food + Beverage 1,184 2,537 2,025 Total Intersegment Sales $ 35,737 $ 38,095 $ 33,190 Net Sales: Pharma $ 1,361,256 $ 1,284,624 $ 1,225,779 Beauty + Home 1,438,534 1,434,022 1,298,151 Food + Beverage 522,459 508,575 405,410 Net Sales $ 3,322,249 $ 3,227,221 $ 2,929,340 Adjusted EBITDA (1): Pharma $ 441,622 $ 425,714 $ 428,469 Beauty + Home 166,465 154,689 129,299 Food + Beverage 71,531 79,377 71,995 Corporate & Other, unallocated (62,930) (52,314) (43,443) Acquisition-related costs (2) (231) (3,811) (6,087) Restructuring Initiatives (3) (6,597) (23,240) (26,492) Net unrealized investment (loss) gain (4) (3,323) 2,709 — Depreciation and amortization (5) (233,706) (234,853) (220,300) Interest Expense (40,827) (30,284) (33,244) Interest Income 2,700 3,668 958 Income before Income Taxes $ 334,704 $ 321,655 $ 301,155 Depreciation and Amortization: Pharma $ 94,396 $ 90,510 $ 75,874 Beauty + Home 93,027 96,611 95,880 Food + Beverage 40,337 40,323 37,768 Corporate & Other 5,946 7,409 10,778 Depreciation and Amortization $ 233,706 $ 234,853 $ 220,300 Capital Expenditures: Pharma $ 164,396 $ 154,077 $ 117,835 Beauty + Home 86,048 100,531 93,980 Food + Beverage 32,378 34,136 29,956 Corporate & Other 29,491 29,686 15,690 Transfer of Corporate Technology Expenditures (6) (1,886) (10,495) (11,507) Capital Expenditures $ 310,427 $ 307,935 $ 245,954 Total Assets: Pharma $ 1,872,843 $ 1,833,512 $ 1,549,781 Beauty + Home 1,625,596 1,615,917 1,610,058 Food + Beverage 552,871 574,269 549,270 Corporate & Other 152,148 117,666 280,944 Total Assets $ 4,203,458 $ 4,141,364 $ 3,990,053 (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs and purchase accounting adjustments related to acquisitions and investments (see Note 19 – Acquisitions and Note 20 – Investment in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the years ended December 31, 2022, 2021 and 2020 as follows (see Note 21 – Restructuring Initiatives for further details): Year Ended December 31, 2022 2021 2020 Restructuring Initiatives by Segment Pharma $ — $ 76 $ 220 Beauty + Home 6,460 10,447 24,464 Food + Beverage 137 404 1,903 Corporate & Other — 12,313 (95) Total Restructuring Initiatives $ 6,597 $ 23,240 $ 26,492 (4) Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 20 - Investment in Equity Securities for further details). (5) Depreciation and amortization includes amortization related to acquisition purchase accounting adjustments. See the reconciliation of Non-U.S. GAAP measures. (6) The transfer of corporate technology expenditures represents amounts of projects managed by corporate for the benefit of specific entities within each segment. Once the projects are complete, all related costs are allocated from corporate to and paid by the appropriate entity and the associated assets are then depreciated at the entity level.
Restructuring Initiatives	Restructuring Initiatives includes expense items for the years ended December 31, 2022, 2021 and 2020 as follows (see Note 21 – Restructuring Initiatives for further details): Year Ended December 31, 2022 2021 2020 Restructuring Initiatives by Segment Pharma $ — $ 76 $ 220 Beauty + Home 6,460 10,447 24,464 Food + Beverage 137 404 1,903 Corporate & Other — 12,313 (95) Total Restructuring Initiatives $ 6,597 $ 23,240 $ 26,492
Schedule of net sales and long-lived asset information by geographic area	The following are net sales and long-lived asset information by geographic area and product information for the years ended December 31, 2022, 2021 and 2020: 2022 2021 2020 Net Sales to Unaffiliated Customers (1): United States $ 1,100,159 $ 1,081,823 $ 965,986 Europe: France 938,637 906,057 854,639 Germany 512,709 486,928 448,405 Italy 154,823 161,676 148,636 Other Europe 167,226 170,521 152,376 Total Europe 1,773,395 1,725,182 1,604,056 China 156,577 148,671 118,791 Other Foreign Countries 292,118 271,545 240,507 Total $ 3,322,249 $ 3,227,221 $ 2,929,340 Property, Plant and Equipment, Net United States $ 346,382 $ 321,511 $ 298,616 Europe: France 482,091 455,105 426,353 Germany 194,898 197,643 194,553 Italy 42,522 50,828 57,333 Other Europe 53,317 58,121 55,933 Total Europe 772,828 761,697 734,172 China 98,469 74,535 46,005 Other Foreign Countries 125,985 118,134 119,955 Total $ 1,343,664 $ 1,275,877 $ 1,198,748 (1) Sales are attributed to countries based upon where the sales invoice to unaffiliated customers is generated.

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Summary of assets acquired and liabilities assumed at estimated fair value	The following table summarizes the assets acquired and liabilities assumed for the Voluntis and Hengyu acquisitions as of the acquisition date at estimated fair value. 2021 Assets Cash and equivalents $ 3,852 Accounts receivable 5,208 Inventories 606 Other receivable 286 Prepaid and other 1,863 Property, plant and equipment 14,081 Goodwill 104,433 Intangible assets 65,981 Operating lease right-of-use assets 2,309 Other miscellaneous assets 78 Liabilities Current maturities of long-term obligations, net of unamortized debt issuance costs 1,410 Accounts payable, accrued and other liabilities 9,663 Deferred income taxes 16,792 Operating lease liabilities 2,306 Deferred and other non-current liabilities 5,770 Net assets acquired $ 162,756
Summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date	The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives for the Voluntis and Hengyu acquisitions as of the acquisition date: 2021 Weighted-Average Estimated Acquired technology 10 $ 34,322 Customer relationships 11.6 30,258 License agreements and other 0.25 1,401 Total $ 65,981

INVESTMENT IN EQUITY SECURITI_2

INVESTMENT IN EQUITY SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Schedule of investments in equity securities	Our investment in equity securities consisted of the following: December 31, 2022 December 31, 2021 Equity Method Investments BTY $ 31,490 $ 33,199 Sonmol 4,997 5,904 Desotec GmbH 863 919 Other Investments PureCycle 5,297 9,006 YAT 5,508 5,978 Loop 2,894 2,894 Others 1,259 1,585 $ 52,308 $ 59,485
Schedule of investment company, financial highlights	We have sold the following PCT shares related to the PureCycle investment: Shares Sold Proceeds Realized Gain October 2021 191,349 $ 2,434 $ 2,000 March 2022 107,600 $ 1,088 $ 841 August 2022 50,000 $ 511 $ 372
Schedule of other nonoperating income (expense)	For the years ended December 31, 2022, 2021 and 2020 we recorded the following net investment gain/(loss) on our investment in PureCycle: 2022 2021 2020 Net investment (loss) gain $ (2,110) $ 4,709 $ 3,064

RESTRUCTURING INITIATIVES (Tabl

RESTRUCTURING INITIATIVES (Tables)	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Schedule of restructuring reserve by type of cost	As of December 31, 2022 we have recorded the following activity associated with the transformation plan: Beginning Reserve at 12/31/2021 Net Charges for the Year Ended 12/31/2022 Cash Paid Interest and Ending Reserve at 12/31/2022 Employee severance $ 3,535 $ 303 $ (3,131) $ (153) $ 554 Professional fees and other costs 260 70 (313) (11) 6 Totals $ 3,795 $ 373 $ (3,444) $ (164) $ 560 During the third quarter of 2022, we began an initiative to optimize our operations and SG&A expenses. For the year ended December 31, 2022, we recognized $6.2 million of restructuring costs related to this plan. As of December 31, 2022, we have recorded the following activity associated with our optimization plan: Beginning Reserve at 12/31/2021 Net Charges for the Year Ended 12/31/2022 Cash Paid Interest and Ending Reserve at 12/31/2022 Employee severance $ — $ 5,454 $ (491) $ 30 $ 4,993 Professional fees and other costs — 770 (770) — — Totals $ — $ 6,224 $ (1,261) $ 30 $ 4,993

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($) segment	Dec. 31, 2020 USD ($) segment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of reportable segments | segment			3	3	3
Restructuring initiatives			$ 6,597	$ 23,240	$ 26,492
Business Transformation
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restructuring initiatives			$ 373	$ 23,200	$ 26,500
Argentina
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Foreign currency, gain recognized	$ 1,400	$ 1,000
Argentina | Maximum | Consolidated net revenues | Geographic concentration risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk			2%

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts receivable	$ 677,000,000
Accounts and notes receivable, less current expected credit loss (in dollars)	9,519,000	$ 7,374,000
Dividends received from affiliates	$ 0	$ 0	$ 0
Common stock repurchased (retired and held in treasury) (in shares)	860,000	615,000	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Research and development expenses incurred net of customer funded research and development or government research and development credits	$ 93,500,000	$ 99,800,000	$ 92,500,000
Foreign currency transaction gain (loss)	(7,200,000)	(1,400,000)	$ (5,600,000)
Accounts payable, accrued and other liabilities	30,800,000	30,100,000
Government | France
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Proceeds from government grants, used for expansion of facility	10,500,000
Funding to be received by US government	14,000,000
Government | United States
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Proceeds from government grants, used for new facility	$ 17,300,000	2,000,000
Funding to be received by US government		$ 19,000,000
Buildings and improvements | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives (in years)	10 years
Buildings and improvements | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives (in years)	40 years
Machinery and equipment | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives (in years)	3 years
Machinery and equipment | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives (in years)	15 years
Finite-Lived Intangible Assets | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Finite-lived intangible asset, useful life (in years)	1 year
Finite-Lived Intangible Assets | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Finite-lived intangible asset, useful life (in years)	50 years

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Supply Chain Finance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
SCF [Roll Forward]
SCF obligations outstanding at the beginning of the year	$ 30,144	$ 23,000
Additions	133,148	108,439
Settlements	(132,459)	(101,295)
SCF obligations outstanding at the end of the year	$ 30,833	$ 30,144

REVENUE - Revenue by Geographic

REVENUE - Revenue by Geographic Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
REVENUE
Net Sales	$ 3,322,249	$ 3,227,221	$ 2,929,340
Pharma
REVENUE
Net Sales	1,361,256	1,284,624	1,225,779
Beauty + Home
REVENUE
Net Sales	1,438,534	1,434,022	1,298,151
Food + Beverage
REVENUE
Net Sales	522,459	508,575	405,410
Europe
REVENUE
Net Sales	1,773,395	1,725,182	1,604,056
Europe | Pharma
REVENUE
Net Sales	836,447	830,552	808,834
Europe | Beauty + Home
REVENUE
Net Sales	801,798	765,071	681,936
Europe | Food + Beverage
REVENUE
Net Sales	135,150	129,559	113,286
Domestic
REVENUE
Net Sales	1,100,159	1,081,823	965,986
Domestic | Pharma
REVENUE
Net Sales	426,401	374,063	350,265
Domestic | Beauty + Home
REVENUE
Net Sales	373,125	412,761	384,004
Domestic | Food + Beverage
REVENUE
Net Sales	300,633	294,999	231,717
Latin America
REVENUE
Net Sales	235,463	216,043	194,043
Latin America | Pharma
REVENUE
Net Sales	27,075	21,482	23,157
Latin America | Beauty + Home
REVENUE
Net Sales	160,827	147,569	141,846
Latin America | Food + Beverage
REVENUE
Net Sales	47,561	46,992	29,040
Asia
REVENUE
Net Sales	213,232	204,173	165,255
Asia | Pharma
REVENUE
Net Sales	71,333	58,527	43,523
Asia | Beauty + Home
REVENUE
Net Sales	102,784	108,621	90,365
Asia | Food + Beverage
REVENUE
Net Sales	$ 39,115	$ 37,025	$ 31,367

REVENUE - Contract Assets and C

REVENUE - Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Contract asset (current)	$ 16,736	$ 16,878
Increase / (decrease) in contract asset (current)	(142)
Contract liability (current)	80,241	86,340
Increase / (decrease) in contract liability (current)	(6,099)
Contract liability (long-term)	25,361	$ 21,905
Increase / (decrease) in contract liability (long-term)	3,456
Revenue recognized previously included in current contract liabilities	141,500
Revenue recognized previously included in current contract liabilities at the beginning of the year	$ 64,200

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventories, by component
Raw materials	$ 159,041	$ 140,818
Work in process	153,592	137,654
Finished goods	174,173	162,992
Total	$ 486,806	$ 441,464

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Changes in the carrying amount of goodwill
Goodwill beginning balance	$ 974,157,000	$ 898,521,000
Acquisition	3,029,000	104,433,000
Foreign currency exchange effects	(31,554,000)	(28,797,000)
Goodwill ending balance	945,632,000	974,157,000	$ 898,521,000
Impairment of goodwill	0	0	0
Operating Segments | Pharma
Changes in the carrying amount of goodwill
Goodwill beginning balance	520,197,000	436,731,000
Acquisition	3,029,000	104,433,000
Foreign currency exchange effects	(24,484,000)	(20,967,000)
Goodwill ending balance	498,742,000	520,197,000	436,731,000
Operating Segments | Beauty + Home
Changes in the carrying amount of goodwill
Goodwill beginning balance	325,719,000	333,111,000
Acquisition	0	0
Foreign currency exchange effects	(6,708,000)	(7,392,000)
Goodwill ending balance	319,011,000	325,719,000	333,111,000
Operating Segments | Food + Beverage
Changes in the carrying amount of goodwill
Goodwill beginning balance	128,241,000	128,679,000
Acquisition	0	0
Foreign currency exchange effects	(362,000)	(438,000)
Goodwill ending balance	$ 127,879,000	$ 128,241,000	$ 128,679,000

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Amortized intangible assets:
Gross Carrying Amount	$ 508,652	$ 516,739
Accumulated Amortization	(192,908)	(154,396)
Net Value	315,744	362,343
Aggregate amortization expense	$ 43,574	41,072	$ 39,787
Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	13 years 2 months 12 days
Patents
Amortized intangible assets:
Gross Carrying Amount	$ 8,044	2,767
Accumulated Amortization	(1,968)	(1,528)
Net Value	$ 6,076	1,239
Patents | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	8 years 9 months 18 days
Acquired technology
Amortized intangible assets:
Gross Carrying Amount	$ 135,191	140,936
Accumulated Amortization	(56,628)	(45,613)
Net Value	$ 78,563	95,323
Acquired technology | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	11 years 6 months
Customer relationships
Amortized intangible assets:
Gross Carrying Amount	$ 305,994	311,964
Accumulated Amortization	(99,130)	(77,512)
Net Value	$ 206,864	234,452
Customer relationships | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	13 years 4 months 24 days
Trademarks and trade names
Amortized intangible assets:
Gross Carrying Amount	$ 43,998	44,893
Accumulated Amortization	(28,190)	(22,886)
Net Value	$ 15,808	22,007
Trademarks and trade names | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	7 years 2 months 12 days
License agreements and other
Amortized intangible assets:
Gross Carrying Amount	$ 15,425	16,179
Accumulated Amortization	(6,992)	(6,857)
Net Value	$ 8,433	$ 9,322
License agreements and other | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	38 years 7 months 6 days

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 43,723
2024	40,547
2025	39,061
2026	36,863
2027	29,720
2028 and thereafter	$ 125,830

ACCOUNTS PAYABLE, ACCRUED AND_3

ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts payable, principally trade	$ 320,281	$ 285,262
Accrued employee compensation costs	209,566	195,308
Customer deposits and other unearned income	80,113	86,953
Other accrued liabilities	184,425	125,342
Total	$ 794,385	$ 692,865

INCOME TAXES - Provision (Benef

INCOME TAXES - Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income before income taxes:
United States	$ 65,350	$ 101,353	$ 91,555
International	269,354	220,302	209,600
Income before Income Taxes	334,704	321,655	301,155
Current:
U.S. Federal	12,791	11,932	9,934
State/Local	2,265	4,917	3,094
International	92,199	75,524	82,235
Total Current	107,255	92,373	95,263
Deferred:
U.S. Federal/State	(882)	(11,168)	(2,270)
International	(11,224)	(3,188)	(5,928)
Total Deferred	(12,106)	(14,356)	(8,198)
Actual income tax provision	$ 95,149	$ 78,017	$ 87,065

INCOME TAXES - Effective Income

INCOME TAXES - Effective Income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax at statutory rate	$ 70,288	$ 67,547	$ 63,243
State income taxes, net of federal tax effect	1,475	1,616	2,396
Excess tax benefits from share-based compensation	(3,306)	(16,060)	(11,625)
Deferred tax (benefits) charges, incl. tax rate changes	(2,349)	(1,040)	4,110
U.S. Global Intangible Low-Taxed Income ("GILTI") and Base Erosion Anti-Abuse Tax ("BEAT")	3,129	0	(3,909)
Valuation allowance	1,486	4,485	1,332
Legal entity reorganization	5,850	0	0
Rate differential on earnings of foreign operations	19,165	20,831	24,901
Other items, net	(589)	638	6,617
Actual income tax provision	$ 95,149	$ 78,017	$ 87,065
Effective income tax rate	28.40%	24.30%	28.90%

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Valuation Allowance [Line Items]
Excess tax benefits from share-based compensation	$ 3,306	$ 16,060	$ 11,625
Legal entity reorganization	5,850	0	0
Deferred tax assets, valuation allowance	46,239	47,149
Net operating loss carryforwards	45,823	47,660
Tax-effected net operating loss subject to expiration	3,300
Tax-effected net operating loss carryforwards not subject to expiration	42,500
Contingent foreign income tax payable on uncertain tax positions	1,300
Unrecognized tax benefits that would impact effective tax rate	6,900
Decrease in unrecognized tax benefits is reasonably possible	3,400
Unrecognized tax benefits, income tax penalties and interest accrued	4,900	4,600	3,600
Unrecognized tax benefits, income tax penalties and interest expense	$ 300	$ 1,100	$ 1,700
Effective Income Tax Reconciliation, Excluding Legal Entity Reorganization Impact	26.70%
State and Local Jurisdiction
Valuation Allowance [Line Items]
Tax-effected net operating loss subject to expiration	$ 6,800
Minimum | Foreign Tax Authority
Valuation Allowance [Line Items]
Estimated additional tax payable on previously unremitted earnings	15,000
Maximum | Foreign Tax Authority
Valuation Allowance [Line Items]
Estimated additional tax payable on previously unremitted earnings	20,000
Deferred tax assets for specified locations
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	39,200
Deferred tax assets related to tax credit carryforwards, U.S. state
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	$ 4,000

INCOME TAXES - Deferred Tax Ass

INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets:
Net operating loss carryforwards	$ 45,823	$ 47,660
Operating and finance leases	20,974	22,492
Pension liabilities	8,178	29,770
Share-based compensation	9,970	6,764
U.S. federal tax credits	0	4,226
U.S. state tax credits	6,777	7,047
Vacation and bonus	14,681	13,450
U.S. capitalized research expenditures	27,840	19,633
Inventory	4,736	6,969
Accrued liabilities and other reserves	10,346	3,109
Other	11,744	16,194
Total gross deferred tax assets	161,069	177,314
Less valuation allowance	(46,239)	(47,149)
Net deferred tax assets	114,830	130,165
Deferred Tax Liabilities:
Acquisition related intangibles	59,084	68,174
Depreciation and amortization	29,142	30,997
Operating and finance leases	23,041	24,560
Other	6,563	7,489
Total gross deferred tax liabilities	117,830	131,220
Net deferred tax liabilities	$ (3,000)	$ (1,055)

INCOME TAXES - Reconciliation o

INCOME TAXES - Reconciliation of Income Tax Uncertainties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of the beginning and ending amount of income tax uncertainties
Balance at the beginning of period	$ 7,225	$ 4,504	$ 3,647
Increases based on tax positions for the current year	1,433	262	212
Increases based on tax positions of prior years	966	3,348	790
Decreases based on tax positions of prior years	(2,582)	0	0
Settlements	(80)	(567)	0
Lapse of statute of limitations	(43)	(322)	(145)
Balance at the end of period	$ 6,919	$ 7,225	$ 4,504

DEBT - Short-term Debt Obligati

DEBT - Short-term Debt Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Short-term Debt [Line Items]
Revolving credit facility and overdrafts	$ 3,810	$ 147,276
Revolving credit facility
Short-term Debt [Line Items]
Interest rate	1.68%
Revolving credit facility and overdrafts	$ 0	144,383
Overdrafts
Short-term Debt [Line Items]
Interest rate	15.37%
Revolving credit facility and overdrafts	$ 3,810	$ 2,893

DEBT - Narrative (Details)

DEBT - Narrative (Details) € in Millions		3 Months Ended		12 Months Ended
	Jun. 30, 2021 USD ($) extension	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 06, 2022	Mar. 07, 2022 USD ($)	Dec. 31, 2021 EUR (€)	Oct. 31, 2020 USD ($)
Debt Instrument [Line Items]
Short-term borrowing				$ 3,810,000	$ 147,276,000
Money Market Borrowing Arrangement
Debt Instrument [Line Items]
Short-term borrowing				0	0
Short-term borrowing, maximum borrowing capacity									$ 30,000,000
Amended Revolving Credit Facility Maturing In June 2026
Debt Instrument [Line Items]
Line of credit facility, number of extensions | extension	2
Line of credit facility, duration of extension (in years)	1 year
Line of credit facility, maximum borrowing capacity	$ 600,000,000
Line of credit facility, increase limit	$ 300,000,000
Compensating balance, amount				0
Interest and fees				1,200,000	1,100,000
Amended Revolving Credit Facility Maturing In June 2026 | United States
Debt Instrument [Line Items]
Short-term borrowing					133,000,000
Amended Revolving Credit Facility Maturing In June 2026 | United Kingdom
Debt Instrument [Line Items]
Short-term borrowing					11,400,000			€ 10
Prior Credit Facility
Debt Instrument [Line Items]
Short-term borrowing					56,000,000
Unsecured Lines Of Credit
Debt Instrument [Line Items]
Line of credit facility, average outstanding amount				$ 38,500,000	$ 37,800,000
Short-term debt, weighted average interest rate, over time				1.20%	1.10%
Senior unsecured notes 3.6%, due in 2032, net of discount of $1.0 million
Debt Instrument [Line Items]
Debt instrument, face amount							$ 400,000,000
Interest rate on notes (as a percent)				3.60%		3.60%	3.60%
Private Placement Notes | Unsecured Debt
Debt Instrument [Line Items]
Interest rate on notes (as a percent)		3.49%	3.25%
Repayments of unsecured debt		$ 125,000,000	$ 75,000,000
Repayment of unsecured debt, make-whole payment			$ 400,000

DEBT - Long-Term Obligations (D

DEBT - Long-Term Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Jul. 06, 2022	Mar. 07, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total finance lease liabilities	$ 26,934			$ 30,185
Unamortized debt issuance costs	(4,558)			(1,085)
Long-term debt and lease obligation, including current maturities	1,171,578			1,049,375
Current maturities of long-term obligations	(118,981)			(142,351)
Long-Term Obligations, net of unamortized debt issuance costs	$ 1,052,597			907,024
Consolidated leverage ratio	1.71
Consolidated interest coverage ratio	15
Minimum
Debt Instrument [Line Items]
Consolidated interest coverage ratio	3
Maximum
Debt Instrument [Line Items]
Consolidated leverage ratio	3.50
Notes payable 0.00% – 16.42%, due in monthly and annual installments through 2030
Debt Instrument [Line Items]
Long-term debt, gross	$ 29,167			22,785
Notes payable 0.00% – 16.42%, due in monthly and annual installments through 2030 | Minimum
Debt Instrument [Line Items]
Interest rate on notes (as a percent)	0%
Notes payable 0.00% – 16.42%, due in monthly and annual installments through 2030 | Maximum
Debt Instrument [Line Items]
Interest rate on notes (as a percent)	16.42%
Senior unsecured notes 3.2%, due in 2022
Debt Instrument [Line Items]
Long-term debt, gross	$ 0			75,000
Interest rate on notes (as a percent)	3.20%
Senior unsecured debts 2.19% USD floating swapped to 1.36% EUR fixed, due in 2022
Debt Instrument [Line Items]
Long-term debt, gross	$ 0			56,000
Interest rate on notes (as a percent)	1.36%
Floating interest rate prior to conversion to a fixed interest rate (as a percent)	2.19%
Senior unsecured notes 3.5%, due in 2023
Debt Instrument [Line Items]
Long-term debt, gross	$ 0			125,000
Interest rate on notes (as a percent)	3.50%
Senior unsecured notes 1.0%, due in 2023
Debt Instrument [Line Items]
Long-term debt, gross	$ 106,995			113,830
Interest rate on notes (as a percent)	1%
Senior unsecured notes 3.4%, due in 2024
Debt Instrument [Line Items]
Long-term debt, gross	$ 50,000			50,000
Interest rate on notes (as a percent)	3.40%
Senior unsecured notes 3.5%, due in 2024
Debt Instrument [Line Items]
Long-term debt, gross	$ 100,000			100,000
Interest rate on notes (as a percent)	3.50%
Senior unsecured notes 1.2%, due in 2024
Debt Instrument [Line Items]
Long-term debt, gross	$ 213,990			227,660
Interest rate on notes (as a percent)	1.20%
Senior unsecured notes 3.6%, due in 2025
Debt Instrument [Line Items]
Long-term debt, gross	$ 125,000			125,000
Interest rate on notes (as a percent)	3.60%
Senior unsecured notes 3.6%, due in 2026
Debt Instrument [Line Items]
Long-term debt, gross	$ 125,000			125,000
Interest rate on notes (as a percent)	3.60%
Senior unsecured notes 3.6%, due in 2032, net of discount of $1.0 million
Debt Instrument [Line Items]
Long-term debt, gross	$ 399,050			$ 0
Interest rate on notes (as a percent)	3.60%	3.60%	3.60%
Debt instrument, discount	$ 1,000

DEBT - Long-Term Maturities (De

DEBT - Long-Term Maturities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 115,815
2024	369,183
2025	133,313
2026	131,647
2027	73
Thereafter	$ 399,171

LEASE COMMITMENTS - Components

LEASE COMMITMENTS - Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Components of lease expense:
Operating lease cost	$ 21,105	$ 23,040
Finance lease cost:
Amortization of right-of-use assets	4,249	4,228
Interest on lease liabilities	1,249	1,360
Total finance lease cost	5,498	5,588
Short-term lease and variable lease costs	$ 15,454	$ 12,259

LEASE COMMITMENTS - Supplementa

LEASE COMMITMENTS - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 20,488	$ 22,821
Operating cash flows from finance leases	1,264	1,374
Financing cash flows from finance leases	3,662	4,349
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	16,754	17,785
Finance leases	$ 1,011	$ 5,922

LEASE COMMITMENTS - Supplemen_2

LEASE COMMITMENTS - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Operating Leases
Operating lease right-of-use assets	$ 58,675	$ 62,454
Accounts payable, accrued and other liabilities	16,985	15,356
Operating lease liabilities	42,948	48,010
Total operating lease liabilities	$ 59,933	$ 63,366
Operating lease, liability, current, Statement of Financial Position [Extensible List]	Accounts payable, accrued and other liabilities	Accounts payable, accrued and other liabilities
Finance Leases
Property, plant and equipment, gross	$ 50,173	$ 51,821
Accumulated depreciation	(12,781)	(9,864)
Property, plant and equipment, net	37,392	41,957
Current maturities of long-term obligations, net of unamortized debt issuance cost	3,234	3,744
Long-term obligations, net of unamortized debt issuance cost	23,700	26,441
Total finance lease liabilities	$ 26,934	$ 30,185
Finance lease, right-of-use asset, Statement of Financial Position [Extensible List]	Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization	Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization
Finance lease, liability, current, Statement of Financial Position [Extensible List]	Long-Term Debt and Lease Obligation, Current	Long-Term Debt and Lease Obligation, Current
Finance lease, liability, noncurrent, Statement of Financial Position [Extensible List]	Long-Term Obligations, net of unamortized debt issuance costs	Long-Term Obligations, net of unamortized debt issuance costs
Weighted Average Remaining Lease Term (in years)
Operating leases	4 years 7 months 6 days	5 years 2 months 12 days
Finance leases	6 years 7 months 6 days	7 years 4 months 24 days
Weighted Average Discount Rate
Operating leases	4.01%	3.80%
Finance leases	4.76%	4.62%

LEASE COMMITMENTS - Maturities

LEASE COMMITMENTS - Maturities of Lease Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Leases
Year 1	$ 19,193,000
Year 2	14,414,000
Year 3	10,011,000
Year 4	8,479,000
Year 5	6,908,000
Thereafter	6,860,000
Total lease payments	65,865,000
Less imputed interest	(5,932,000)
Total operating lease liabilities	59,933,000	$ 63,366,000
Finance Leases
Year 1	4,454,000
Year 2	3,691,000
Year 3	3,572,000
Year 4	2,807,000
Year 5	6,003,000
Thereafter	11,832,000
Total lease payments	32,359,000
Less imputed interest	(5,425,000)
Total finance lease liabilities	26,934,000	$ 30,185,000
Amount of additional operating leases that have not yet commenced	400,000
Amount of additional finance leases that have not yet commenced	$ 0
Minimum
Finance Leases
Term of operating and finance leases that have not yet commenced (in years)	3 years
Operating Leased Assets [Line Items]
Term of operating and finance leases that have not yet commenced (in years)	3 years
Maximum
Finance Leases
Term of operating and finance leases that have not yet commenced (in years)	5 years
Operating Leased Assets [Line Items]
Term of operating and finance leases that have not yet commenced (in years)	5 years

RETIREMENT AND DEFERRED COMPE_3

RETIREMENT AND DEFERRED COMPENSATION PLANS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
United States
Change in benefit obligation:
Benefit obligation at beginning of year	$ 255,457	$ 272,471
Service cost	15,784	16,356	$ 14,278
Interest cost	6,970	6,366	7,046
Curtailment/Settlement	0	0
Prior service cost	0	0
Actuarial gain	(92,724)	(18,526)
Benefits paid	(21,615)	(21,210)
Foreign currency translation adjustment	0	0
Benefit obligation at end of year	163,872	255,457	272,471
Change in plan assets:
Fair value of plan assets at beginning of year	193,770	192,034
Actual return on plan assets	(25,517)	22,480
Employer contribution	15,513	466
Benefits paid	(21,615)	(21,210)
Transfer	0	0
Foreign currency translation adjustment	0	0
Fair value of plan assets at end of year	162,151	193,770	192,034
Funded status at end of year	(1,721)	(61,687)
Funded status amounts recognized in Consolidated Balance Sheet
Non-current assets	9,304	0
Current liabilities	(515)	(500)
Non-current liabilities	(10,510)	(61,187)
Funded status amount	(1,721)	(61,687)
Amounts recognized in accumulated other comprehensive loss
Net actuarial (gain) loss	(3,338)	57,627
Net prior service cost	0	0
Tax effects	2,271	(12,873)
Net amount recognized	(1,067)	44,754
Changes in benefit obligations and plan assets recognized in other comprehensive income
Current year actuarial gain (loss)	54,295	28,714	(33,335)
Amortization of net loss	6,670	10,099	5,684
Net amount recognized	60,965	38,813	(27,651)
Components of net periodic benefit cost:
Service cost	15,784	16,356	14,278
Interest cost	6,970	6,366	7,046
Expected return on plan assets	(12,912)	(12,293)	(12,248)
Amortization of net loss	6,670	10,099	5,684
Net periodic benefit cost	16,512	20,528	$ 14,760
Accumulated benefit obligation	152,400	236,300
Projected benefit obligation ("PBO"), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets
Projected benefit obligation	11,025	255,457
Accumulated benefit obligation	10,087	236,295
Fair value of plan assets	0	193,770
PBO, ABO, and fair value of plan assets for all pension plans with a PBO in excess of plan assets
Projected benefit obligation	11,025	255,457
Accumulated benefit obligation	10,087	236,295
Fair value of plan assets	$ 0	$ 193,770
Weighted-average assumptions used to determine benefit obligations
Discount rate	5.15%	2.75%	2.40%
Rate of compensation increase	3.20%	3.17%	3.19%
Weighted-average assumptions used to determine net periodic benefit cost
Discount rate	2.75%	2.40%	3.20%
Expected long-term return on plan assets	7%	7%	7%
Rate of compensation increase	3.20%	3.17%	4%
Plan assets, actual allocation percentage	100%	100%
Plan Assets:
Total investments	$ 162,151	$ 193,770	$ 192,034
United States | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	193,770
Fair value of plan assets at end of year	162,151	193,770
Plan Assets:
Total investments	$ 162,151	$ 193,770
United States | Equity securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	47%	48%
Target allocation percentage	58%
United States | Fixed income securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	27%	27%
United States | Corporate debt securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
United States | Investment Funds
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
United States | Infrastructure
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	8%	8%
United States | Hedge funds
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	10%	11%
United States | Money market
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	1%	1%
United States | Real estate
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	7%	5%
United States | Fixed income securities and infrastructure
Weighted-average assumptions used to determine net periodic benefit cost
Target allocation percentage	42%
United States | Fair Value, Inputs, Level 1, 2 and 3 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	$ 119,375
Fair value of plan assets at end of year	96,041	$ 119,375
Plan Assets:
Total investments	96,041	119,375
United States | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,864
Fair value of plan assets at end of year	1,260	1,864
Plan Assets:
Total investments	1,260	1,864
United States | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	82,927
Fair value of plan assets at end of year	66,338	82,927
Plan Assets:
Total investments	66,338	82,927
United States | Fair Value, Inputs, Level 1, 2 and 3 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	34,584
Fair value of plan assets at end of year	28,443	34,584
Plan Assets:
Total investments	28,443	34,584
United States | Fair Value, Inputs, Level 1, 2 and 3 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	119,375
Fair value of plan assets at end of year	96,041	119,375
Plan Assets:
Total investments	96,041	119,375
United States | Level 1 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,864
Fair value of plan assets at end of year	1,260	1,864
Plan Assets:
Total investments	1,260	1,864
United States | Level 1 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,864
Fair value of plan assets at end of year	1,260	1,864
Plan Assets:
Total investments	1,260	1,864
United States | Level 1 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	82,927
Fair value of plan assets at end of year	66,338	82,927
Plan Assets:
Total investments	66,338	82,927
United States | Level 1 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	49,637
Fair value of plan assets at end of year	37,537	49,637
Plan Assets:
Total investments	37,537	49,637
United States | Level 1 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	9,112
Fair value of plan assets at end of year	7,918	9,112
Plan Assets:
Total investments	7,918	9,112
United States | Level 1 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	24,178
Fair value of plan assets at end of year	20,883	24,178
Plan Assets:
Total investments	20,883	24,178
United States | Level 1 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	34,584
Fair value of plan assets at end of year	28,443	34,584
Plan Assets:
Total investments	28,443	34,584
United States | Level 1 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Net Asset Value per Share | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	74,395
Fair value of plan assets at end of year	66,110	74,395
Plan Assets:
Total investments	66,110	74,395
Foreign Plans
Change in benefit obligation:
Benefit obligation at beginning of year	123,386	134,426
Service cost	7,547	8,159	7,311
Interest cost	1,388	843	1,410
Curtailment/Settlement	68	5
Prior service cost	813	0
Actuarial gain	(26,826)	(6,489)
Benefits paid	(4,615)	(4,555)
Foreign currency translation adjustment	(7,762)	(9,003)
Benefit obligation at end of year	93,999	123,386	134,426
Change in plan assets:
Fair value of plan assets at beginning of year	85,421	85,087
Actual return on plan assets	(4,897)	2,811
Employer contribution	1,871	7,966
Benefits paid	(4,615)	(4,555)
Transfer	0	124
Foreign currency translation adjustment	(5,257)	(6,012)
Fair value of plan assets at end of year	72,523	85,421	85,087
Funded status at end of year	(21,476)	(37,965)
Funded status amounts recognized in Consolidated Balance Sheet
Non-current assets	0	1,832
Current liabilities	(31)	(33)
Non-current liabilities	(21,445)	(39,764)
Funded status amount	(21,476)	(37,965)
Amounts recognized in accumulated other comprehensive loss
Net actuarial (gain) loss	11,383	32,269
Net prior service cost	1,150	509
Tax effects	(5,518)	(11,049)
Net amount recognized	7,015	21,729
Changes in benefit obligations and plan assets recognized in other comprehensive income
Current year actuarial gain (loss)	19,181	6,257	(2,530)
Current year prior service cost	(818)	0	2,701
Transfer actuarial loss	17	0	0
Amortization of net loss	1,688	2,325	2,121
Amortization of prior service cost	177	166	398
Net amount recognized	20,245	8,748	2,690
Components of net periodic benefit cost:
Service cost	7,547	8,159	7,311
Interest cost	1,388	843	1,410
Expected return on plan assets	(2,728)	(2,838)	(2,620)
Amortization of net loss	1,688	2,325	2,121
Amortization of prior service cost	177	166	398
Net periodic benefit cost	8,072	8,655	8,620
Curtailment	(24)	5	(8)
Total Net periodic benefit cost	8,048	8,660	$ 8,612
Accumulated benefit obligation	73,800	96,000
Projected benefit obligation ("PBO"), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets
Projected benefit obligation	54,455	89,595
Accumulated benefit obligation	40,481	63,614
Fair value of plan assets	34,446	49,916
PBO, ABO, and fair value of plan assets for all pension plans with a PBO in excess of plan assets
Projected benefit obligation	71,730	97,221
Accumulated benefit obligation	52,173	69,630
Fair value of plan assets	$ 47,236	$ 56,228
Weighted-average assumptions used to determine benefit obligations
Discount rate	3.69%	1.09%	0.54%
Rate of compensation increase	3.21%	3.05%	3.05%
Weighted-average assumptions used to determine net periodic benefit cost
Discount rate	1.20%	0.66%	1.12%
Expected long-term return on plan assets	3.53%	3.56%	3.59%
Rate of compensation increase	3.20%	3.05%	3.05%
Plan assets, actual allocation percentage	100%	100%
Plan Assets:
Total investments	$ 72,523	$ 85,421	$ 85,087
Foreign Plans | Equity securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	5%	6%
Foreign Plans | Fixed income securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	1%	1%
Foreign Plans | Corporate debt securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	1%	2%
Foreign Plans | Investment Funds
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	92%	90%
Target allocation percentage	100%
Foreign Plans | Infrastructure
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
Foreign Plans | Hedge funds
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
Foreign Plans | Money market
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	1%	1%
Foreign Plans | Real estate
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	$ 85,421
Fair value of plan assets at end of year	72,523	$ 85,421
Plan Assets:
Total investments	72,523	85,421
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	547
Fair value of plan assets at end of year	516	547
Plan Assets:
Total investments	516	547
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	4,881
Fair value of plan assets at end of year	3,769	4,881
Plan Assets:
Total investments	3,769	4,881
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	772
Fair value of plan assets at end of year	723	772
Plan Assets:
Total investments	723	772
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,413
Fair value of plan assets at end of year	1,135	1,413
Plan Assets:
Total investments	1,135	1,413
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	77,808
Fair value of plan assets at end of year	66,380	77,808
Plan Assets:
Total investments	66,380	77,808
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 1 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	33,994
Fair value of plan assets at end of year	28,095	33,994
Plan Assets:
Total investments	28,095	33,994
Foreign Plans | Level 1 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	547
Fair value of plan assets at end of year	516	547
Plan Assets:
Total investments	516	547
Foreign Plans | Level 1 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 1 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	539
Fair value of plan assets at end of year	505	539
Plan Assets:
Total investments	505	539
Foreign Plans | Level 1 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	8
Fair value of plan assets at end of year	11	8
Plan Assets:
Total investments	11	8
Foreign Plans | Level 1 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	4,881
Fair value of plan assets at end of year	3,769	4,881
Plan Assets:
Total investments	3,769	4,881
Foreign Plans | Level 1 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 1 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 1 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	4,881
Fair value of plan assets at end of year	3,769	4,881
Plan Assets:
Total investments	3,769	4,881
Foreign Plans | Level 1 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	772
Fair value of plan assets at end of year	723	772
Plan Assets:
Total investments	723	772
Foreign Plans | Level 1 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,413
Fair value of plan assets at end of year	1,135	1,413
Plan Assets:
Total investments	1,135	1,413
Foreign Plans | Level 1 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,413
Fair value of plan assets at end of year	1,135	1,413
Plan Assets:
Total investments	1,135	1,413
Foreign Plans | Level 1 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	26,381
Fair value of plan assets at end of year	21,952	26,381
Plan Assets:
Total investments	21,952	26,381
Foreign Plans | Level 1 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	4,576
Fair value of plan assets at end of year	5,221	4,576
Plan Assets:
Total investments	5,221	4,576
Foreign Plans | Level 1 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	20,810
Fair value of plan assets at end of year	15,901	20,810
Plan Assets:
Total investments	15,901	20,810
Foreign Plans | Level 1 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	995
Fair value of plan assets at end of year	830	995
Plan Assets:
Total investments	830	995
Foreign Plans | Level 2 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	51,427
Fair value of plan assets at end of year	44,428	51,427
Plan Assets:
Total investments	44,428	51,427
Foreign Plans | Level 2 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	51,427
Fair value of plan assets at end of year	44,428	51,427
Plan Assets:
Total investments	44,428	51,427
Foreign Plans | Level 2 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	51,427
Fair value of plan assets at end of year	44,428	51,427
Plan Assets:
Total investments	44,428	51,427
Foreign Plans | Level 3 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	$ 0	$ 0

RETIREMENT AND DEFERRED COMPE_4

RETIREMENT AND DEFERRED COMPENSATION PLANS - Defined Benefit Plans Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
United States
Changes in the benefit obligations and plan assets
Employer contribution	$ 15,513,000	$ 466,000
Minimum funding requirement by employer	0
Expected contribution in next fiscal year	500,000
Current year actuarial gain (loss)	54,295,000	28,714,000	$ (33,335,000)
United States | Supplemental Employee Retirement Plan
Changes in the benefit obligations and plan assets
Liability, defined benefit plan	11,000,000	14,900,000
Foreign Plans
Changes in the benefit obligations and plan assets
Employer contribution	1,871,000	7,966,000
Expected contribution in next fiscal year	500,000
Current year actuarial gain (loss)	$ 19,181,000	$ 6,257,000	$ (2,530,000)

RETIREMENT AND DEFERRED COMPE_5

RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Estimated Benefit Payments to Defined Benefit Plans (Details) $ in Thousands	Dec. 31, 2022 USD ($)
United States
Changes in the benefit obligations and plan assets
2023	$ 10,184
2024	10,948
2025	11,241
2026	12,743
2027	11,828
2028 - 2032	70,372
Foreign Plans
Changes in the benefit obligations and plan assets
2023	2,652
2024	4,781
2025	6,658
2026	5,136
2027	7,700
2028 - 2032	$ 38,262

RETIREMENT AND DEFERRED COMPE_6

RETIREMENT AND DEFERRED COMPENSATION PLANS - Defined Contribution and Other Plans Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
United States
Defined contribution plan
Total contributions by company	$ 5	$ 4.5	$ 4.3
United States | Aptar Retirement Savings Account
Defined contribution plan
Total contributions by company	$ 2	0.7
United States | Maximum
Defined contribution plan
Employer matching contribution as a percentage of salary	3%
United States | Maximum | Aptar Retirement Savings Account
Defined contribution plan
Employer matching contribution as a percentage of salary	5%
Foreign Plans
Defined contribution plan
Total contributions by company	$ 2.9	$ 2.9	$ 2.4

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) - Changes in Accumulated Other Comprehensive Income/(Loss) by Component (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accumulated other comprehensive income activity
Balance at the beginning of the period	$ 1,969,407
Other comprehensive (loss) income before reclassifications	(31,757)	$ (36,482)	$ 44,538
Amounts reclassified from accumulated other comprehensive income	6,432	2,150	15,701
Net current-period other comprehensive (loss) income	(25,325)	(34,332)	60,239
Balance at the end of the period	2,053,935	1,969,407
Accumulated Other Comprehensive (Loss)Income
Accumulated other comprehensive income activity
Balance at the beginning of the period	(316,041)	(281,709)	(341,948)
Balance at the end of the period	(341,366)	(316,041)	(281,709)
Foreign Currency
Accumulated other comprehensive income activity
Balance at the beginning of the period	(249,500)	(178,025)	(257,124)
Other comprehensive (loss) income before reclassifications	(79,240)	(71,475)	79,099
Amounts reclassified from accumulated other comprehensive income	0	0	0
Net current-period other comprehensive (loss) income	(79,240)	(71,475)	79,099
Balance at the end of the period	(328,740)	(249,500)	(178,025)
Defined Benefit Pension Plans
Accumulated other comprehensive income activity
Balance at the beginning of the period	(66,486)	(102,322)	(83,147)
Other comprehensive (loss) income before reclassifications	54,149	26,409	(25,389)
Amounts reclassified from accumulated other comprehensive income	6,386	9,427	6,214
Net current-period other comprehensive (loss) income	60,535	35,836	(19,175)
Balance at the end of the period	(5,951)	(66,486)	(102,322)
Derivatives
Accumulated other comprehensive income activity
Balance at the beginning of the period	(55)	(1,362)	(1,677)
Other comprehensive (loss) income before reclassifications	(6,666)	8,584	(9,172)
Amounts reclassified from accumulated other comprehensive income	46	(7,277)	9,487
Net current-period other comprehensive (loss) income	(6,620)	1,307	315
Balance at the end of the period	$ (6,675)	$ (55)	$ (1,362)

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) - Reclassifications out of Accumulated Other Comprehensive Income/(Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Amount Reclassified from Accumulated Other Comprehensive Income
Interest expense	$ (40,827)	$ (30,284)	$ (33,244)
Miscellaneous, net	(4,799)	(3,094)	(7,678)
Income before Income Taxes	334,704	321,655	301,155
Tax benefit	(95,149)	(78,017)	(87,065)
Net Income	239,555	243,638	214,090
Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Net Income	6,432	2,150	15,701
Defined Benefit Pension Plans | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Amortization of net loss	8,358	12,424	7,805
Amortization of prior service cost	177	166	398
Income before Income Taxes	8,535	12,590	8,203
Tax benefit	(2,149)	(3,163)	(1,989)
Net Income	6,386	9,427	6,214
Derivatives | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Income before Income Taxes	46	(7,277)	9,487
Tax benefit	0	0	0
Net Income	46	(7,277)	9,487
Derivatives | Changes in cross currency swap: interest component | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Interest expense	(171)	(13)	(1,474)
Derivatives | Changes in cross currency swap: foreign exchange component | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Miscellaneous, net	$ 217	$ (7,264)	$ 10,961

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) $ in Thousands, € in Millions	Jul. 06, 2022 EUR (€)	Jul. 20, 2017 USD ($)	Dec. 31, 2022 USD ($)	Jul. 06, 2022 USD ($)	Jul. 06, 2022 EUR (€)	Mar. 07, 2022 USD ($)	Dec. 31, 2021 USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative assets			$ 1,107				$ 842
Derivative liabilities			9,109				221
Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative assets			1,107				331
Derivative liabilities			269				221
Cross Currency Swap Contract | Prepaid and other | Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative assets			0				0
Cross Currency Swap Contract | Accounts payable and accrued liabilities | Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative liabilities			0				0
Cross Currency Swap Contract | Derivatives in Cash Flow Hedging Relationships
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount hedged		$ 280,000
Cross Currency Swap Contract | Net Investment Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount hedged				$ 203,000	€ 200
Derivative, term of contract	7 years
Derivative, fixed interest rate				2.5224%	2.5224%
Derivative, annual fixed interest payments receivable				$ 3,700
Cash flow hedge derivative instrument liability at fair value			8,800
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount			52,200
Foreign Exchange Contracts | Prepaid and other | Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative assets			1,107				331
Foreign Exchange Contracts | Accounts payable and accrued liabilities | Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative liabilities			$ 269				$ 221
Notes payable
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Proceeds from debt		$ 280,000
Interest rate on notes (as a percent)		1.36%
Senior unsecured notes 3.6%, due in 2032, net of discount of $1.0 million
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate on notes (as a percent)			3.60%	3.60%	3.60%	3.60%
Debt instrument, face amount						$ 400,000
Debt instrument, periodic payment | €	€ 2.5

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Fair Value of Derivative Instruments in the Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value of Derivative Instruments
Derivative assets	$ 1,107	$ 842
Derivative liabilities	9,109	221
Derivatives Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative assets	0	511
Derivative liabilities	8,840	0
Derivatives Designated as Hedging Instruments | Foreign Exchange Contracts | Prepaid and other
Fair Value of Derivative Instruments
Derivative assets	0	0
Derivatives Designated as Hedging Instruments | Foreign Exchange Contracts | Accounts payable and accrued liabilities
Fair Value of Derivative Instruments
Derivative liabilities	0	0
Derivatives Designated as Hedging Instruments | Cross Currency Interest Rate Contract | Prepaid and other
Fair Value of Derivative Instruments
Derivative assets	0	511
Derivatives Designated as Hedging Instruments | Cross Currency Interest Rate Contract | Accounts payable and accrued liabilities
Fair Value of Derivative Instruments
Derivative liabilities	8,840	0
Derivatives not Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative assets	1,107	331
Derivative liabilities	269	221
Derivatives not Designated as Hedging Instruments | Foreign Exchange Contracts | Prepaid and other
Fair Value of Derivative Instruments
Derivative assets	1,107	331
Derivatives not Designated as Hedging Instruments | Foreign Exchange Contracts | Accounts payable and accrued liabilities
Fair Value of Derivative Instruments
Derivative liabilities	269	221
Derivatives not Designated as Hedging Instruments | Cross Currency Interest Rate Contract | Prepaid and other
Fair Value of Derivative Instruments
Derivative assets	0	0
Derivatives not Designated as Hedging Instruments | Cross Currency Interest Rate Contract | Accounts payable and accrued liabilities
Fair Value of Derivative Instruments
Derivative liabilities	$ 0	$ 0

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Derivative Instruments on the Consolidated Statements of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative instruments, gain or (loss)
Interest expense	$ 40,827	$ 30,284	$ 33,244
Miscellaneous, net	(4,799)	(3,094)	$ (7,678)
Amount of (Loss) Gain Recognized in Income on Derivatives	606	(87)
Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	(6,665)	8,584
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	(46)	7,277
Changes in cross currency swap: interest component | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	229	1,319
Interest expense	40,827
Changes in cross currency swap: interest component | Interest expense | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	171	13
Changes in cross currency swap: foreign exchange component | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	(6,894)	7,265
Miscellaneous, net	(4,799)
Changes in cross currency swap: foreign exchange component | Miscellaneous, net | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	(217)	7,264
Foreign Exchange Contracts
Derivative instruments, gain or (loss)
Amount of (Loss) Gain Recognized in Income on Derivatives	$ 606	$ (87)

DERIVATIVE INSTRUMENTS AND HE_6

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Derivative Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Derivative Assets
Gross Amount	$ 1,107	$ 842
Net Amounts Presented in the Statement of Financial Position	1,107	842
Net Amount	$ 1,107	842
DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag	Net AmountsPresented inthe Statement ofFinancial Position
Derivative Liabilities
Gross Amount	$ 9,109	221
Net Amounts Presented in the Statement of Financial Position	9,109	221
Net Amount	$ 9,109	$ 221
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag	Net AmountsPresented inthe Statement ofFinancial Position

FAIR VALUE - Financial Assets a

FAIR VALUE - Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Liabilities
Fair value of long-term obligations	$ 900,000			$ 900,000
Level 3
Liabilities
Contingent consideration obligation	25,310			33,908
Level 3 | Enable Injections, Inc.
Assets
Convertible notes			$ 5,000
Level 3 | Siklus Refill Pte Ltd
Assets
Convertible notes		$ 1,000
Liabilities
Proceeds from collection of notes receivable	400
Fair Value, Recurring
Assets
Investment in equity securities	5,297			9,006
Foreign exchange contracts	1,107			331
Cross currency swap contract				511
Convertible notes	5,650
Total assets at fair value	12,054			9,848
Liabilities
Foreign exchange contracts	269			221
Cross currency swap contract	8,840
Contingent consideration obligation	25,310			33,908
Total liabilities at fair value	34,419			34,129
Fair Value, Recurring | Level 1
Assets
Investment in equity securities	5,297			9,006
Foreign exchange contracts	0			0
Cross currency swap contract				0
Convertible notes	0
Total assets at fair value	5,297			9,006
Liabilities
Foreign exchange contracts	0			0
Cross currency swap contract	0
Contingent consideration obligation	0			0
Total liabilities at fair value	0			0
Fair Value, Recurring | Level 2
Assets
Investment in equity securities	0			0
Foreign exchange contracts	1,107			331
Cross currency swap contract				511
Convertible notes	0
Total assets at fair value	1,107			842
Liabilities
Foreign exchange contracts	269			221
Cross currency swap contract	8,840
Contingent consideration obligation	0			0
Total liabilities at fair value	9,109			221
Fair Value, Recurring | Level 3
Assets
Investment in equity securities	0			0
Foreign exchange contracts	0			0
Cross currency swap contract				0
Convertible notes	5,650
Total assets at fair value	5,650			0
Liabilities
Foreign exchange contracts	0			0
Cross currency swap contract	0
Contingent consideration obligation	25,310			33,908
Total liabilities at fair value	$ 25,310			$ 33,908

FAIR VALUE - Contingent Conside

FAIR VALUE - Contingent Consideration Fair Value (Details) - Level 3 - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration obligation	$ 25,310	$ 33,908
Fusion Packaging
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration obligation	25,310	27,166
Noble Acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration obligation	$ 0	$ 6,742

FAIR VALUE - Roll Forward (Deta

FAIR VALUE - Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 33,908	$ 31,140
Increase in fair value recorded in earnings	(8,598)	2,768
Balance at end of period	$ 25,310	$ 33,908
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	Selling, research & development and administrative

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Commitments and contingencies
Unconditional purchase commitment	$ 82,600,000
Purchase commitment, term	5 years
Brazil | Reduction of gross receipts tax
Commitments and contingencies
Recovery of part of claim		$ 7,400,000	$ 700,000
Brazil | Reduction of gross receipts tax | Cost of sales
Commitments and contingencies
Recovery of part of claim		5,600,000	$ 700,000
Brazil | Reduction of gross receipts tax | Interest Income
Commitments and contingencies
Recovery of part of claim		$ 1,800,000
Indemnification agreements
Commitments and contingencies
Liabilities recorded under indemnification agreements	$ 0
Tax Assessment
Commitments and contingencies
Liabilities recorded under indemnification agreements	0
Estimated loss contingency	13,000,000
Tax Assessment, Penalites | Maximum
Commitments and contingencies
Estimated loss contingency	6,000,000
Tax Assessment Interest and Penalties | Minimum
Commitments and contingencies
Estimated loss contingency	$ 5,000,000

STOCK REPURCHASE PROGRAM (Detai

STOCK REPURCHASE PROGRAM (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Apr. 18, 2019
Stock repurchase program
Common stock repurchased (retired and held in treasury) (in shares)	860,000	615,000	0
Common stock repurchased (retired and held in treasury)	$ 92,100,000	$ 78,100,000
Remaining authorized repurchase amount	$ 108,300,000
Stock Repurchase Program April 18, 2019
Stock repurchase program
Share repurchases authorized amount				$ 350,000,000

CAPITAL STOCK (Details)

CAPITAL STOCK (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Authorized common stock (in shares)	199,000,000	199,000,000
Common stock and treasury stock and the share activity
Balance at the beginning of the year (in shares)	70,400,000
Balance at the end of the year (in shares)	70,800,000	70,400,000
Cash dividends paid on the common stock	$ 99,461	$ 98,509	$ 92,658
Common Shares
Common stock and treasury stock and the share activity
Balance at the beginning of the year (in shares)	70,370,812	69,516,805	68,608,508
Restricted stock vestings (in shares)	176,535	171,935	79,700
Balance at the end of the year (in shares)	70,848,810	70,370,812	69,516,805
Common Shares | Employee option exercises
Common stock and treasury stock and the share activity
Stock option exercises (in shares)	301,463	634,572	802,046
Common Shares | Director option exercises
Common stock and treasury stock and the share activity
Stock option exercises (in shares)	0	47,500	26,551
Treasury Stock
Common stock and treasury stock and the share activity
Balance at the beginning of the year (in shares)	4,852,709	4,528,051	4,836,027
Common stock repurchased (in shares)	860,000	614,974	0
Balance at the end of the year (in shares)	5,555,027	4,852,709	4,528,051
Treasury Stock | Employee option exercises
Common stock and treasury stock and the share activity
Stock option exercises (in shares)	157,682	290,316	307,976

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award
Proceeds from stock option exercises	$ 28,512	$ 59,906	$ 68,555
Time-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSUs granted (in shares)	205,403
RSUs vested (in shares)	256,872
Time-Based RSUs | Director option exercises
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	1 year
RSUs granted (in shares)	11,797
RSUs vested (in shares)	10,007
Performance-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSUs granted (in shares)	249,656
RSUs vested (in shares)	43,388
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Tax benefit	$ 8,000
Unrecognized compensation expense	$ 47,800
Weighted-average period cost will be recognized over	1 year 10 months 24 days
Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
Tax benefit	$ 4,400
Expiration period (in years)	10 years
Proceeds from stock option exercises	$ 28,500

STOCK-BASED COMPENSATION - Assu

STOCK-BASED COMPENSATION - Assumptions Used (Details) - Performance-Based RSUs - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award
Fair value per stock award (in dollars per share)	$ 141.95	$ 171.63	$ 94.98
Grant date stock price (in dollars per share)	$ 114.52	$ 141.59	$ 83.93
Aptar's stock price expected volatility	20.20%	21.40%	23.80%
Expected average volatility of peer companies	41.70%	50%	48.50%
Correlation assumption	41.20%	58.10%	63.50%
Risk-free interest rate	2.04%	0.32%	0.31%
Dividend yield assumption	1.33%	1.02%	1.72%

STOCK-BASED COMPENSATION - Rest

STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Time-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) | shares	485,479
RSUs granted (in shares) | shares	205,403
RSUs vested (in shares) | shares	(256,872)
RSUs forfeited (in shares) | shares	(7,649)
Nonvested outstanding ending balance (in shares) | shares	426,361
Weighted Average Grant Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) | $ / shares	$ 108.73
Granted, Weighted average grant date fair value (in dollars per share) | $ / shares	111.50
Vested, Weighted average grant date fair value (in dollars per share) | $ / shares	106.07
Forfeited, Weighted average grant date fair value (in dollars per share) | $ / shares	111.73
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) | $ / shares	$ 111.60
Performance-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) | shares	650,553
RSUs granted (in shares) | shares	249,656
RSUs vested (in shares) | shares	(43,388)
RSUs forfeited (in shares) | shares	(245,950)
Nonvested outstanding ending balance (in shares) | shares	610,871
Weighted Average Grant Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) | $ / shares	$ 111.04
Granted, Weighted average grant date fair value (in dollars per share) | $ / shares	123.97
Vested, Weighted average grant date fair value (in dollars per share) | $ / shares	134.97
Forfeited, Weighted average grant date fair value (in dollars per share) | $ / shares	100.75
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) | $ / shares	$ 118.77

STOCK-BASED COMPENSATION - Comp

STOCK-BASED COMPENSATION - Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 40,937	$ 38,643	$ 32,085
Fair value of units vested	32,013	32,414	12,038
Intrinsic value of units vested	$ 33,024	42,970	14,446
Options
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense		227	2,063
Compensation expense, net of tax		174	1,573
Grant date fair value of options vested		2,421	7,601
Options | Selling Research And Development And Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense		185	1,693
Options | Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense		$ 42	$ 370

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Option Activity (Details) - Options - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee option exercises
Stock options activity
Outstanding at the beginning of the period (in shares)	3,072,503
Exercised (in shares)	(447,109)
Forfeited or expired (in shares)	(1,450)
Outstanding at the end of the period (in shares)	2,623,944	3,072,503
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 71.99
Options exercised, Weighted average exercise price per share (in dollars per share)	64.05
Options forfeited or expired, Weighted average exercise price per share (in dollars per share)	78.30
Outstanding at the end of the period (in dollars per share)	$ 73.34	$ 71.99
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	2,623,944
Options exercisable, Weighted average exercise price per share (in dollars per share)	$ 73.34
Options outstanding, Weighted average remaining contractual term (in years)	3 years 3 months 18 days
Options exercisable, Weighted average remaining contractual term (in years)	3 years 3 months 18 days
Options outstanding, Aggregate intrinsic value (in USD)	$ 96,149
Options exercisable, Aggregate intrinsic value (in USD)	96,149
Options exercised, Intrinsic value, at end of period	$ 20,608	$ 69,862	$ 59,179
Director option exercises
Stock options activity
Outstanding at the beginning of the period (in shares)	51,700
Exercised (in shares)	0
Forfeited or expired (in shares)	0
Outstanding at the end of the period (in shares)	51,700	51,700
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 63.91
Options exercised, Weighted average exercise price per share (in dollars per share)	0
Options forfeited or expired, Weighted average exercise price per share (in dollars per share)	0
Outstanding at the end of the period (in dollars per share)	$ 63.91	$ 63.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	51,700
Options exercisable, Weighted average exercise price per share (in dollars per share)	$ 63.91
Options outstanding, Weighted average remaining contractual term (in years)	1 year 1 month 6 days
Options exercisable, Weighted average remaining contractual term (in years)	1 year 1 month 6 days
Options outstanding, Aggregate intrinsic value (in USD)	$ 2,382
Options exercisable, Aggregate intrinsic value (in USD)	2,382
Options exercised, Intrinsic value, at end of period	$ 0	$ 4,248	$ 2,318

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income (Numerator)
Income available to common stockholders, basic	$ 239,288	$ 244,097	$ 214,040
Income available to common stockholders, diluted	$ 239,288	$ 244,097	$ 214,040
Shares (Denominator)
Basic (in shares)	65,402	65,663	64,418
Total average equivalent shares (in shares)	66,719	67,682	66,657
Per Share Amount
Net income per share, basic (in dollars per share)	$ 3.66	$ 3.72	$ 3.32
Net income per share, diluted (in dollars per share)	$ 3.59	$ 3.61	$ 3.21
Stock options
Shares (Denominator)
Effect of dilutive stock based compensation (in shares)	978	1,600	1,800
Restricted stock
Shares (Denominator)
Effect of dilutive stock based compensation (in shares)	339	419	439

SEGMENT INFORMATION - Summary o

SEGMENT INFORMATION - Summary of Reportable Segments (Details) $ in Thousands		12 Months Ended
	Jan. 01, 2023 segment	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($) segment	Dec. 31, 2020 USD ($) segment
Segment Reporting [Abstract]
Number of reportable segments | segment		3	3	3
Financial information regarding the Company's reportable segments
Net Sales		$ 3,322,249	$ 3,227,221	$ 2,929,340
Acquisition-related costs		(231)	(3,811)	(6,087)
Restructuring initiatives		(6,597)	(23,240)	(26,492)
Net unrealized investment gain		(3,323)	2,709	0
Depreciation and amortization		(233,706)	(234,853)	(220,300)
Interest expense		(40,827)	(30,284)	(33,244)
Interest income		2,700	3,668	958
Income before Income Taxes		334,704	321,655	301,155
Capital Expenditures:		310,427	307,935	245,954
Total Assets		$ 4,203,458	$ 4,141,364	$ 3,990,053
Number of reportable segments | segment		3	3	3
Subsequent Events
Segment Reporting [Abstract]
Number of reportable segments | segment	3
Financial information regarding the Company's reportable segments
Number of realigned segments | segment	2
Number of reportable segments | segment	3
Pharma
Financial information regarding the Company's reportable segments
Net Sales		$ 1,361,256	$ 1,284,624	$ 1,225,779
Restructuring initiatives		0	(76)	(220)
Beauty + Home
Financial information regarding the Company's reportable segments
Net Sales		1,438,534	1,434,022	1,298,151
Restructuring initiatives		(6,460)	(10,447)	(24,464)
Food + Beverage
Financial information regarding the Company's reportable segments
Net Sales		522,459	508,575	405,410
Restructuring initiatives		(137)	(404)	(1,903)
Operating Segments
Financial information regarding the Company's reportable segments
Net Sales		3,357,986	3,265,316	2,962,530
Operating Segments | Pharma
Financial information regarding the Company's reportable segments
Net Sales		1,372,449	1,297,996	1,234,107
Adjusted EBITDA		441,622	425,714	428,469
Depreciation and amortization		(94,396)	(90,510)	(75,874)
Capital Expenditures:		164,396	154,077	117,835
Total Assets		1,872,843	1,833,512	1,549,781
Operating Segments | Beauty + Home
Financial information regarding the Company's reportable segments
Net Sales		1,461,894	1,456,208	1,320,988
Adjusted EBITDA		166,465	154,689	129,299
Depreciation and amortization		(93,027)	(96,611)	(95,880)
Capital Expenditures:		86,048	100,531	93,980
Total Assets		1,625,596	1,615,917	1,610,058
Operating Segments | Food + Beverage
Financial information regarding the Company's reportable segments
Net Sales		523,643	511,112	407,435
Adjusted EBITDA		71,531	79,377	71,995
Depreciation and amortization		(40,337)	(40,323)	(37,768)
Capital Expenditures:		32,378	34,136	29,956
Total Assets		552,871	574,269	549,270
Intersegment
Financial information regarding the Company's reportable segments
Net Sales		(35,737)	(38,095)	(33,190)
Intersegment | Pharma
Financial information regarding the Company's reportable segments
Net Sales		(11,193)	(13,372)	(8,328)
Intersegment | Beauty + Home
Financial information regarding the Company's reportable segments
Net Sales		(23,360)	(22,186)	(22,837)
Intersegment | Food + Beverage
Financial information regarding the Company's reportable segments
Net Sales		(1,184)	(2,537)	(2,025)
Corporate & Other
Financial information regarding the Company's reportable segments
Adjusted EBITDA		(62,930)	(52,314)	(43,443)
Restructuring initiatives		0	(12,313)	95
Depreciation and amortization		(5,946)	(7,409)	(10,778)
Capital Expenditures:		29,491	29,686	15,690
Transfer of Corporate Technology Expenditures		(1,886)	(10,495)	(11,507)
Total Assets		$ 152,148	$ 117,666	$ 280,944

SEGMENT INFORMATION - Summary_2

SEGMENT INFORMATION - Summary of Net Sales and Long-Lived Assets By Geographic Area (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Net sales and long-lived asset information by geographic area
Net Sales	$ 3,322,249	$ 3,227,221	$ 2,929,340
Property, Plant and Equipment, Net	$ 1,343,664	$ 1,275,877	$ 1,198,748
Customer Concentration Risk | Net sales
Net sales and long-lived asset information by geographic area
Concentration risk, threshold percentage	0.05	0.05	0.05
United States
Net sales and long-lived asset information by geographic area
Net Sales	$ 1,100,159	$ 1,081,823	$ 965,986
Property, Plant and Equipment, Net	346,382	321,511	298,616
Europe
Net sales and long-lived asset information by geographic area
Net Sales	1,773,395	1,725,182	1,604,056
Property, Plant and Equipment, Net	772,828	761,697	734,172
France
Net sales and long-lived asset information by geographic area
Net Sales	938,637	906,057	854,639
Property, Plant and Equipment, Net	482,091	455,105	426,353
Germany
Net sales and long-lived asset information by geographic area
Net Sales	512,709	486,928	448,405
Property, Plant and Equipment, Net	194,898	197,643	194,553
Italy
Net sales and long-lived asset information by geographic area
Net Sales	154,823	161,676	148,636
Property, Plant and Equipment, Net	42,522	50,828	57,333
Other Europe
Net sales and long-lived asset information by geographic area
Net Sales	167,226	170,521	152,376
Property, Plant and Equipment, Net	53,317	58,121	55,933
China
Net sales and long-lived asset information by geographic area
Net Sales	156,577	148,671	118,791
Property, Plant and Equipment, Net	98,469	74,535	46,005
Other Foreign Countries
Net sales and long-lived asset information by geographic area
Net Sales	292,118	271,545	240,507
Property, Plant and Equipment, Net	$ 125,985	$ 118,134	$ 119,955

ACQUISITIONS - Narrative (Detai

ACQUISITIONS - Narrative (Details) € / shares in Units, € in Millions, ¥ in Millions								1 Months Ended				3 Months Ended				12 Months Ended			18 Months Ended
	Aug. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2021 EUR (€)	Sep. 02, 2021 USD ($)	Sep. 02, 2021 EUR (€) € / shares	Aug. 17, 2021 USD ($)	Aug. 17, 2021 CNY (¥)	Sep. 30, 2021 USD ($)	Sep. 30, 2021 EUR (€)	Aug. 31, 2021 USD ($)	Aug. 31, 2021 CNY (¥)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CNY (¥)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Feb. 17, 2023 USD ($)	Feb. 17, 2023 CNY (¥)	Sep. 30, 2021 EUR (€)	Aug. 17, 2021 CNY (¥)
Acquisitions
Payments to acquire businesses, net of cash acquired																$ 4,100,000	$ 148,420,000	$ 164,181,000
Restricted cash included in prepaid and other												$ 1,000,000		$ 0		1,000,000	0	4,833,000
Acquisition-related costs																231,000	3,811,000	6,087,000
Goodwill												945,632,000		$ 974,157,000		945,632,000	$ 974,157,000	$ 898,521,000
Metaphase
Acquisitions
Payments to acquire businesses, net of cash acquired	$ 5,100,000
Cash and equivalents	100,000
Restricted cash included in prepaid and other	$ 1,000,000
Acquisition-related costs																200,000
Goodwill												3,000,000				3,000,000
Goodwill deductible for tax purposes												0				$ 0
Voluntis
Acquisitions
Percentage of interest acquired					64.30%									25.10%			25.10%
Business acquisition, share price (in Euros per share) | € / shares					€ 8.70
Payments to acquire businesses, gross				$ 60,400,000	€ 50.8			$ 9,900,000	€ 8.4					$ 22,600,000	€ 19.5
Valuation of full company equity of acquired company				93,900,000	€ 79.1
Business acquisition, value of total investment		$ 70,300,000	€ 59.2
Non-controlling interest value		$ 23,600,000						$ 23,600,000													€ 19.9
Voluntis | Technology-Based Intangible Assets
Acquisitions
Acquired intangible assets				27,900,000
Voluntis | Other Intangible Assets
Acquisitions
Acquired intangible assets				$ 8,400,000
Voluntis | Voluntis
Acquisitions
Ownership percentage by Aptar		74.90%						74.90%						100%			100%				74.90%
Weihai Hengyu Medical Products
Acquisitions
Percentage of interest acquired						80%																80%
Payments to acquire businesses, gross										$ 53,600,000	¥ 347.7
Valuation of full company equity of acquired company						$ 74,800,000	¥ 484.9
Percent of total consideration transferred										0.90	0.90
Purchase price adjustment to be paid												$ 200,000	¥ 1.5
Non-controlling interest value						15,000,000																¥ 97
Remaining percentage of interest to be acquired												0.20				0.20
Weihai Hengyu Medical Products | Other Intangible Assets
Acquisitions
Acquired intangible assets						5,600,000
Weihai Hengyu Medical Products | Customer relationships
Acquisitions
Acquired intangible assets						$ 24,100,000
Weihai Hengyu Medical Products | Forecast
Acquisitions
Payments to acquire businesses, gross																			$ 6,000,000	¥ 38.7
Remaining percent of consideration to be transferred																			0.10	0.10
Business acquisition, financing term																			18 months	18 months
Simple interest included with consideration																			0.04	0.04
2021 Acquisitions
Acquisitions
Cash and equivalents														$ 3,852,000			$ 3,852,000
Acquisition-related costs																	3,800,000
Goodwill														104,433,000			104,433,000
Goodwill deductible for tax purposes														$ 0			$ 0

ACQUISITIONS - Assets Acquired

ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets
Goodwill	$ 945,632	$ 974,157	$ 898,521
2021 Acquisitions
Assets
Cash and equivalents		3,852
Accounts receivable		5,208
Inventories		606
Other receivable		286
Prepaid and other		1,863
Property, plant and equipment		14,081
Goodwill		104,433
Intangible assets		65,981
Operating lease right-of-use assets		2,309
Other miscellaneous assets		78
Liabilities
Current maturities of long-term obligations, net of unamortized debt issuance costs		1,410
Accounts payable, accrued and other liabilities		9,663
Deferred income taxes		16,792
Operating lease liabilities		2,306
Deferred and other non-current liabilities		5,770
Net assets acquired		$ 162,756

ACQUISITIONS - Acquired Intangi

ACQUISITIONS - Acquired Intangibles (Details) - 2021 Acquisitions $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Acquired finite-lived intangible assets
Estimated Fair Value of Asset	$ 65,981
Acquired technology
Acquired finite-lived intangible assets
Weighted average useful life (in years)	10 years
Estimated Fair Value of Asset	$ 34,322
Customer relationships
Acquired finite-lived intangible assets
Weighted average useful life (in years)	11 years 7 months 6 days
Estimated Fair Value of Asset	$ 30,258
License agreements and other
Acquired finite-lived intangible assets
Weighted average useful life (in years)	3 months
Estimated Fair Value of Asset	$ 1,401

INVESTMENT IN EQUITY SECURITI_3

INVESTMENT IN EQUITY SECURITIES - Schedule of Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Total equity method investments and other investments	$ 52,308	$ 59,485
BTY
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	31,490	33,199
Sonmol
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	4,997	5,904
Desotec GmbH
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	863	919
PureCycle
Schedule of Equity Method Investments [Line Items]
Other Investments	5,297	9,006
YAT
Schedule of Equity Method Investments [Line Items]
Other Investments	5,508	5,978
Loop
Schedule of Equity Method Investments [Line Items]
Other Investments	2,894	2,894
Others
Schedule of Equity Method Investments [Line Items]
Other Investments	$ 1,259	$ 1,585

INVESTMENT IN EQUITY SECURITI_4

INVESTMENT IN EQUITY SECURITIES - Narrative (Details) € in Thousands, $ in Thousands

1 Months Ended

3 Months Ended

12 Months Ended

60 Months Ended

Jul. 07, 2021 USD ($)

Apr. 01, 2020 USD ($)

Jan. 01, 2020 USD ($) company

Aug. 31, 2022 USD ($) shares

Mar. 31, 2022 USD ($) shares

Oct. 31, 2021 USD ($) shares

Nov. 30, 2020 USD ($)

Aug. 31, 2019 USD ($)

Jun. 30, 2022 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Dec. 31, 2017 USD ($)

Dec. 31, 2009 EUR (€)

Dec. 31, 2021 USD ($)

Mar. 31, 2021

Schedule of Equity Method Investments [Line Items]

Investment in unconsolidated affiliate

$ 0

$ 6,870

$ 39,628

Income (Loss) from equity method investment

467

(692)

(1,443)

Proceeds from sale of investment in equity securities

1,599

2,434

0

Net unrealized investment gain

(3,323)

2,709

0

BTY

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

49%

Investment in unconsolidated affiliate

$ 32,000

Initial lock-up period (in years)

5 years

Second lock-up period (in years)

3 years

Equity Method Investments, Number of Companies Acquired | company

3

BTY | Minimum | Call Option

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

26%

BTY | Maximum | Call Option

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

31%

Sonmol

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

30%

Investment in unconsolidated affiliate

$ 5,000

Kali Care

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

20%

Investment in unconsolidated affiliate

$ 5,000

Income (Loss) from equity method investment

$ (1,600)

Investment impairment

400

3,000

Investment impairment, net

300

2,300

Note receivable

$ 1,500

Financing receivable, allowance for credit loss

$ 1,500

Proceeds from collection of notes receivable

$ 100

Notes receivable, collection period

3 years

Desotec GmbH

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

23%

Investment in unconsolidated affiliate | €

€ 574

Loop | Preferred equity stocks

Schedule of Equity Method Investments [Line Items]

Investment in unconsolidated affiliate

$ 2,500

400

PureCycle

Schedule of Equity Method Investments [Line Items]

Investment ownership percentage

0.01

PureCycle | Preferred equity stocks

Schedule of Equity Method Investments [Line Items]

Investment in unconsolidated affiliate

$ 1,000

1,000

Increase (decrease) in value of preferred equity stock investment

$ 3,100

Equity received in exchange for services

333

$ 333

FDA milestone tranche

$ 1,000

Number of shares sold (in shares) | shares

50,000

107,600

191,349

Proceeds from sale of investment in equity securities

$ 511

$ 1,088

$ 2,434

Realized Gain

$ 372

$ 841

$ 2,000

YAT

Schedule of Equity Method Investments [Line Items]

Investment in unconsolidated affiliate

$ 5,900

Investment ownership percentage

0.10

INVESTMENT IN EQUITY SECURITI_5

INVESTMENT IN EQUITY SECURITIES - Purecycle Investment (Details) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Aug. 31, 2022	Mar. 31, 2022	Oct. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Proceeds				$ 1,599	$ 2,434	$ 0
PureCycle | Preferred stock
Schedule of Equity Method Investments [Line Items]
Shares Sold (in shares)	50,000	107,600	191,349
Proceeds	$ 511	$ 1,088	$ 2,434
Realized Gain	$ 372	$ 841	$ 2,000

INVESTMENT IN EQUITY SECURITI_6

INVESTMENT IN EQUITY SECURITIES - Net Investment Gain/Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Net investment (loss) gain	$ (2,110)	$ 4,709	$ 3,064
PureCycle | Preferred stock
Schedule of Equity Method Investments [Line Items]
Net investment (loss) gain	$ (2,110)	$ 4,709	$ 3,064

RESTRUCTURING INITIATIVES (Deta

RESTRUCTURING INITIATIVES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring initiatives
Impairment loss	$ 307	$ 376	$ 0
Capital Expenditures:	310,427	307,935	245,954
Restructuring reserve
Restructuring initiatives	6,597	23,240	26,492
Business Transformation
Restructuring initiatives
Restructuring charges including asset impairment			26,500
Impairment loss			2,500
Cumulative expense incurred	136,600
Restructuring reserve
Restructuring reserve, balance at the beginning of the period	3,795
Restructuring initiatives	373	23,200	$ 26,500
Cash Paid	(3,444)
Interest and FX Impact	(164)
Restructuring reserve, balance at the end of the period	560	3,795
Business Transformation | Employee severance
Restructuring reserve
Restructuring reserve, balance at the beginning of the period	3,535
Restructuring initiatives	303
Cash Paid	(3,131)
Interest and FX Impact	(153)
Restructuring reserve, balance at the end of the period	554	3,535
Business Transformation | Professional fees and other costs
Restructuring reserve
Restructuring reserve, balance at the beginning of the period	260
Restructuring initiatives	70
Cash Paid	(313)
Interest and FX Impact	(11)
Restructuring reserve, balance at the end of the period	6	260
Business Optimization
Restructuring reserve
Restructuring reserve, balance at the beginning of the period	0
Restructuring initiatives	6,224
Cash Paid	(1,261)
Interest and FX Impact	30
Restructuring reserve, balance at the end of the period	4,993	0
Business Optimization | Employee severance
Restructuring reserve
Restructuring reserve, balance at the beginning of the period	0
Restructuring initiatives	5,454
Cash Paid	(491)
Interest and FX Impact	30
Restructuring reserve, balance at the end of the period	4,993	0
Business Optimization | Professional fees and other costs
Restructuring reserve
Restructuring reserve, balance at the beginning of the period	0
Restructuring initiatives	770
Cash Paid	(770)
Interest and FX Impact	0
Restructuring reserve, balance at the end of the period	0	$ 0
Optimization Plan
Restructuring reserve
Restructuring initiatives	$ 6,200

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
CECL
VALUATION AND QUALIFYING ACCOUNTS
Balance at Beginning Of Period	$ 7,374	$ 5,918	$ 3,626
Charged to Costs and Expenses	3,213	1,601	865
Charged to Other Accounts	0	391	1,647
Deductions from Reserve	(1,068)	(536)	(220)
Balance at End of Period	9,519	7,374	5,918
Deferred tax valuation allowance
VALUATION AND QUALIFYING ACCOUNTS
Balance at Beginning Of Period	47,149	23,105	23,320
Charged to Costs and Expenses	3,754	5,355	3,085
Charged to Other Accounts	380	20,572	700
Deductions from Reserve	(5,044)	(1,883)	(4,000)
Balance at End of Period	$ 46,239	47,149	$ 23,105
Deferred tax valuation allowance | Voluntis
VALUATION AND QUALIFYING ACCOUNTS
Charged to Other Accounts		$ 20,500

Uncategorized Items - atr-20221

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2016-13 [Member]